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Obesity and the metabolic syndrome
For years, obesity has been a public health problem that remained limited to the 
developing countries. However, over the last decade obesity rates have reached 
pandemic proportions worldwide and obesity has developed into a global health 
problem. Now, for the first time in history the world has more overweight than 
underweight people (1). Moreover, children are increasingly at risk of becoming 
obese (2,3). In parallel with the obesity epidemic, obesity-related disorders, such 
as the metabolic syndrome are rising. The metabolic syndrome is characterized 
by a cluster of several metabolic disorders that are highly prevalent in developing 
countries, such as central obesity, dyslipidemia, insulin resistance and hypertension 
(4) (Fig. 1).




Figure 1. The metabolic disorders that are clustered in the metabolic syndrome.
Since 1920 these disorders have been clustered and different names have been 
given such as syndrome X, insulin resistance syndrome, Reaven’s syndrome, and 
CHAOS (5). The presence of the metabolic syndrome is known to increase the risk 
for the development of type 2 diabetes (T2D) (6) and is highly predictive of new-onset 
T2D (7,8). In addition, the metabolic syndrome is associated with other diseases, 
including non-alcoholic fatty liver disease affecting up to a third of the population 
worldwide and has been shown to significantly enhance the risk of developing 
cardiovascular disease (9,10).
Although insulin resistance plays a crucial role in the pathogenesis of all of these 
disorders, its etiology is still poorly understood. There is growing evidence connecting 
obesity and its associated pathologies including non-alcoholic fatty liver disease 
(NAFLD) to the presence of a chronic low-grade inflammatory state (11,12). According 
to this commonly held view, inflammation leads to aberrant insulin receptor substrate 
(IRS) phosphorylation and reduced AKT phosphorylation, causing impaired glucose 
tolerance and insulin resistance. The liver is an important metabolic organ, which is 
affected by adiposity/obesity (13). The production of pro-inflammatory cytokines, by 
resident macrophages in the liver, contributes to hepatic inflammation and has been 
linked to disruption of (hepatic) insulin signaling (11). However, the contribution of 
hepatic inflammation to the etiology of fatty liver disease and insulin resistance is still 
elusive. This thesis describes the role of hepatic inflammation in the development of 




to develop novel therapies. This introduction aims to provide the background 
information on which the studies performed in this thesis are founded. 
The liver as a central organ
Already in the ancient times, the Greek physician Galen considered the liver as the 
most essential organ of the human body stating that the liver was “the principal organ 
of sanguifi cation” (14). Although the role of the liver was somewhat overstated by the 
ancient Greeks, it is now known that the liver is a major metabolic organ that plays 
a central role in whole body metabolism by its ability to metabolize carbohydrates, 
lipids and proteins (15). Its main functions are glycogen storage, decomposition of 
red blood cells, plasma protein synthesis, and hormone production (15). The liver 
also produces and secretes bile to support the digestion and uptake of lipids from the 
intestine (15). In addition, the liver has also a detoxifi cation function; it serves as a 
fi rst pass organ. About 30% of the total blood passes through the liver every minute 
(16). Moreover, the liver is an important part of the bodies immune response and is 
important in acute phase responses and innate immunity (17,18).
The liver is comprised of parenchymal cells, the hepatocytes (19,20), and a variety 
of non-parenchymal resident cells. These include Kupffer cells, endothelial cells, 
stellate cells and immune cells (17). Hepatocytes are the so-called “liver cells”, and 
represent approximately two thirds of the total cells in the liver (16). Hepatocytes 
perform critical metabolic, endocrine, and secretory functions, which includes 
the synthesis of carbohydrates, cholesterol, bile salts, fatty acids, triglycerides, 
phospholipids, and proteins (reviewed in (21)). In hepatocytes, free fatty acids (FFA) 
are converted to triglycerides (TG) or oxidized as fuel. Mitochondrial β-oxidation of 
FFA will produce both energy for the cell and ketone bodies that are used as fuel for 
the brain. Stellate cells are the main cellular source of extracellular matrix proteins 
in the liver and represent 5 to 8% of the total liver mass (22). Moreover, Kupffer 
cells and lymphocytes account for the bulk of immune cells in the liver. Lymphocyte 
subpopulations include the innate (natural killer (NK) and NKT cells) and adaptive 
immune systems (T and B cells) (16). NKT cells account for up to 30% of the total 
lymphocytes in the liver (reviewed in (23)). Finally, liver endothelial cells form a lining 
of the hepatic sinusoids and separate the sinusoid lumen from the hepatocyte. An 
important function of the endothelial cells is to free the bloodstream from a variety of 
macromolecular waste products by endocytosis (24).
NAFLD
Non-alcoholic fatty liver disease (NAFLD) is tightly associated with insulin resistance, 
affecting up to 90% of the obese population (25). Driven by the obesity-epidemic, 
NAFLD has become the main cause of chronic liver in Western countries. Although, 
NAFLD is considered to be the hepatic manifestation of the metabolic syndrome, 
NAFLD is a strong, independent predictor for the development of T2D (26). NAFLD 
describes a wide spectrum of liver disorders, including hepatic steatosis, non-
alcoholic steatohepatitis (NASH), advanced fi brosis, cirrhosis and ultimately liver 
cancer/failure (Fig. 2) (27,28).
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Figure 2. Histological pictures of a normal liver, a liver with NAFLD and NASH.
Figure 3. Metabolic defects leading to the development of hepatic steatosis. Hepatic steatosis 
arises from an imbalance between triglyceride (TG) acquisition and removal. Several 
mechanisms can lead to the development of hepatic steatosis. (Adapted from Postic et al, 
JCI 2008).
The hallmark of NAFLD is intrahepatic fat accumulation (steatosis) (29) and the 
accumulation of certain lipid species (e.g. diacylglycerol, long-chain acyl-CoA, 
ceramides) is thought to directly interfere with hepatic insulin signaling by inducing 
serine phosphorylation of IRS-1 (30). Hepatic steatosis arises from an imbalance 
between TG acquisition and removal (26). Causes of increased lipid content in 
hepatic steatosis may include 1) increased dietary fat associated with overeating or 
calorie dense foods that reach the liver as chylomicron particles from the intestine; 2) 
increased TG synthesis in the liver from fatty acids formed from de novo lipogenesis; 
3) excess fatty acid influx into the liver from lipolysis of adipose tissue in obese 
and insulin resistant states and subsequent conversion to TG; 4) diminished export 
of lipids from the liver in very-low-density lipoproteins (VLDL); and 5) reduced 




















Hepatic steatosis may have a macro- or micro-vesicular appearance depending on 
size and number of fat droplets within the hepatocyte (31). The diagnosis of steatosis 
is made when the lipid content in the liver exceeds the 95th percentile for lean, 
healthy individuals (i.e.,> 55 mg per g of liver) or if the presence of cytoplasmic TG 
droplets is more than 5% of hepatocytes (32,33). A preliminary diagnosis of NAFLD 
can be made in patients with elevated liver enzymes, although a defi nitive diagnosis 
can only be made by liver biopsy (34).
NASH
Hepatic steatosis can progress to non-alcoholic steatohepatitis (NASH), the more 
advanced stage of NAFLD (26). NASH was originally defi ned by Ludwig and colleagues 
as a condition indistinguishable by histology from alcoholic steatohepatitis, although 
most patients carried the hallmarks of obesity and the metabolic syndrome (35). About 
one-third of individuals with NAFLD who undergo liver biopsy, upon elevated levels 
of ALT/AST, have evidence of NASH (36). NASH can be distinguished from simple 
steatosis by the presence of hepatocyte injury including hepatocyte ballooning and 
cell death, an infl ammatory infi ltrate, and/or collagen deposition (fi brosis). It is not 
known whether steatosis always precedes NASH or whether infl ammation occurs 
independently of hepatic steatosis (26). However, the infl amed liver preludes further 
disease progression and allows for later stages of the disease to develop, such as 
liver fi brosis, cirrhosis and eventually liver failure or hepatocellular carcinoma (37,38). 
Moreover, the infl ammatory component in addition to steatosis carries a higher risk 
of cardiovascular disease and mortality than simple steatosis (39). Approximately 
25–30% of the patients with simple steatosis will develop NASH (40). In addition, 
20-30% of the NASH patients progresses to severe fi brosis within 10 years (36). 
Moreover, 10 to 29% of the individuals with NASH will develop cirrhosis within 10 
years (41). Cirrhosis can ultimately progress to liver cancer; 4 to 27% of individuals 
with NASH-induced cirrhosis develop hepatocellular carcinoma (42).
An increasing amount of evidence supports a central role for pro-infl ammatory 
cytokines, particularly TNF-α in the development of NASH (43). TNF-α levels are 
elevated in the liver and blood of patients with NASH, and inhibition of TNF-α by 
administration of recombinant TNF-α has been demonstrated to improve NAFLD in 
rodents (reviewed in (44)). Hepatic infl ammation in NASH has also been reported 
to induce hepatic and systemic insulin resistance (13), making NASH an important 
contributing factor to the development of T2D. The factors causing progression of 
NAFLD to fi brosis and cirrhosis have not been defi ned in humans, in part because of 
the relative inaccessibility of liver tissue thus impeding detailed studies.
Role of Kupffer cells in development of NASH
Kupffer cells were discovered in 1876 by Karl Wilhelm von Kupffer (45). Kupffer cells 
are now defi ned as specialized tissue macrophages in the hepatic sinusoid and are 
derived from circulating monocytes that arise from bone marrow progenitors (46). It 
has been calculated that up to 50% of the circulating monocytes are destined for the 
liver (47). Kupffer cells represent 10-15% of the total liver cell population (24), and 
comprise of 80-90% of all tissue macrophages in the body (48). Kupffer cells are 
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responsible for the rapid repression and clearance of exogenous particulates and 
immunoreactive materials that are perceived by the body to be foreign and harmful 
(24). Like other macrophages, Kupffer cells sense endogenous molecular signals 
that may result from the perturbed homeostasis of the host. Activated Kupffer cells 
are able to: 1) initiate interactions with hepatocytes and other liver cells through the 
release of active mediators, including cytokines, chemokines, eicosanoids, proteolytic 
enzymes, reactive oxygen species and nitric oxide; 2) recruit and retain neutrophils 
and NK T lymphocytes, NK cells and blood monocyte-derived macrophages; 3) 
engulf, ingest and eliminate solid particles, including micro-organisms, apoptotic 
cells and cellular debris; and 4) process and present antigens to attract cytotoxic 
and regulatory T cells, thereby contributing to adaptive immunity (16,17,24,49,50). 
All of these functions need to be rigorously controlled to avoid escalation of the 
inflammatory response. Therefore, Kupffer cells have been thought to contribute 
to the pathogenesis of many different kinds of liver injury (51,52). In addition, the 
production of pro-inflammatory cytokines secreted by Kupffer cells in the liver is 
linked to disruption of hepatic insulin signaling (11). Indeed, Kupffer cell activation 
upon high fat feeding has been linked to NASH and the development of hepatic 
insulin resistance (53,54). Therefore, inflammation and hepatic insulin resistance 
can be exacerbated through the release of locally acting cytokines by activated 
Kupffer cells (55,56).
Therapy
Given the close relationship between obesity, the metabolic syndrome and NAFLD, 
treatment of NASH is mainly aimed to target several parameters of the metabolic 
syndrome, such as obesity, hyperlipidemia and insulin resistance. Steatosis itself 
is generally considered a rather benign and reversible condition (4). However, the 
presence of inflammation in a fatty liver represents an irreversible step and has a 
poor prognosis (4). Despite the rapidly growing recognition of NAFLD/NASH over 
the past decade, therapy directed at treating or preventing the disease remains 
limited to weight loss.
Simple lifestyle modifications, such as body weight management and regular 
physical exercise are the primary therapy options for patients with the metabolic 
syndrome (6). Weight loss has been shown to reduce steatosis (57). However, its 
effect on inflammation and fibrosis, is still unclear (58,59). In line with this, bariatric 
surgery, which alleviates NAFLD (60), is associated with increased insulin sensitivity 
in human patients (61). The quick improvement of insulin resistance after bariatric 
surgery may be due to decreased intrahepatic fat accumulation in response to 
caloric restriction (62,63). This suggests that targeting NAFLD and NASH may be an 
attractive strategy to improve insulin resistance and T2D.
In addition to lifestyle changes and bariatric surgery, current therapies used for 
NASH include insulin sensitizers such as metformin and thiazolidinediones (TZDs). 
The primary mode of action of TZDs is through binding and activation of the nuclear 
receptor PPAR-γ to improve insulin sensitivity (64,65). Unfortunately, discontinuation 
of TZDs treatment after 48 weeks abolishes the therapeutic effects on NASH, resulting 
in increased liver fat, inflammation, and aggravation of histopathological scores 




muscle glucose uptake and metabolism (68). Given the fact that hypertriglyceridemia 
and low HDL levels are defi ning elements of the metabolic syndrome, lipid-lowering 
agents are also possible candidates for NASH treatment. For example, statins and 
fi brates, or a combination of the two, are considered to be good treatment options 
for NASH. Fibrates are ligands of PPAR-α and are an effective therapy promoting 
lipid oxidation, lowering serum TG levels, and increasing serum HDL by stimulating 
lipoprotein lipase and regulating apolipoprotein expression (69,70). Statins lower 
serum lipid concentrations by inhibiting HMG-CoA reductase, the key enzyme in 
cholesterol biosynthesis (71). However, the use of lipid-lowering drugs is controversial 
because of their potential hepatotoxicity in patients with underlying hepatic disease 
(reviewed in (72)).
As none of the above treatments have shown convincing benefi ts, new therapy 
options should be considered. At the moment liver transplantation remains the only 
curative treatment for end-stage liver failure.
The role of adipose tissue and systemic infl ammation in the 
etiology of insulin resistance
As early as the 1950s and 1960s, studies have suggested an association between 
infl ammation, T2D and obesity, but the mechanistic links were unknown. Obese 
subjects were found to have elevated circulating concentrations of systemic 
markers of infl ammation including fi brinogen and acute-phase reactants (73,74). 
However, these fi ndings failed to infl uence thoughts about the pathogenesis of 
T2D. Experiments with the adipose tissue-derived pro-infl ammatory cytokine TNF-α 
showed that TNF-α was able to induce insulin resistance (75). In the last decades, 
it has become increasingly clear that obesity and the concomitant development 
of infl ammation are major players in the etiology of insulin resistance. It was a 
groundbreaking idea that a cytokine, which was produced by the adipose tissue, 
had not only local but also systemic effects on metabolism. It did not take long 
before other cytokines and bioactive substances produced by the adipose tissue 
were discovered, which include leptin, IL-6, resistin, and monocyte chemoattractant 
protein-1 (MCP-1) (76,77).
As part of the chronic infl ammatory process, locally secreted chemokines attract 
pro-infl ammatory macrophages into the adipose tissue where they form crown-like 
structures around dead or dying adipocytes. These tissue macrophages then release 
cytokines that further activate the infl ammatory program in neighboring adipocytes, 
thereby exacerbating infl ammation and insulin resistance. A major mechanistic 
breakthrough into the understanding of how obesity and infl ammation are connected 
was by the discovery of adipose tissue being infi ltrated with increased numbers of 
macrophages in obese mice and humans (78). Pharmacological or genetic inhibition 
of pathways that are involved in the infl ammatory response have been found to 
protect experimental animals and humans from diet-induced insulin resistance 
(56,79). Two transcription factor-signaling pathways have been linked to the pro-
infl ammatory effects of obesity and insulin resistance: the NF-κB pathway, which 
is activated by inhibitor of NF-κB (IκB) kinase β (IKKβ), and the c-Jun NH2-terminal 
kinase (JNK) pathway. Genetic disruption of NF-κB and JNK signaling pathways has 
been shown to protect against insulin resistance.
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Cross-talk and insulin resistance
In obese subjects and rodent models of obesity and T2D, inflammation and 
insulin resistance does not remain restricted to the adipose tissue. Also the liver 
and skeletal muscle are affected (Fig. 4). Upon obesity, the hepatic inflammatory 
pathway can be activated by steatosis and/or the increased hepatocyte stress 
pathway responses. Obesity overloads the functional capacity of the endoplasmic 
reticulum (ER), triggering intracellular ER stress. Moreover, ER stress leads to the 
activation of inflammatory signaling pathways and contributes to the development 
of insulin resistance (80,81). Moreover, Kupffer cells are activated and lead to the 
production of locally acting cytokines, which further exacerbate inflammation and 
hepatic insulin resistance (reviewed in (82)). In skeletal muscle, obesity results in 
increased FFA uptake and also the activation and recruitment of macrophages and 
eventually leading to the development of skeletal muscle insulin resistance.
Obesity 
IR IR IR 
Systemic inflammation  
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•Increased lipid content 
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Figure 4. Obesity and the development of inflammation and insulin resistance. Obesity-
induced changes in different metabolic organs resulting in localized inflammation and insulin 
resistance. Endocrine-mediated cross-talk between insulin target tissues contributes to insulin 
resistance in distant tissues. Systemic inflammation and insulin resistance are the net effect of 
these changes. (Adapted from de Luca et al, FEBS Letters 2008).
It is known that obesity-induced adipose tissue inflammation has an effect on liver 
metabolism and insulin resistance (83,84). Activated adipose tissue macrophages 
secrete different cytokines that can leak out of the tissue, resulting in raised circulating 
levels and produce endocrine effects on distant organs, such as the liver and skeletal 
muscle, eventually leading to exacerbation of systemic insulin resistance (reviewed 
in (82)). However, it has been suggested that cross-talk between the adipose tissue 
and liver is bidirectional. Of note, the liver produces and secretes cytokines (i.e., 




other organs through endocrine effects (85,86). In line with this, Kupffer cell depletion 
studies have been shown to prevent hepatic insulin resistance, but also protects 
against adiposity, adipose tissue infl ammation and whole-body insulin resistance 
induced by a HFD (87). Therefore, it has been suggested that endocrine-mediated 
cross-talk between insulin target tissues contributes to insulin resistance in distant 
tissues. Further studies are needed to decipher the communication between the 
metabolic active tissues to assess the role of obesity-induced infl ammation and 
the development of insulin resistance. Recent data showed that increased hepatic 
and skeletal muscle infl ammation only became apparent after establishment of 
obesity (88). In line with this, obesity is a confounding factor in the development 
of infl ammation–induced insulin resistance, making it diffi cult to assess inter-organ 
effects.
Moreover, cell-cell interactions are also important in the development of obesity-
induced insulin resistance. One study showed that deletion of IKKβ in the hepatocytes 
resulted in insulin sensitivity in the liver; however these mice became insulin 
resistant in muscle and adipose tissue. In contrast, deletion of IKKβ in myeloid cells 
led to a global improvement in insulin sensitivity. Therefore, it has been suggested 
that myeloid cells are responsible for the major form of cross-talk between insulin-
responsive tissues involving pro-infl ammatory cytokines (89). More studies should 
be performed assessing the role of different cell types in the development of obesity-
induced insulin resistance.
Study objectives
Considerable evidence now points towards a crucial role for infl ammation as a causal 
factor in obesity-induced insulin resistance and T2D (reviewed in (85)). Mouse 
models show that in the absence of other confounding factors, hepatic infl ammation 
alone is suffi cient to cause hepatic and systemic insulin resistance (13). However, 
the exact role of hepatic infl ammation and the involvement of Kupffer cells in the 
development of insulin resistance remains to be elucidated. In this thesis, we used 
3 different mouse models, i.e., Ldlr-/- mice, Myd88-/- mice, and Csf1op/+ mice (Fig. 5) 
to investigate the role of hepatic infl ammation in the etiology of NAFLD and insulin 
resistance. The models and specifi c hypotheses that will be tested are described 
below.
(1) Low-density lipoprotein receptor (Ldlr knock out mouse 
model)
Mice defi cient for the low-density lipoprotein receptor (Ldlr-/-) (90) exhibit many 
features of the metabolic syndrome when fed a western style or diabetogenic diet, 
including obesity, insulin resistance, dyslipidemia, infl ammation and atherosclerosis 
(91,92). When triggered with a high-fat cholesterol (HFC) diet (21% milk butter, 0.2% 
cholesterol), Ldlr-/- mice also display many features of human NAFLD, including 
NASH (93,94). This is in contrast to C57BL/6 mice that develop hepatic steatosis 
and insulin resistance without further progression towards NASH (95).
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The function of the LDL receptor (LDLR) is clearing of LDL and lipoprotein remnants 
containing ApoE and ApoB (96,97). Moreover, the LDLR is thought to play a role 
in regulating hepatic lipoprotein production (98). Deletion of the LDLR would lead 
to elevated levels of LDL. In humans, mutations in the LDL receptor leads to one 
of the most severe forms of human hyperlipidemia, familial hypercholesterolemia, 
causing elevated levels of the atherogenic lipoprotein LDL and atherosclerosis (90). 
Notably, Ldlr-/- mice are hyperlipidemic and show a lipoprotein profi le resembling 
dyslipidemia in human obesity and T2D. Whereas, Ldlr-/- mice develop moderate 
hypercholesterolemia on a chow diet, on a high-fat/high-cholesterol diet Ldlr-/- mice 
rapidly develop severe hyperlipidemia and extensive atherosclerosis (90).
Although Ldlr-/- mice are now a well established model to study NASH (93,94,99), it 
is not known what the metabolic consequences are in terms of insulin resistance. 
Therefore, we aimed to unravel the extent to which hepatic infl ammation contributes 
to the development of hepatic and systemic insulin resistance in the absence and 
presence of obesity using hyperlipidemic Ldlr-/- mice (Chapter 2).
(2) Myeloid differentiation factor response gene 88 (Myd88)
Toll-like receptors (TLRs) are potential “sensors” that may link obesity to infl ammation 
and insulin resistance. Myeloid differentiation primary response gene 88 (Myd88) is 
a key intracellular adaptor protein in the TLR and IL-1 signaling cascade linked to 
NASH and insulin resistance (100-104). Since both TLR and IL-1 signal through 
Myd88 to activate NF-κB, it is likely that Myd88 plays an essential role in the 
pathogenesis of NAFLD/NASH and insulin resistance.
TLRs are part of a family of pattern-recognition receptors (PRRs) that detect 
microbial components and activate the immune system, providing a fi rst line of host 
Figure 5. The different mouse models used in this thesis. 1) Ldlr-/- mouse; 2) Myd88-/- mouse; 
and 3) Csf1op/+ mouse. Deletion of the LDLR leads to enhanced hepatic infl ammation and 
NASH. Myd88-/- mice show reduced NF-κB-mediated infl ammation. Heterozygous mice 
defi cient for CSF1 (Csf1op/+ mice) exhibit reduced infl ammation. 
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defense against infections (105-107). Each TLR recognizes different pathogens 
(viruses, bacteria, fungi, parasites) via PAMPs (pathogen-associated molecular 
patterns) and initiate the immune response. TLR2 and TLR4, have an important role 
in infl ammation associated with both atherosclerosis and insulin resistance (108). 
TLRs signal via various adaptor molecules, including Myd88 (106,107). Mice defi cient 
for Myd88 have previously been show to be protected against the development of 
atherosclerosis (109) and therefore represents a good model to study the role of 
Myd88 on the development of NAFLD and insulin resistance. Furthermore, we will 
investigate the contribution of hematopoietic-cell-derived Myd88 on the development 
of obesity-induced infl ammation and insulin resistance (Chapter 3).
(3) Macrophage colony stimulating factor (MCSF)/Osteopetrotic 
(Op)
Mice which are insuffi cient for colony-stimulating factor 1 (Csf1) have impaired 
macrophage development. Therefore this model is ideally suited to investigate the 
role of macrophages in NAFLD and insulin resistance.
The colony-stimulating factors (CSFs) are a family of cytokine growth factors 
originally identifi ed by their ability to support the proliferation and differentiation 
of hematopoietic progenitor stem cells into mature monocytes/macrophages and 
granulocytes (110). The CSF family comprises of macrophage CSF (M-CSF or 
CSF-1), granulocyte-macrophage CSF (GM-CSF or CSF-2), and granulocyte CSF 
(G-CSF or CSF-3). M-CSF functions as a chemotactic factor for monocytes, regulates 
the effector functions of mature monocytes and macrophages, and modulates the 
infl ammatory responses by stimulating the production of other cytokines and growth 
factors (111).
Osteopetrotic (op/op) mice lack M-CSF due to a point mutation (thymidine insertion) 
in the coding region of the M-CSF gene (112). Lack of M-CSF in op/op mice results 
in impaired growth and differentiation of monocytes and their precursors in bone 
marrow (112,113). Homozygous mice insuffi cient for Csf1 (Csf1op/op) show a severe 
defi ciency of osteoclasts, resulting in impaired bone remodeling, skeletal deformities 
(domed skulls), and absence of teeth, impairing consumption of solid food (114). 
Chronic injection of recombinant M-CSF partially corrects the phenotypic defects in 
Csf1op/op mice (115). In contrast to Csf1op/op mice, heterozygous mice insuffi cient for 
Csf1 (Csf1op/+ mice) do not exhibit growth or skeletal defects and do not lack teeth 
making dietary intervention studies and obesity research possible (114,116). CSF-
1 has been shown to play an important role in chronic diseases and infl ammatory 
disease states, including atherosclerosis (111,117,118). Therefore, Csf1 insuffi cient 
mice allow us to study the hypothesis that macrophages via Csf1 regulation contribute 




Glycosphingolipids (GSLs) are known to be involved in the development of 
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insulin resistance (119,120). Moreover, it has been demonstrated that inhibitors of 
glucosylceramide (GlcCer) synthase lead to inhibition of GSL biosynthesis (121). 
Furthermore, these GlcCer synthase inhibitors have been shown to hold great promise 
as novel therapeutics in metabolic disease. N-(5-adamantane-1-yl-methoxy-pentyl)-
deoxynojirimycin (AMP-DNM), an inhibitor of GlcCer synthase, improved glucose 
tolerance and enhanced insulin signaling in rodent models of type 2 diabetes (122-
124). Moreover, AMP-DNM-treated mice exhibited improved adipocyte function, 
reduced adipose tissue and liver inflammation and diminished and corrected hepatic 
steatosis (123-126). Since food intake is reduced in AMP-DNM-treated animals, we 
assessed the role of AMP-DNM as a caloric restriction mimetic and the therapeutic 
potential of AMP-DNM in metabolic disease (Chapter 5).
Finally, in Chapter 6 we will discuss the major findings of this thesis, place them in 
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Objective It is generally assumed that hepatic inflammation in obesity is linked to the 
pathogenesis of insulin resistance. Several recent studies have shed doubt on this 
view, which questions the causality of this association. This study focuses on Kupffer 
cell-mediated hepatic inflammation as a possible driver of insulin resistance in the 
absence and presence of obesity.
Methods We used male mice deficient for the low-density lipoprotein receptor 
(Ldlr-/-) and susceptible to cholesterol-induced hepatic inflammation. Whole body 
and hepatic insulin resistance was measured in mice fed 4 diets for 2 and 15 weeks, 
i.e., chow, high-fat (HF), HF-cholesterol (HFC; 0.2% cholesterol) and HF without 
cholesterol (HFnC). Biochemical parameters in plasma and liver were measured and 
inflammation was determined using immunohistochemistry and RT-PCR.
Results At 2 weeks, we did not find significant metabolic effects in either diet group, 
except for the mice fed a HFC diet which showed pronounced hepatic inflammation 
(p<0.05) but normal insulin sensitivity. At 15 weeks, a significant increase in insulin 
levels, HOMA-IR, and hepatic insulin resistance was observed in mice fed a HFC, 
HFnC, and HF diet compared to chow-fed mice (p<0.05). Regardless of the level of 
hepatic inflammation (HFC > HF, HFnC; p<0.05) insulin resistance in mice fed HFC 
was no worse compared to mice on a HFnC and HF diet.
Conclusion These data show that cholesterol-induced hepatic inflammation does 
not contribute to the development of insulin resistance in male Ldlr-/- mice. This 
study suggests that Kupffer cell-driven hepatic inflammation is a consequence, not a 
cause, of metabolic dysfunction in obesity.




Chronic infl ammation, particularly when it occurs in metabolically important organs 
such as the liver and adipose tissue, is considered to play a crucial role in the etiology of 
many metabolic diseases, including type 2 diabetes, non-alcoholic fatty liver disease 
(NAFLD) and cardiovascular disease (1,2). As in adipose tissue, obesity leads to 
an increase in pro-infl ammatory gene expression in the liver (3). Pro-infl ammatory 
pathways in Kupffer cells are activated in obesity and the production of infl ammatory 
cytokines secreted by these liver macrophages is linked to disruption of hepatic 
insulin signaling and reduced insulin sensitivity in mice (2-4). For instance, LIKK mice 
with hepatocyte specifi c expression of the IκB kinase β (IKKβ), an upstream kinase 
that activates NF-κB, a master regulator of infl ammation, exhibit profound hepatic 
insulin resistance with moderate systemic insulin resistance (3). In line with this, 
mice lacking IKKβ in hepatocytes retain liver insulin sensitivity in response to high-fat 
feeding, obesity or aging (5). Although these and many other studies suggest that 
insulin resistance is causally linked to hepatic infl ammation (3,5,6), recent studies 
show a disconnection between insulin resistance and hepatic infl ammation (7-11). 
Moreover, obesity is a confounding factor in most studies making it diffi cult to dissect 
the role of hepatic infl ammation in the development of insulin resistance.
As Kupffer cells have been studied less extensively than adipose tissue macrophages 
in the context of obesity and insulin resistance (12) and Kupffer cell depletion studies 
have shown controversial fi ndings (8,13-15), we aimed to study the role of Kupffer 
cell-driven hepatic infl ammation in the development of insulin resistance in the onset 
and presence of obesity. We used mice defi cient for the low-density lipoprotein 
receptor (Ldlr-/-) (16), a humanized mouse model exhibiting many features of the 
metabolic syndrome when fed a western style or diabetogenic diet, including obesity, 
insulin resistance, dyslipidemia, infl ammation and atherosclerosis (17,18). When 
triggered with low levels of cholesterol (0.15-0.2%), Ldlr-/- mice also display many 
features of human NAFLD, including Kupffer cell-driven hepatic infl ammation (19-
21). This is in contrast to C57BL/6 mice that develop hepatic steatosis and insulin 
resistance without hepatic infl ammation and further progression towards non-
alcoholic steatohepatitis (22). Importantly, we have previously shown that dietary 
cholesterol can provoke hepatic infl ammation within 7 days, in the absence of obesity 
(21), thereby serving as an attractive model to unravel the role of Kupffer cell-driven 
hepatic infl ammation in the development of insulin resistance.
 Materials and methods
Mice and Diet Intervention. All procedures were performed with approval of the 
University of Groningen Ethical Committee for Animal Experiments, which adheres 
to the principles and guidelines established by the European Convention for the 
Protection of Laboratory Animals. Experiments were carried out on male Ldlr-/- mice 
(Jackson Laboratory, Bar Harbor, USA, ME), housed individually in a temperature- 
and light-controlled facility with ad libitum access to food and water.
At the age of 8-10 weeks, mice were divided into 4 groups of 6-8 mice: (1) mice fed 
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chow diet (2181, RMH-B, Hope Farms, Woerden, the Netherlands); (2) mice fed a 
high-fat-diet containing 36% (w/w) fat from lard and 0.03% (w/w) cholesterol (HF; 
diet 4031.45, Abdiets, Woerden, the Netherlands.); (3) mice fed HF-diet containing 
21% milk butter and 0.2% cholesterol (HFC; diet 0035, Scientific Animal Food and 
Engineering, Villemoisson-sur-orge, France); and (4) mice fed HF-diet containing 
21% milk butter and 0% cholesterol (HFnC; diet 0136, Scientific Animal Food and 
Engineering, Villemoisson-sur-orge, France). Mice were kept on these diets for 2 
and 15 weeks and experiments were carried out simultaneously using diets from the 
same batch number. After 2 and 15 weeks animals were killed for the collection of 
blood, liver and muscle samples.
Dual-Energy X-ray Absorptiometry (DEXA) scan analysis. Fat and lean mass was 
determined in the same mice at 2 and 15 weeks following dietary intervention using 
Dual-Energy X-ray Absorptiometry (p-DEXA, Norland Stratec Medizintechnik GmbH, 
Birkenfeld, Germany). Mice were scanned under fed conditions while anesthesized 
using isoflurane and data was analyzed according to the manufacturer’s instructions.
Oral Glucose Tolerance Test. Mice were fasted for 9 hours and a glucose bolus 
(2 g/kg of 20% glucose solution) was given by oral gavage. Glucose levels were 
measured with an OneTouch Ultra glucometer (Lifescan Benelux, Beerse, Belgium) 
before and 15, 30, 60, 90, and 120 minutes after the gavage.
Insulin Signalling Studies in vivo. The mice were fasted overnight and subjected 
to an intraperitoneal injection with saline or human recombinant insulin (0.75 U/kg 
body weight, Actrapid, Novo Nordisk Canada inc., Ontario, Canada) 15 minutes 
before killing. Tissues were isolated and snap-frozen in liquid nitrogen.
Analysis of plasma parameters. Insulin was determined in plasma from overnight 
fasted mice using the Mercodia ultrasensitive mouse insulin-linked immunosorbent 
assay (Orange Medica, Tilburg, the Netherlands). NEFA, triglycerides (TG), and 
total cholesterol (TC) were determined by commercially available kits (NEFA: NEFA-
HR, Wako Chemicals GmbH, Neuss, Germany; TG: Hitachi, Roche, Woerden, the 
Netherlands; TC: cholesterol CHOD-PAP, Roche, Woerden, the Netherlands).
Liver Lipids. Total liver lipids were extracted according to Bligh and Dyer (23). 
Total cholesterol and triglycerides were quantified using commercially available 
kits (Cholesterol CHOD-PAP, Roche, Woerden, the Netherlands and Triglycerides 
Hitachi, Roche, Woerden, the Netherlands), respectively.
Liver Histology. Paraffin embedded sections of the liver (4 μm) were stained with 
Hematoxillin/Eosin (H/E). Frozen-cut liver sections (5 μm) were fixated in liquid 
nitrogen and stained with antibodies against Cd68 (FA11, Abcam, Cambridge, UK), 
to detect activated hepatic macrophages and Kupffer cells (24), and Cd11b (M1/70, 
Abcam, Cambridge, UK) to identify monocytes/macrophages including Cd11b+ 
Kupffer cells with cytokine-producing capacity (24). Microscopy was performed with 
a Leica DM 3000 microscope with a DFC420 camera (Leica Microsystems, Rijswijk, 
the Netherlands). The slides where scanned with a NanoZoomer 2.0-HT slide 
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scanner (Hamamatsu, Herrsching am Ammersee, Germany) and analyzed using 
Imagescope software (Aperio, Vista, USA).
RT-PCR. Total RNA was isolated from the liver with TRIzol reagent (Sigma 
Alderich, Zwijndrecht, the Netherlands) and total RNA (1 μg) from each individual 
mouse was converted into cDNA with Quantitect Reverse Transcription kit 
(QIAGEN, Venlo, the Netherlands). Real time PCR (RT-PCR) was performed 
using a 7900HT system (Applied Biosystems, Warrington, UK) and values were 
corrected using the housekeeping gene Cyclophillin A (Ppia). The following 
primers were used: Mcp-1 forward GCTGGAGAGCTACAAGAGGATCA, 
reverse ACAGACCTCTCTCTTGAGCTTGGT; Cmklr1, forward 
AACAGCCACTACCAGAACAAC, reverse CGTGACTGGAAATACCTTCTC; 
Tnf-α, forward CATCTTCTCAAAATTCGAGTGACAA, reverse 
TGGGAGTAGACAAGGTACAACCC and Il-1β, forward 
TGCAGCTGGAGAGTGTGG, reverse TGCTTGTGAGGTGCTGATG; Ppia forward 
TTCCTCCTTTCACAGAATTATTCCA, reverse CCGCCAGTGCCATTATGG.
Immunoblot Analysis. Tissues were homogenized in ice-cold buffer (liver: NaCl 150 
mM, Tris-HCl pH 7.5 50 mM, EDTA 5 mM, Pyrophophate 30 mM, NaF 50 mM, Triton 
X-100, PMSF 100 mM, phosphatase inhibitor cocktails; skeletal muscle: as shown 
previously (25)). Equal amounts of protein were separated by SDS-PAGE, and 
transferred to Polyvinylidene Difl uoride membranes (GE Healthcare Life Sciences, 
Diegem, Belgium). Phosphorylated and total AKT antibodies were purchased from 
Cell Signaling Technology (Leiden, the Netherlands). Immune-complexes were 
visualized by chemiluminescence (GE Healthcare Life Sciences, Diegem, Belgium) 
and quantifi ed by densitometry (imageJ software, National Institute of Health).
Statistical Analysis. Data are expressed as means ± SEM for the indicated number 
of observations. Statistical signifi cance between groups was determined using a 
two-tailed Mann-Whitney U test. Multiple comparison analysis was performed using 
two-way ANOVA with a Bonferroni post hoc test to correct for multiple testing. Two-
way ANOVA for repeated measurements was used to test for comparisons in body 
weight and fat mass between the 2- and 15-week time points. Values of p<0.05 were 
considered statistically signifi cant. The software used for the analysis was GraphPad 
Prism (version 5.00 for Windows, GraphPad Software, San Diego, CA, USA).
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Figure 1. Dietary cholesterol triggers Kupffer cell activation. (A) Representative pictures of 
Cd68 staining and morphometric analysis of Cd68 stained liver sections from Ldlr-/- mice fed 
a chow, HF, HFC or HFnC diet for 2 and 15 weeks. Original magnification x 200. Kupffer 
cells are indicated with arrows. (B) RT-PCR analysis of hepatic Mcp-1 and Cmklr1 mRNA 
expression. Data is expressed as fold induction versus 2-week chow-fed Ldlr-/- mice. Data are 
expressed as means ± SEM, n = 6 in each group. * P<0.05 vs chow-fed mice (Mann-Whitney 
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Results
Dietary cholesterol triggers Kupffer cell activation.
To confirm Kupffer cell involvement following cholesterol supplementation to the diet, 
immunostaining against Cd68 and Cd11b was performed in liver sections of Ldlr-/- 
mice fed chow, HF, HFC and HFnC diet for 2 and 15 weeks. Indeed, macrophage 
size and number (Fig. 1A) was significantly increased in the livers of 2-week HFC-
fed mice when compared to mice fed chow, HF and HFnC diet (p<0.05, ANOVA). 
Consistent with this, the number of Cd11b+-macrophages was significantly increased 
in Ldlr-/- mice after 2 weeks of HFC feeding when compared to mice fed chow, HF and 
HFnC diet (Supplemental Fig. 1; p<0.05, ANOVA). Consistent with this, HFC feeding 
resulted in a concomitant increase in the expression level of monocyte chemotactic 
protein-1 (Mcp-1, Fig. 1B) and chemokine-like receptor 1 (Cmklr1, Fig. 1B; p<0.05 
vs chow, HF, HFnC, ANOVA), genes known to be involved in monocyte/macrophage 
migration and infiltration (12,26).
Similar to 2 weeks of HFC feeding, feeding mice a HFC diet for 15 weeks resulted in 
a marked increase in Kupffer cell size and number (Fig. 1A), and Cd11b cell count 
(Supplemental Fig. 1) when compared to mice fed chow, HF and HFnC diet for 15 
weeks (p<0.05, ANOVA). In addition, Kupffer cell number was significantly enhanced 
in liver sections of Ldlr-/- mice subjected to 15 weeks of HFC feeding compared to 2 
weeks of HFC feeding (Fig. 1A). However, the number of Cd11b+-macrophages in 
liver sections of Ldlr-/- mice fed a HFC diet did not change overtime (Supplemental 
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Figure 2. Kupffer cell-mediated hepatic infl ammation is sustained after long-term HFC feeding 
in Ldlr-/- mice. (A) RT-PCR analysis of Tnf-α and (B) Il-1β mRNA expression in livers from 
Ldlr-/- mice fed a chow, HF, HFC or HFnC diet for 2 and 15 weeks. Data is expressed as fold 
induction versus 2-week chow-fed Ldlr-/- mice. Data are expressed as means ± SEM, n = 6 in 
each group. * P<0.05 vs chow-fed mice (Mann-Whitney U Test); # P<0.05 2- vs 15-week diet 
period (two-way ANOVA). 
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Fig. 1). Furthermore, hepatic Mcp-1 and Cmklr1 levels were increased in 15-week 
HFC-fed mice compared to 2-week HFC-fed mice (Fig. 1B). 15 week s of high-fat 
feeding with low levels of cholesterol (HF, HFnC) also led to a signifi cant increase 
in both Mcp-1 and Cmklr1 expression compared to chow-fed Ldlr-/- mice (Fig. 1B). 
However, this increase was relatively small compared to mice fed a HFC diet for 15 
weeks (Mcp-1, HF vs HFC p<0.01; HFnC vs HFC p<0.01; Cmklr, HF vs HFC p<0.01; 
HFnC vs HFC p<0.01).
Hepatic infl ammation is sustained after long-term HFC feeding in 
Ldlr-/- mice.
To assess whether enhanced Kupffer cell activation translates into increased hepatic 
infl ammation, we performed gene expression analysis for the infl ammatory mediators 
Tnf-α and Il-1β in the livers of Ldlr-/- mice at both time points. The expression of 
these genes was signifi cantly increased in Ldlr-/- mice fed a HFC diet for 2 weeks 
when compared to mice fed chow, HF and HFnC diet (Fig. 2A, B; p<0.05, ANOVA). 
Mice fed a HF diet containing 0.03% cholesterol also showed a signifi cant up 
regulation of these genes above chow levels (Fig. 2A, B), but this was only modest 
compared to HFC-fed mice (Tnf-α, HF vs HFC p<0.01; Il-1β, HF vs HFC p<0.01). 
Moreover, hepatic infl ammation was absent in the mice fed a HFnC diet for 2 weeks, 
highlighting the specifi city of our cholesterol supplementation model in inducing 
hepatic infl ammation.
In addition, 15 weeks of HFC feeding led to a similar signifi cant increase in 
infl ammatory gene expression compared to 2 weeks of HFC feeding (Fig. 2A, B). 
However, it did not further increase the levels of these genes above the 2-week time 
point. 15 weeks of HF-feeding also led to signifi cant increase in hepatic infl ammation, 
albeit less pronounced compared to HFC feeding (Tnf-α, HF vs HFC p<0.01; Il-1β, 
HF vs HFC p<0.05). Similar results were obtained for 15 weeks of HFnC feeding 




Figure 3. Dietary cholesterol does not lead to overt changes in adiposity in Ldlr-/- mice. (A) 
Body weight of Ldlr-/- mice fed a chow, HF, HFC or HFnC diet for 2 (n = 12 in each group) 
and 15 weeks (n = 12 in each group). (B) Fat mass was determined by DEXA scan analysis 
(n = 6 in each group). Data are expressed as means ± SEM. * P<0.05 vs chow-fed mice 
(Mann-Whitney U Test); # P<0.05 2- vs 15-week diet period (two-way ANOVA for repeated 
measurements).
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Dietary cholesterol does not lead to overt changes in adiposity in 
Ldlr-/- mice.
As body weight adversely affects insulin sensitivity, Ldlr-/- mice were subjected to 
DEXA scan analysis to determine fat mass at the end of the 2- and 15-week diet 
period. After 2 weeks, body weight (Fig. 3A) and fat mass (Fig. 3B) did not differ 
significantly amongst the 4 diet groups. At the end of the 15-week diet period body 
weight (Fig. 3A) and fat mass (Fig. 3B) were significantly increased in mice fed a 
HFC and HF diet compared to the 15-week chow controls and the respective 2-week 
time points (Fig. 3A, B). However, body weight was lower in 15-week HFC-fed mice 
compared to HF-fed mice (p<0.05), although fat mass did not differ significantly 
between these groups (Fig. 3B; HFC vs HF p=0.20). In addition, body weight was 
significantly lower in HFnC-fed mice compared to both HFC- and HF-fed mice (Fig. 
3A; HFnC vs HFC p<0.05; HFnC vs HF p<0.01). Plasma and liver cholesterol levels 
were increased in Ldlr-/- mice fed a HFC, HF and HFnC diet compared to chow-fed 
mice at either time point (Supplemental Table 1, 2). In addition, plasma and liver 
cholesterol levels were markedly increased in HFC-fed mice compared to mice fed 
HFnC and HF diet. Plasma triglycerides (TG) were elevated in all mice following 
HF feeding at 2 and 15 weeks compared to chow controls and no differences were 
observed between HFC-, HFnC- and HF-fed mice at both time points (Supplemental 
Table 1, 2). Furthermore, hepatic TG levels were significantly increased in mice fed 
a HFC, HF and HFnC diet compared to chow-fed mice at the 2-week time point 
(Supplemental Table 1) and did not differ at the 15-week time point (Supplemental 
Table 2).
Hepatic inflammation does not induce insulin resistance in lean Ldlr-/- 
mice.
To investigate whether hepatic inflammation may affect glucose metabolism, we 
assessed glucose tolerance, plasma insulin levels, and the calculated HOMA-IR 
index as markers of insulin resistance. At 2 weeks, Ldlr-/- mice fed a HFC diet did 
not exhibit elevated fasted insulin levels compared to mice fed a HF and HFnC diet 
(Fig. 4A) nor was their glucose tolerance negatively affected (Fig. 4B). Consistent 
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Figure 4. Hepatic infl ammation does not induce insulin resistance in lean Ldlr-/- mice. (A) 
Plasma insulin levels in Ldlr-/- mice fed a chow, HF, HFC or HFnC diet for 2 weeks (n = 6 in 
each group). (B) Blood glucose levels during an oral glucose tolerance test (n = 6 in each 
group). (C) HOMA-IR as a surrogate marker of insulin resistance (n = 6 in each group). (D) 
Western blot analysis of phosphorylated and total AKT in skeletal muscle and liver after an 
insulin injection (n = 8 in each group). * P<0.05 vs chow-fed mice (Mann-Whitney U Test). 
Data are expressed as means ± SEM. 
with this, HOMA-IR was not signifi cantly increased in the mice fed a HFC diet (Fig. 
4C) compared to chow-, HF-, or HFnC-fed mice, suggesting that cholesterol-induced 
hepatic infl ammation does not induce the development of systemic insulin resistance. 
In addition, no differences were observed in phosphorylation status of AKT in either 
skeletal muscle or liver (Fig. 4D) in the Ldlr-/- mice fed a HFC diet compared to 
chow-, HF-, or HFnC-fed mice, suggesting that insulin signalling in these metabolically 
active tissues was not impaired.
Hepatic infl ammation does not aggravate insulin resistance in obese 
Ldlr-/- mice.
Although our data indicate that Kupffer cell-mediated hepatic infl ammation may not 
increase the susceptibility towards the development of insulin resistance during 
the onset of obesity, it may still aggravate insulin resistance in obese Ldlr-/- mice. 
However, glucose tolerance was not affected in Ldlr-/- mice fed either HFC or HFnC 
diet, and was only impaired in mice fed the diabetogenic HF diet (Fig. 5A). In spite 
of this, fasted insulin levels (Fig. 5B) and HOMA-IR (Fig. 5C) were all signifi cantly 
increased compared to the chow controls but did not differ between the HFC-, 
HFnC-, and HF-fed groups. Whereas, insulin signalling in skeletal muscle did not 
seem to be impaired after 15 weeks of HFC-, HFnC- and HF-feeding compared 
to chow-fed mice, hepatic insulin resistance was observed in mice on a HFC diet 
but again was no worse compared to mice on a HFnC and HF diet (Fig. 5D). This 
was indicated by a similar reduction in insulin-stimulated AKT phosphorylation in the 
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Figure 5. Hepatic inflammation does not aggravate insulin resistance in obese Ldlr-/- mice. (A) 
Blood glucose levels during an oral glucose tolerance test and AUC for the glucose tolerance 
test in Ldlr-/- mice at 15 weeks on a chow, HF, HFC or HFnC diet (n = 6 in each group). 
(B) Plasma insulin levels (n = 6 in each group). (C) HOMA-IR (n = 6 in each group). (D) 
Representative western blot analysis of phosphorylated and total AKT in skeletal muscle and 
liver after an insulin injection (n = 8 in each group). * P<0.05 vs chow-fed mice (Mann-Whitney 
U Test). Data are expressed as means ± SEM.




I n this study, we have explored the role of hepatic infl ammation as a possible driver 
of insulin resistance in the onset and presence of obesity. We show that Ldlr-/- mice 
with pronounced hepatic infl ammation, induced by a 2-week HFC-diet, do not exhibit 
signs of insulin resistance in comparison to mice fed a HFnC-diet (Fig. 4). We also 
show that insulin resistance is not aggravated in obese Ldlr-/- mice with sustained 
hepatic infl ammation induced by a 15-week HFC-diet (Fig. 5) compared to mice fed 
a HFnC-diet. Moreover, we did not fi nd any correlation between the level of hepatic 
infl ammation, insulin resistance and/or obesity in these mice (Supplemental Table 
3). Therefore, our data show that HFC-induced hepatic infl ammation per sé does not 
cause insulin resistance in Ldlr-/- mice.
Although previous studies have elegantly shown that insulin resistance is causally 
related to hepatic infl ammation (3,5), our data do not support these fi ndings. The 
reason for this is unclear; however, it may be related to the experimental model 
used to assess the causality of this association. In this study, we used a Kupffer 
cell-based approach to drive hepatic infl ammation, whereas hepatic infl ammation in 
LIKK mice (3) and IkbkbΔhep mice (5) is hepatocyte-driven. This raises the question 
whether hepatocyte-driven infl ammation is functionally different from Kupffer cell-
driven infl ammation and whether or not there is a distinctive role in their control of 
insulin resistance. Nonetheless, it should be noted that IkbkbΔhep mice retain liver 
insulin responsiveness in response to a high-fat diet, obesity and aging, but continue 
to develop peripheral insulin resistance in muscle and fat (5). By contrast, LIKK mice 
expressing constitutively active (IKKβ) in hepatocytes exhibit insulin resistance both 
locally in liver and systemically (3). Therefore, the possibility arises that a causal 
relationship between hepatic infl ammation and insulin resistance may only exist in 
the liver and not systemically. In addition, deletion of Ikbkb in myeloid cells was 
reported to lead to a global improvement in insulin sensitivity in IkbkbΔmye mice (5) 
but this effect may not be attributed to Kupffer cells in the liver as the LysM promotor 
used to generate these mice is not active in Kupffer cells (27). However, Kupffer cell 
depletion studies have shown confl icting results, and have both been associated 
with improvement (13-15) and deterioration of hepatic insulin resistance (8), thereby 
questioning a role of Kupffer cells in control of hepatic and global insulin sensitivity.
In this study we have assessed parameters on two different scales, i.e. infl ammation 
and insulin resistance. On these two scales, changes may not be in the same 
magnitude. Therefore, we cannot exclude that the absence of insulin resistance 
at week 2 of HFC-feeding may in fact refl ect a temporal delay of onset of insulin 
resistance induced by hepatic infl ammation. Nevertheless, several other reports 
have also raised doubts on the current concept that hepatic infl ammation causes 
insulin resistance in mice. Mice lacking the TNF receptors, p55 and p75, do not show 
improvement of insulin resistance despite reduced levels of hepatic infl ammation 
(11). Consistent with this, mice defi cient for Myd88, an adaptor protein for TLR/IL-1 
receptor signaling, are more prone to develop metabolic disease in response to 
HF feeding despite lower levels of infl ammation (9). Furthermore, hepatic insulin 
resistance is not always associated with the presence of infl ammation in the liver as 
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Liv-diacylglycerol O-acyltransferase 2 (DGAT2) mice fed a chow diet show hepatic 
insulin resistance in the absence of liver inflammation (10). In addition, we have 
recently shown that hepatic inflammation is not associated with insulin resistance in 
TNFR1 non-sheddable mice with a gain of function mutation in the TNFR1 resulting 
in chronic low-grade inflammation in the liver (7). Moreover, mice with the non-
shedding mutation fed a chow diet for one year were not prone to developing insulin 
resistance, nor did 12 weeks of HF feeding at the age of one year accelerate the 
onset of insulin resistance in these mice (7). Therefore, our data and the above-
discussed studies all show, using different experimental approaches (genetically 
engineered mouse models, Kupffer cell depletion, and dietary intervention), a 
disconnection between hepatic inflammation and the existence of insulin resistance. 
A similar dissociation has also been observed between hepatic steatosis and insulin 
resistance in various genetically and pharmacologically manipulated mouse models 
(28-31) and warrants further study.
Our data also suggest that other obesity-associated factors may be responsible 
for the development of insulin resistance in our mice. Obesity is known to promote 
insulin resistance and adiposity was significantly increased in all HF diet groups 
following 15 weeks of HF feeding (Fig. 3) whereas inflammatory gene expression in 
the liver did not increase above the 2-week time point (Fig. 2). Moreover, systemic 
and hepatic insulin resistance only became apparent with increasing adiposity in 
Ldlr-/- mice suggesting that signals originating from the adipose tissue rather than 
the liver may have interfered with proper insulin signalling in the Ldlr-/- mice. This is 
consistent with recent data showing that increased inflammation in both liver and 
muscle only became apparent after establishment of obesity (4). Our studies cannot 
answer the question whether total adiposity may be the driving force behind the 
development of insulin resistance in our model or whether site-specific fat depots 
(visceral or subcutaneous adipose tissue), a reduced capacity to store excess 
nutrients, and/or an altered secretion of adipokines may be involved.
In summary, our results demonstrate that the level of Kupffer cell-mediated hepatic 
inflammation is not directly correlated to the development of insulin resistance in 
male Ldlr-/- mice. Similar to the dissociation between hepatic steatosis and insulin 
resistance, we show dissociation between hepatic inflammation and the development 
of insulin resistance in mice. Therefore, our data provides evidence to question a 
possible role of Kupffer cell-driven hepatic inflammation in insulin resistance in mice.
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Supplemental tables and fi gures
Ldlr-/- mice were fed a chow, HF, HFC or HFnC diet for 2 weeks (n = 6 in each group). Plasma 
samples were analyzed for total cholesterol (TC), triglycerides (TG) and NEFA. Liver samples 
were analyzed for TC and TG. Data are expressed as means ± SEM. * P<0.05 vs chow-fed 
mice; # P<0.05 vs HF-fed mice and $ P<0.05 vs HFnC (Mann-Whitney U Test).
Supplemental Table 1. Plasma and liver lipids of 2 week-fed Ldlr-/- mice.
Ldlr-/- mice were fed a chow, HF, HFC or HFnC diet for 15 weeks (n = 6 in each group). Plasma 
samples were analyzed for total cholesterol (TC), triglycerides (TG) and NEFA. Liver samples 
were analyzed for TC and TG. Data are expressed as means ± SEM. * P<0.05 vs chow-fed 
mice; # P<0.05 vs HF-fed mice and $ P<0.05 vs HFnC (Mann-Whitney U Test).
Overview of the level of hepatic infl ammation, the occurrence of insulin resistance and obesity 
in Ldlr-/- mice fed a chow, HF, HFC or HFnC diet for 2 and 15 weeks. (-) = absent, (√) = present, 
(+) = mild infl ammation, and (+++) = strong infl ammation. 
Chow HF HFC HFnC
Plasma TC (mmol/L) 6.01 ± 0.25 17.25 ± 0.84 30.16 ± 1.01*#$ 22.49 ± 1.67*#
Plasma TG (mmol/L) 4.03 ± 0.11 9.20 ± 0.31 9.08 ± 0.37* 10.03 ± 1.15*
Plasma NEFA (mmol/L) 0.35 ± 0.01 0.72 ± 0.03 0.65 ± 0.04* 0.63 ± 0.07*
Hepatic TC (μmol/g liver) 11.55 ± 0.46 13.55 ± 0.30* 36.91 ± 2.89*#$ 19.03 ± 1.48*#
Hepatic TG (μmol/g liver) 11.34 ± 2.62 40.03 ± 2.38 27.53 ± 2.68*#$ 35.60 ± 3.39*
Supplemental Table 2. Plasma and liver lipids of 15 week-fed Ldlr-/- mice.
Supplemental Table 3. Dissociation of hepatic infl ammation and insulin resistance.
Chow HF HFC HFnC
Plasma TC (mmol/L) 9.88 ± 0.25 23.65 ± 1.70* 51.23 ± 3.08*#$ 25.96 ± 2.29*
Plasma TG (mmol/L) 1.35 ± 0.19 4.35 ± 0.32* 5.69 ± 1.05* 4.36 ± 0.71*
Plasma NEFA (mmol/L) 0.63 ± 0.05 0.80 ± 0.19 0.68 ± 0.11#$ 0.60 ± 0.07#
Hepatic TC (μmol/g liver) 14.33 ± 0.55 21.31 ± 0.68* 61.04 ± 3.30*#$ 32.52 ± 3.42*#
Hepatic TG (μmol/g liver) 24.43 ± 8.54 33.00 ± 2.85 28.17 ± 2.55 22.60 ± 2.68#
2 weeks 15 weeks
Infl ammation Insulin 
Resistance
Obesity Infl ammation Insulin 
Resistance
Obesity
Chow - - - - -
HF - - - + √ -√
HFC +++ - - +++ √ √
HFnC - - - + √ √
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Supplemental Figure 1. Increased Cd11b+ macrophages in HFC-fed Ldlr-/- mice. (A) 
Representative pictures of Cd11b staining and morphometric analysis of Cd11b stained liver 
sections from Ldlr-/- mice fed a chow, HF, HFC or HFnC diet for 2 and 15 weeks. Data are 
expressed as means ± SEM, n = 6 in each group. * P<0.05 vs chow-fed mice (Mann-Whitney 
U Test); # P<0.05 2- vs 15-week diet period (two-way ANOVA).
Chow HF HFC HFnC 
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Objective Chronic inflammation plays an important role in the etiology of non-
alcoholic fatty liver disease (NAFLD) and insulin resistance. The toll-like receptor 
(TLR) and interleukin 1 (IL-1) signaling pathways converge on myeloid differentiation 
primary response gene 88 (MYD88) to initiate nuclear factor-kappa B (NF-κB)-
mediated transcription of pro-inflammatory genes. To evaluate the role of Myd88 in 
the pathogenesis of NAFLD, we assessed the role of Myd88 in mouse models.
Methods  To this end, male WT and Myd88-/- mice were fed chow or high-fat 
cholesterol diet for 10 weeks.
Results  Myd88 deficiency leads to markedly decreased hepatic inflammation as 
judged by reduced expression of inflammatory genes. Also, hepatic triglyceride 
levels were reduced. Overall, this indicates a reduced susceptibility to develop 
steatohepatitis in Myd88-/- mice. Next, we assessed the role of Myd88 in 
macrophages in a model of non-alcoholic steatohepatitis (NASH) by studying the 
effects of hematopoietic deficiency of Myd88 on a low-density lipoprotein receptor 
(Ldlr) knockout background. Similarly, we found a strong reduction in hepatic 
inflammatory genes and a lowering of hepatic triglycerides by ~55%, indicating 
reduced steatohepatitis. In addition, the Ldlr-/- model is susceptible to develop diet-
induced insulin resistance, which was protected by hematopoietic Myd88 deficiency 
as observed by ~35% reduction in HOMA-IR. To further explore the role of MYD88 in 
metabolic disease in humans, we determined hepatic MYD88 expression in obese 
subjects with different stages of NAFLD. Increased MYD88 expression in the liver 
positively correlates with increased levels of C-reactive protein (CRP), aspartate 
aminotransferase (ASAT) and a higher Kleiner score for steatosis (p<0.001, p<0.01 
and p<0.01, respectively).
Conclusion Our data strongly suggest that MYD88 plays a role in the development 
of NAFLD, by impacting on steatosis and inflammation.




Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver 
disease in Western countries. NAFLD is considered to be the hepatic manifestation of 
the metabolic syndrome (1) and covers a broad spectrum of liver manifestations, from 
simple steatosis to non-alcoholic steatohepatitis (NASH), which can further progress 
to liver cirrhosis and end-stage liver disease (2). The frequency of NASH has risen 
dramatically, as it parallels the growing number of individuals with obesity. Due to 
the irreversible character of NASH, it leads to liver failure and has become the most 
important reason for liver transplantation (2). In particular, in fl ammatory signaling 
through nuclear factor-κB (NF-κB) plays a central role in the progression of NASH 
(3) and the development of hepatic insulin resistance. The latter was demonstrated 
by a mouse model with hepatocyte specifi c expression of a constitutively active form 
of inhibitor of κB kinase 2 (IKK2) showing hepatic and systemic insulin resistance 
(4). Conversely, IKK2 defi ciency protects against diet-induced insulin resistance (5). 
Two signaling pathways are known to activate the IKK complex and drive NF-κB-
mediated transcription of infl ammatory genes. First, IKK can be activated through 
the tumor necrosis factor (TNF) signaling pathway. Although the TNF pathway is 
important in NASH (6-8), it remains doubtful if low-grade TNF signaling can also 
cause insulin resistance (6,9). Second, the toll-like receptor (TLR) and interleukin-1 
(IL-1) pathways converge on myeloid differentiation primary response gene 88 
(Myd88) and subsequently activate the IKK complex (10).
There is considerable evidence that TLRs contribute to NASH and insulin resistance, 
in particular in the obese state (11-13). TLRs are the major cell surface receptors 
responding to a broad spectrum of infl ammatory microbial components and lipids 
(14). Mice defi cient in Tlr4 signaling are protected from diet-induced NASH (12). 
Moreover, Tlr9 defi cient mice showed less steatohepatitis compared to WT mice on 
a choline defi cient diet and demonstrated reduced insulin resistance (11). The role of 
TLRs has recently gained even more interest, after the discovery that products of the 
gut microbiota can cause hepatic infl ammation by activating TLRs (15). The other 
activation route of the MYD88/NF-κB pathway is mediated by IL-1/IL-1R. Obese 
individuals exhibit elevated levels of pro-infl ammatory cytokine IL-1β, and elevated 
levels of IL-1β are predictive of type 2 diabetes (T2D) (16). Moreover, interleukin-1 
receptor (IL-1R) knockout mice have lower plasma glucose and insulin levels, and 
improved insulin sensitivity compared with control mice (17). In addition, serum 
concentrations of IL-1 receptor antagonist (IL-1Ra) are elevated in obesity and pre-
diabetes (18). In line with this, IL1Ra-/- mice have lower fasting glucose and insulin 
levels and improved insulin sensitivity compared with WT controls (19).
Because TLR and IL-1 signaling activate NF-κB via Myd88, which is non-redundant, 
Myd88 is likely to play a central role in the pathogenesis of NAFLD. We therefore 
reasoned that Myd88 defi ciency would attenuate hepatic infl ammation, thereby 
protecting against NAFLD and insulin resistance. Understanding the role of Myd88 is 
likely to further strengthen the importance of the proposed pathway and its relevance 
as a therapeutic target.
Chapter 3
48
However, at present, work in Myd88-/- mice does not support its proposed role in 
disease, because Myd88 deficient mice fed a high-fat diet show a paradoxical 
insulin resistant phenotype (20,21), which is in contrast to what is expected based 
on TLR and IL-1 knockout studies. To better understand the role of Myd88 in the 
pathogenesis of NAFLD, we used Myd88 deficient mice and exposed these mice to 
a high fat diet with cholesterol to induce hepatic inflammation. Our results reveal that 
Myd88-/- mice have reduced hepatic inflammatory gene expression levels and 
steatosis, but are not protected from the development of insulin resistance. 
Subsequently, we focused our study on the role of macrophage Myd88 in NASH 
and insulin resistance and therefore we made use of the cholesterol-fed low-density 
lipoprotein receptor knockout (Ldlr-/-) mouse, recently developed as a model for NASH 
(22). In this model, NASH is driven by oxidized lipids activating the macrophages and 
Kupffer cells (23,24). We studied Ldlr-/- mice deficient in Myd88 in their hematopoietic 
compartment using bone marrow transplantation. These mice show a marked 
reduction in hepatic inflammatory gene expression and steatosis and are protected 
from the development of insulin resistance. To validate the role of MYD88 in humans, 
we examined whether the level of MYD88 expression in livers from obese subjects 
correlated with different indices of NAFLD. Here, we found that MYD88 expression in 
the liver positively correlates with disease progression, supporting a role for Myd88 
in the development of NAFLD.
Materials and methods
Mice and Diet intervention. All experiments were performed according to Dutch 
law and approved by the Ethical Committee for Animal Experiments, University of 
Groningen, the Netherlands. Experiments were carried out on male Myd88-/- mice 
and their wildtype littermates (Myd88+/+ referred to as WT mice) and maintained 
on a C57BL/6J background. These mice were generously provided by Dr. Akira 
(Osaka University, Japan). For the bone marrow transplantation Ldlr-/- mice (Jackson 
Laboratory, Bar Harbor, USA, ME) were used as recipients and Myd88-/- and GFP 
(WT) mice (Jackson Laboratory, Bar Harbor, USA, ME) were used as donors. The 
mice were housed individually in a temperature-and light-controlled facility with ad 
libitum access to food and water.
At the age of 8-10 weeks, mice were split into 2 groups and diet was either 
maintained in the case of standard chow (2181, RMH-B, Hope Farms, Woerden, the 
Netherlands) or switched to a high-fat cholesterol diet containing 21% milk butter 
and 0.2% cholesterol (HFC; diet 0035, Scientific Animal Food and Engineering, 
Villemoisson-sur-Orge, France). Mice were kept on these diets for 10 weeks. 
Myd88-/- mice are susceptible to infections and therefore all the mice were treated 
with 0.35% Neomycin (Spryt-Hillen, Utrecht, the Netherlands) added to the drinking 
water.
Bone marrow transplantation. Chimeric mice with a deletion of the Myd88 gene in 
hematopoietic cells, including Kupffer cells, were generated using the bone marrow 
transplantation approach as described previously (25). Briefly, at 8-10 weeks of age 
Ldlr-/- recipient mice were exposed to a single dose of 9.5 Gy of total body irradiation, 
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using 137Cs γ- rays, (IBL 637, CIS Biointernational, Gif-sur Yvette, Cedex, France). 
Irradiated mice were transplanted by intravenous injection of 107 bone marrow cells, 
isolated from GFP (WT) or Myd88-/- donor mice. After bone marrow injections, the 
radiation chimeras, from now on referred to as WT- tp and Myd88-/--tp mice, were 
maintained on a regular chow diet for 10 weeks to allow the reconstitution of bone 
marrow derived cells, including Kupffer cells. After reconstitution, chimeric mice were 
placed on a HFC diet for 10 weeks.
Determination of chimerism. Genomic DNA was isolated from blood with the 
QIAamp DNA Blood Mini Kit (QIAGEN, Venlo, the Netherlands) according to 
manufacturer’s instructions and a PCR using PCR plates from Greiner Bio-One B.V. 
(Alphen a/d Rijn, the Netherlands) was performed to genotype the WT and Myd88 
knockout allele. Myd88 primer a: 5’-AGACAGGCTGAGTGCAAACTTGTGCTG-3’; 
primer b: 5’-AGCCTCTACACCCTTCTCTTCTCCACA-3’; primer c: 
5’-ATCCCCTTCTATCGCCTTCTTGACGAG-3’. For detection of the WT allele; we 
used primers “a” and “b” and for the Myd88 mutated allele; we use primers “b” and 
“c”.
Glucose Tolerance and Insulin Tolerance Test. Mice were fasted for 9 hours 
after which either a glucose bolus (2g/kg of a 20% glucose solution) was given by 
oral gavage (glucose tolerance test) or human recombinant insulin (Actrapid, Novo 
Nordisk Canada Inc, Ontario, Canada) was injected intraperitoneally (0.5U/kg body 
weight; insulin tolerance test). Glucose levels were measured with an OneTouch 
Ultra glucometer (Lifescan Benelux, Beerse, Belgium) before and 15, 30, 60, 90, and 
120 minutes after the gavage or injection.
Analysis of plasma parameters. Insulin was determined in plasma from overnight 
fasted mice using an enzyme-linked immunosorbent assay kit (Insulin (mouse) 
Ultrasensitive EIA, Alpco Diagnostics, Salem, USA). Free fatty acids (FFA), 
triglycerides (TG), total cholesterol (TC), alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) were determined by commercially available kits, 
according to the manufacturer’s instructions (FFA: NEFA-HR, Wako Chemicals 
GmbH, Neuss, Germany; TG: Hitachi, Roche, Woerden, the Netherlands; TC: 
cholesterol CHOD-PAP, Roche, Woerden, the Netherlands; ALT and AST: Spinreact, 
Santa Coloma, Spain).
Liver lipids. Total liver lipids were extracted from the liver according to Bligh and Dyer 
(26). Hepatic free and total cholesterol (respectively FC and TC) and triglycerides 
(TG) were quantifi ed using commercially available kits (FC: DiaSys Diagnostic 
Systems GmbH, Holzheim, Germany; TC: cholesterol CHOD-PAP, Roche, Woerden, 
the Netherlands; TG: Hitachi, Roche, Woerden, the Netherlands).
Liver Histology. Liver tissues were isolated, fi xated in 4% paraformaldehyde and 
embedded in paraffi n. Paraffi n embedded sections of the liver (4 μm) were stained 
with Hematoxylin & Eosin (H&E) for morphological examination. Liver sections 
(5 μm) were snap-frozen in liquid nitrogen and stained with Oil Red O and Cd68 
antibody (FA11, Abcam, Cambridge, UK). Microscopy was performed with a LEICA 
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DM 3000 microscope with a DFC420 camera (Leica Microsystems, Rijswijk, the 
Netherlands). The slides were scanned with the NanoZoomer 2.0-HT slide scanner 
from Hamamatsu, Herrsching am Ammersee, Germany) and analyzed using 
Imagescope software from Aperio (Vista, USA).
Real-time polymerase chain reaction (RT-PCR), Total RNA was isolated from 
the liver with QIAzol reagent (QIAGEN, Venlo, the Netherlands) according to the 
manufacturer’s instructions. Total RNA (1 μg) from each individual mouse was 
converted into cDNA with Quantitect Reverse Transcription kit (QIAGEN, Venlo, 
the Netherlands) according to manufacturer’s instructions. RT-PCR was performed 
using a 7900HT system (Applied Biosystems, Warrington, UK) by using Power 
SYBR Green Master Mix (Biorad, Veenendaal, the Netherlands). For each gene, a 
standard curve was generated with a serial dilution of pooled cDNA pool of all the 
mice. Values were corrected using the housekeeping gene Cyclophillin A (Ppia). 
Primer sequences are listed in Supplemental Table 1.
Human study population. Wedge biopsies of liver, visceral adipose tissue (VAT, 
omentum majus), subcutaneous adipose tissue (SAT, abdominal), and muscle 
(musculus rectus abdominis) were obtained from 93 severely obese (BMI>35) subjects 
undergoing elective bariatric surgery at the Maastricht University Medical Centre. 
Subject characteristics are presented in Supplemental Table 2. None of the subjects 
reported excessive alcohol intake (>10g/day) or suffered from autoimmune diseases 
or viral hepatitis. The study was approved by the local Medical Ethics Committee and 
conducted according to the revised version of the Declaration of Helsinki (October 
2008, Seoul). Written informed consent was obtained from every patient before 
study participation. NASH severity was assessed by an independent pathologist in 
the field of hepatology according to the NAFLD Activity Score (NAS score) (27) and 
according to the Brunt classification (28). The study population comprised severely 
obese subjects displaying the full spectrum of NAFLD (Supplemental Table 3).
RNA profiling in four tissues and MYD88 co-expression with liver histology. 
RNA was isolated from liver, VAT, SAT and muscle using the QIAGEN Lipid Tissue 
Mini Kit (QIAGEN, Crawley, West Sussex, UK, 74804). Assessment of RNA quality 
and concentration was done with an Agilent Bioanalyzer (Agilent Technologies, 
Santa Clara, USA). Starting with 200 ng of RNA, the Ambion Illumina TotalPrep 
Amplification Kit was used for anti-sense RNA synthesis, amplification, and 
purification according to the protocol provided by the manufacturer (Ambion, Austin, 
USA). 750 ng of complementary RNA was hybridized to Illumina HumanHT12 
BeadChips and scanned on the Illumina BeadArray Reader. Raw probe intensity 
data for these samples was extracted using Illumina’s BeadStudio Gene expression 
module v3.2.
Statistical analysis. For the mouse studies, data were expressed as mean ± SEM. 
Data were statistically analyzed by performing a non-parametric Mann-Whitney 
U Test using GraphPad Prism to compare experimental groups (version 5.00 for 
Windows, GraphPad Software, San Diego, CA, USA). The level of significance was 
set at P < 0.05. For the human studies, the raw expression intensities from four 
A role for Myd88 in NAFLD 
51
3
tissues were jointly quantile normalized and log2 transformed. Expression data has 
been deposited in GEO with accession numbers GSE22070. The correlation between 
MYD88 expression in four tissues and NAFLD were calculated using Spearman 
correlation. The signifi cance was controlled at P < 0.01. Some patients were scored 
with a 1-2 for steatosis according to the Kleiner system, for these patients 1.5 is used 
for the Kleiner score for steatosis. Correlations of MYD88 expression in four different 




Figure 1. Hepatic inflammation in Myd88 deficient mice. Real-time polymerase chain 
reaction (RT-PCR) analysis was performed to measure mRNA expression levels of hepatic 
inflammatory genes Cd68, and monocyte chemoattractant protein 1 (Mcp1), and the cytokines 
tumor necrosis factor α (Tnfα) and interleukin-1β (Il-1β) (A). (□) = WT mice on chow diet, (■) = 
Myd88-/- on chow diet, (■) = WT mice on high-fat cholesterol (HFC) diet and (■) = Myd88-/- mice 
on HFC diet. Representative pictures of the immunohistochemical staining of Cd68 on liver 
sections (B) and quantification of the Cd68 staining (C). (□) = WT mice, (■) = Myd88-/- mice. 
Data are expressed as mean ± SEM, n = 6. The mRNA data is expressed as fold induction 
versus chow-fed WT mice and the levels are normalized for Cyclophillin A (Ppia). * P < 0.05 
versus WT mice (Mann-Whitney U Test); ** P < 0.05 versus chow diet (two-way ANOVA test).
Results
Hepatic inflammation in Myd88 deficient mice.
In order to explore the role of Myd88 in liver disease, Myd88-/- mice and their WT 
littermates were fed a chow or high-fat cholesterol (HFC) diet for 10 weeks. Hepatic 
inflammation was investigated by establishing the mRNA expression levels of 
inflammatory genes and macrophage markers. Myd88-/- mice showed reduced mRNA 
expression levels of cluster of differentiation 68 (Cd68), monocyte chemoattractant 
protein 1 (Mcp1), tumor necrosis factor α (Tnfα) and interleukin-1β (Il-1β) in the 
liver (Fig. 1A). To investigate whether reduced hepatic inflammation was due to 
decreased number of macrophages, we counted Cd68-positive cells in the liver. In 
contrast to the markedly reduced gene expression level of inflammatory markers, 
the number of macrophages was not different between WT and 
Myd88-/- mice (Fig. 1B, 1C). Moreover, the levels of alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST), surrogate markers of liver damage, were not 
affected by the diet (Table 1). Thus, Myd88 deficiency leads to a marked reduction in 
HFC-induced hepatic inflammatory gene expression.
Plasma and hepatic lipid levels in Myd88 deficient mice.
Body weight was unaltered in Myd88-/- mice compared to WT controls (Table 1). Plasma 
cholesterol and triglycerides were not different between WT and Myd88-/- mice (Table 
1). However, plasma cholesterol levels were increased upon HFC feeding (Table 1). 
Of note, whereas plasma free fatty acid (FFA) levels were significantly reduced in 
chow-fed Myd88-/- mice compared to WT mice, no differences in plasma FFA levels 
on a HFC diet (Table 1). No difference in hepatic cholesterol levels between WT and 
Myd88-/- mice on either diet, however hepatic cholesterol levels were increased upon 
HFC feeding (Fig. 2A). In addition, hepatic triglyceride (TG) content was reduced in 
chow-fed and HFC-fed Myd88-/- mice (Fig. 2B). This was confirmed by histological 




WT Myd88-/- WT Myd88-/-
Body weight (g) 29.5 ± 0.8 28.2 ± 1.6 42.2 ± 2.3 40.3 ± 3.8
Liver weight (g) 1.53 ± 0.05 1.09 ± 0.03* 2.69 ± 0.20 1.85 ± 0.11*
Liver/body weight ratio (%) 5.19 ± 0.17 3.91 ± 0.19* 6.41 ± 0.45 4.78 ± 0.54*
Plasma glucose (mmol/L) 6.22 ± 0.28 6.88 ± 0.52 8.20 ± 0.40 6.68 ± 0.63
Plasma cholesterol (mmol/L)  2.13 ± 0.21 2.32 ± 0.27 6.22 ± 0.14 5.54 ± 0.41
Plasma free fatty acids 
(μmol/L)
619.60  ± 34.69 425.71 ± 16.97* 684.07 ± 35.96 603.69 ± 30.37
Plasma triglycerides (mmol/L) 0.87 ± 0.13 0.86 ± 0.08 0.56 ± 0.07 0.74 ± 0.10
Plasma ALT (U/L) 18.71 ± 0.43 19.61 ± 0.84 20.03 ± 0.75 18.92 ± 0.55
Plasma AST (U/L) 4.13 ± 0.22 4.46 ± 0.50 3.92 ± 0.31 4.14 ± 0.30
Table 1. Plasma and liver parameters of WT and Myd88-/- mice on a chow and HFC diet for 
10 weeks.
Myd88-/- and WT mice were fed a chow or high-fat cholesterol (HFC) diet for 10 weeks. Body 
weight, liver weight and liver/body weight ratio were assessed. Fasted glucose levels were 
determined and plasma samples were analyzed for cholesterol (TC), free fatty acids (FFA), 
triglycerides (TG), alanine aminotransferase (ALT) and aspartate aminotransferase (AST). 
Data are expressed as mean ± SEM, n = 6 per group. * P < 0.05 versus WT (Mann-Whitney 
U Test). 
analysis of hematoxylin and eosin (H&E) and Oil red O (ORO) stainings in the livers 
of these mice (Fig. 2C, 2D). In line with reduced hepatic TG levels, liver weight 
and liver/body weight ratios were lower in Myd88-/- mice compared to WT mice, 
irrespective of the diet (Table 1). Thus, Myd88 defi ciency leads to a marked reduction 
in hepatic TG, which is mirrored by a lower liver weight.
HFC-fed Myd88-/- mice are not protected from the development of insulin 
resistance.
Since hepatic infl ammation has been linked to systemic insulin resistance (4), we 
evaluated the development of insulin resistance in Myd88-/- mice. Fasted plasma 
glucose levels were not signifi cantly altered between chow- or HFC-fed WT and 
Myd88-/- mice (Table 1). However, HFC feeding increased plasma insulin levels 
(Supplemental Fig. 1A) and homeostasis model of assessment-insulin resistance 
(HOMA-IR) (Supplemental Fig. 1B) in WT mice and lead to a further increase in 
Myd88-/- mice. In line with the normal glucose values (Table 1), the response to an 
oral glucose tolerance test did not differ upon HFC feeding and was unaffected by 
the genotype (Supplemental Fig. 1C, 1D). The HFC lead to a mild decrease in the 
response to insulin in an insulin tolerance tests (ITT), but Myd88-/- mice showed no 
signifi cant improvement (Supplemental Fig. 1E, 1F). Taken together, these results 
demonstrate that Myd88-/- mice are not protected from the development of insulin 
resistance in response to a HFC diet and even show a mild increase in insulin 
resistance as indicated by increased insulin levels and a higher HOMA-IR index.
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Figure 2. Plasma and hepatic lipid levels in Myd88 defi cient mice. Quantitative measurement 
of hepatic total cholesterol levels (A) and triglyceride levels (B). Representative pictures of 
immunohistochemical stainings of Hematoxylin & Eosin (H&E) (C) and Oil red O (ORO) on 
liver sections (D). Data are expressed as mean ± SEM, n = 6. (□) = WT mice, (■) = Myd88-/- 
mice.* P < 0.05 versus WT mice (Mann-Whitney U Test). 
Hematopoietic defi ciency of Myd88 reduces hepatic infl ammatory genes and 
steatosis in the Ldlr-/- mouse.
Because the leukocytes are the primary infl ammatory cells of the body, we would 
like to address if our fi ndings could be replicated studying hematopoietic Myd88 
defi ciency by generating bone marrow chimeras. As a host, we made use of the low 
density lipoprotein receptor knockout (Ldlr-/-) mouse strain because this mouse shows 
increased susceptibility to HFC-induced hepatic infl ammation through activation of 
hepatic macrophages and Kupffer cells (22,23). Hence, WT or 
Myd88-/- bone marrow cells were transplanted into lethally irradiated Ldlr-/- mice 
generating respectively WT-tp and Myd88-/--tp mice. Transplantation effi cacy was 
assessed by genotyping genomic DNA isolated from blood leukocytes using PCR 
analysis. Since no residual host bands were observed, a near 100% of engraftment 
of transplanted cells into the recipient mice was achieved (Supplemental Fig. 2A). 
The infl ammatory profi le of the liver was determined by gene expression analysis 
of infl ammatory genes and macrophage markers. The expression levels of Cd68, 
Mcp1, Tnfα and Il-1β were signifi cantly reduced in Myd88-/--tp mice compared to 
WT-tp controls (Fig. 3A). However, immunostaining of Cd68 positive cells showed no 
difference in the number of macrophages between Myd88-/--tp mice and WT-tp mice 
(Fig. 3B). We next investigated whether lipid metabolism was altered in 
Myd88-/--tp mice. Strikingly, Myd88-/--tp mice displayed signifi cantly increased 
plasma TG and TC levels compared to WT-tp mice (Table 2). In addition, hepatic 
triglyceride accumulation was reduced in the livers of Myd88-/--tp mice compared 











Figure 3. Hematopoietic defi ciency of Myd88 reduces hepatic infl ammatory genes and 
steatosis in the Ldlr-/- mouse. Real-time polymerase chain reaction (RT-PCR) analysis was 
performed to measure mRNA expression levels of hepatic infl ammatory genes Cd68, and 
monocyte chemoattractant protein 1 (Mcp1), and the cytokines tumor necrosis factor α (Tnfα) 
and interleukin-1β (Il-1β) (A). Representative pictures of the immunohistochemical staining 
of Cd68 on liver sections and the quantifi cation of Cd68 positive cells (B). Quantitative 
measurement of hepatic triglyceride levels (C). Representative pictures of Hematoxylin & 
Eosin (H&E) and Oil red O (ORO) staining (D). Data are expressed as mean ± SEM, n = 
8 per group. The mRNA data is expressed as fold induction versus HFC-fed WT-tp mice 
and the levels are normalized for Cyclophillin A (Ppia). (□) = low-density lipoprotein receptor 
knockout (Ldlr-/-) mice transplanted with WT bone marrow cells, (■) = Ldlr-/- mice transplanted 
with myeloid differentiation primary response gene 88 (Myd88)-/- bone marrow cells. * P < 0.05 
versus WT-tp mice (Mann-Whitney U Test). 
to WT-tp mice (Fig. 3C). This was confi rmed by histological analysis of hematoxylin 
and eosin (H&E) and Oil red O (ORO) stainings in the livers of these mice (Fig. 3D). 
Myd88-/--tp mice showed reduced expression of the fi brotic genes (data not shown), 
but fi brosis was not observed in WT-tp and Myd88-/--tp mice after 10 weeks of HFC 
feeding. Taken together, deletion of Myd88 from the hematopoietic compartment 
leads to reduction of hepatic infl ammatory genes and steatosis. The lack of steatosis 
is remarkable, in view of the increased levels of plasma lipids in the Myd88-/--tp mice.
Hematopoietic defi ciency of Myd88 improves insulin sensitivity in the Ldlr-/- 
mouse.
In view of the reduced infl ammation, Myd88-/--tp mice were predicted to be protected 
from the development of insulin resistance. No differences were observed in body 
weight between Myd88-/--tp and WT-tp mice (Fig. 4A). Glucose tolerance was 
signifi cantly improved in HFC-fed Myd88-/--tp mice compared to WT-tp mice (Fig. 
4B and 4C). Moreover, fasting plasma glucose (Fig. 4D) and insulin levels (Fig. 4E) 
were signifi cantly reduced in Myd88-/--tp mice compared to WT-tp mice. In line with 
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Myd88-/--tp and WT-tp mice were fed a HFC diet for 10 weeks. Liver weight and liver/body 
weight ratio were assessed. Fasted plasma samples were analyzed for cholesterol (TC) and 
triglycerides (TG). Liver free and total cholesterol (FC and TC respectively), and cholesterol 
esters (CE) were biochemically determined. Data are expressed as mean ± SEM, n = 8 per 
group. * P < 0.05 versus WT-tp (Mann-Whitney U Test).
HFC
WT-tp Myd88-/--tp
Liver weight (g) 1.09 ± 0.06 0.90 ± 0.03*
Liver/body weight ratio (%) 4.45 ± 0.15 3.79 ± 0.11*
Plasma cholesterol (mmol/L) 29.25 ± 2.10 37.80 ± 3.62*
Plasma triglycerides (mmol/L) 4.50 ± 0.70 13.66 ± 1.06*
Liver free cholesterol (μmol/g liver) 6.10 ± 0.29 3.82 ± 0.21* 
Liver cholesterol (μmol/g liver) 17.06 ± 1.66 14.31 ± 1.71
Liver cholesterol esters (μmol/g liver) 10.96 ± 1.43 10.49 ± 1.53
Table 2. Plasma and liver parameters of WT-tp and Myd88-/--tp mice on a HFC diet for 10 
weeks.
these data, HOMA-IR was markedly lower in Myd88-/--tp mice compared to WT-tp 
mice (Fig. 4F). These data show an overall improvement in insulin sensitivity as a 
result of Myd88 deficiency in the hematopoietic cell compartment.
MYD88 expression in humans with NAFLD.
After exploring the relationship between Myd88, NAFLD and insulin resistance in 
rodents, we assessed if hepatic MYD88 expression could play a role in the disease 
progression in humans. Therefore, using Illumina HT12 Beadchips the level of 
hepatic MYD88 expression was determined in 93 biopsied subjects showing different 
stages of NAFLD (Supplemental Table 3). The hepatic expression levels of MYD88 
were positively associated with the degree of steatosis as evaluated according to 
Kleiner (27). Subjects expressing the highest levels of MYD88 showed the higher, 
less favorable, Kleiner score for steatosis (Fig. 5; Table 3; rs=0.31, p<0.01). 
Furthermore, plasma levels of ASAT, known to increase with liver injury, were also 
positively associated with increased levels of hepatic MYD88 expression (Fig. 5; 
Table 3; rs=0.30, p<0.01). An even stronger correlation (rs=0.42, p<0.001) was 
observed between MYD88 expression in the liver and plasma levels of C-reactive 
protein (CRP; Fig. 5; Table 3), a marker of systemic inflammation that is known to 
be increased in subjects with NAFLD and T2D (29). However, no correlation was 
found between hepatic MYD88 expression and plasma glucose (rs=-0.16, p=0.159), 
plasma insulin (rs=0.05, p=0.694) or HbA1c levels (Table 4; rs=-0.02, p=0.834), 
as measurements of insulin resistance and T2D. These data show that increased 
expression of MYD88 is associated with an unfavorable hepatic phenotype in the 
human population.







Figure 4. Hematopoietic defi ciency of Myd88 improves insulin sensitivity in the Ldlr-/- mouse. 
Body weight was measured (A). Blood glucose levels during an oral glucose tolerance test 
(OGTT) (B). Area under the curve (AUC) was calculated for the glucose tolerance test (C). 
Glucose (D) and insulin levels (E) following a 9-hr fast in plasma. Homeostasis model of 
assessment- insulin resistance (HOMA-IR) was assessed as a surrogate marker of insulin 
resistance (F). Data are expressed as mean ± SEM, n = 8 per group. (□) = low-density 
lipoprotein receptor knockout (Ldlr-/-) mice transplanted with WT bone marrow cells, (■) = 
Ldlr-/- mice transplanted with myeloid differentiation primary response gene 88 (Myd88)-/- bone 
marrow cells. * P < 0.05 versus WT-tp mice (Mann-Whitney U Test). 
A B C 
Figure 5. Correlation between MYD88 expression and CRP, ASAT and Kleiner score for 
steatosis. The graphs show the correlation between hepatic MYD88 expression and CRP 




Phenotype Spearman Correlation R Spearman P value
CRP 0.42 1.29x10-4





Table 3. Hepatic MYD88 expression correlates with features of the metabolic syndrome in 
severly obese subjects.
CRP, C-reactive protein; ASAT, aspartate aminotransaminase.




TLR and IL-1 signaling pathways have been established to play a role in NAFLD and 
insulin resistance (11-13,17,19). The signals of both TLR and IL-1 pathways converge 
on MYD88, subsequently leading to the activation of NF-κB-mediated infl ammation. 
Therefore, silencing MYD88 is a promising target to reduce infl ammation, and protect 
against NAFLD and insulin resistance. Here, we provide evidence for a role for 
Myd88 in the pathogenesis of NAFLD using complementary approaches. First, the 
two mouse models, i.e., Myd88-/- and Myd88-/--tp mice, show that Myd88 is involved 
in infl ammation during NAFLD. Second, we show that these mouse models with 
Myd88 defi ciency show decreased hepatic triglyceride levels. This role of Myd88 is 
mirrored in humans, where increased MYD88 expression is associated with a higher 
Kleiner score for steatosis. In addition, the Ldlr-/- model with hematopoietic Myd88 
defi ciency showed that the decreased hepatic infl ammation and lipid accumulation 
is accompanied by improved systemic insulin sensitivity.
Myd88 defi ciency leads to reduced infl ammation in chow- and HFC-fed C57BL6/J 
mice, as well as in the Myd88-/--tp mice on the Ldlr-/- background. It is well established 
that the HFC causes low-grade infl ammation in C57BL6/J mice (30). In particular the 
cholesterol in the HFC diet is a cause of infl ammation (31). However, the mechanisms 
of the infl ammation have remained unclear. Here we show, that in the absence of 
Myd88, infl ammation is attenuated in C57BL6/J mice, indicating that the HFC diet 
may provide ligands for TLRs or the infl ammasome. Recently, we have delineated 
the mechanism of HFC-induced infl ammation in more detail in cholesterol-fed 
Ldlr-/- mice as a model to understand the etiology of NASH (22,23). We found that 
the susceptibility to develop infl ammation in this mouse model originates from the 
high levels of oxidized LDL in the plasma (24). This oxidized LDL is cleared from the 
circulation by the Kupffer cells and hepatic macrophages. Because oxidized LDL 
remains trapped in the lysosomes, it induces infl ammation (32). An important step in 
the induction of the infl ammation is the activation of the infl ammasome. Interestingly, 
we noted that the cholesterol diet induced the formation of cholesterol crystals, which 
are capable of activating the infl ammasome (33). As the infl ammasome activates the 
IL-1-MYD88 pathway to activate the IKK complex (34), we reasoned that Kupffer 
cell/macrophage Myd88 defi ciency could interrupt this infl ammatory pathway and 
attenuate hepatic infl ammation and possibly improve insulin sensitivity. Our current 
data strongly supports this model.
Interestingly, both the mice with a complete knockout of Myd88 as well as the mice 
with hematopoietic Myd88 defi ciency show a decrease in hepatic steatosis. These 
latter fi nding strongly argues for a crucial role of hepatic macrophages and Kupffer 
cells controlling hepatic lipid levels. This is in agreement with earlier studies using 
intraperitoneal injections with clodronate-encapsulated liposomes showing that 
Kupffer cell depletion leads to reduced hepatic lipid levels (35,36). Interestingly, 
it was found that ablation of Kupffer cells leads to decreased IL-1β suppression 
of peroxisome proliferator activated receptor alpha (PPARα,), sustained fatty acid 
oxidation and a reduction in hepatic lipid content (35). In both of our models, we 
fi nd a reduction in IL-1β expression, indicating that Myd88 defi ciency may lead to a 
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similar mechanism where decreased IL-1β signaling leads to a lower hepatic lipid 
accumulation.
We have shown that Myd88-/- mice are not protected against the development of 
insulin resistance. Similarly, others have also shown that Myd88-/- mice fed a high-
fat diet developed a diabetic phenotype, characterized by glucose intolerance and 
increased blood glucose and insulin levels (20,37). This is in contrast with data 
obtained from Tlr4-/- or IL1R-/- mice showing that these mice are protected against 
the development of insulin resistance (12,13,17,19). It has been demonstrated that 
stearoyl-Coenzyme A desaturase 1 (Scd1) is up regulated in Myd88-/- mice (37). 
Moreover, it has been suggested that SCD1 is a key factor in the pathogenesis of 
lipid-induced insulin resistance (38). Since it has been shown that the circulating 
levels of free and esterified cholesterol are increased in Myd88-/- mice fed a high-
fat diet (20) and the production of cholesterol esters from monounsaturated fatty 
acids in the mouse liver is highly dependent on Scd1 (39), it has been suggested 
that the high levels of Scd1 in Myd88-/- mice fed a high-fat diet contribute to the 
production of cholesterol esters, leading to the abnormal cholesterol homeostasis or 
lipid metabolism which results in insulin resistance. This finding corroborated studies 
with Scd1-/- mice (40) and could explain the paradoxical insulin resistant phenotype 
of Myd88-/- mice.
To focus more on the role of Myd88 in hematopoietic cells, we carried out bone 
marrow transplantation experiments. Strikingly, Myd88-/--tp mice are protected from 
HFC-induced hyperinsulinemia, hyperglycemia and whole-body insulin resistance. 
These results are in line with recent studies in which hematopoietic deficiency of 
Tlr4 resulted in the protection against HFD-induced hyperinsulinemia and insulin 
tolerance (41). Tlr4 deletion in the hematopoietic compartment did not affect obesity 
nor adiposity, but markedly reduced hepatic inflammation (41). Altogether, these 
data show that deletion of Myd88 in the hematopoietic compartment specifically 
protects against high-fat diet mediated-insulin resistance. It is of interest that both of 
our models showed a decrease in inflammation and steatosis, but have contrasting 
phenotypes for glucose metabolism.
In summary, we have demonstrated that Myd88 deficiency leads to decreased 
steatohepatitis in mouse models. In addition, we show that MYD88 expression in the 
livers of subjects with different stages of NAFLD correlates with the levels of CRP, 
ASAT and Kleiner score for steatosis. Altogether, these data indicate an important 
role for Myd88 in the development of NAFLD.
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Means ± SD Minimal/maximal values
Male/Female 26/67
Age (years) 44.20 ± 9.74 17-67
BMI (kg/m2) 46.15 ± 9.54 30.7-73.6
Glucose (mmol/L) 6.45 ± 1.98 4.3-14.5
HbA1c (%) 6.54 ± 1.34 5.1-12.1
Insulin (mU/L) 18.95 ± 10.61 3.8-53
Triglycerides (mmol/L) 2.22 ± 1.98 0.63-16.4
NEFA (nmol/L) 0.70 ± 0.70 0.12-6.4
ALAT( U/L) 26.53 ± 16.05 6-124
ASAT (U/L) 24.07 ± 12.44 7-72
C-reactive protein (mg/L) 10.17 ± 8.10 1-37
Supplemental tables and figures
Supplemental Table 1. Primer sequences used for RT-PCR.
Supplemental Table 2. Clinical and plasma parameters of the study population.
Data are means ± standard deviation (SD) and the minimal and maximal values for each 
trait. NEFA, non-esterified fatty acid; ALAT, alanine amintransaminase; ASAT, aspartate 
aminotransaminase.
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Total number of 
individuals scored
No. of individuals with score
0 1 2 3
Steatosis (0-3) 93 25 26 29 13
Fibrosis (0-3) 91 62 15 11 3
Lobular Infl ammation 88 36 35 12 5
Data are the number of individuals scored for different grades of hepatic steatosis and features 
of non-alcoholic steatohepatitis (NASH) as described by Kleiner et al (27). The table also 
shows the total number of individuals per trait that were scored. 
Spearman Correlation Coeffi cient with MYD88 Expression (P value)
Trait Liver SAT VAT Muscle
Sex -0.161 (P=0.149) 0.201 (P=0.0575) 0.106 (P=0.338) 0.0423 (P=0.149)
Age -0.249 (P=0.024) 0.0559 (P=0.601) 0.0771 (P=0.486) -0.065 (P=0.024)
BMI 0.257 (P=0.0205) 0.199 (P=0.0613) 0.00738 (P=0.947) -0.042 (P=0.0205)
Waist-hip ratio -0.0142 (P=0.914) 0.249 (P=0.0527) 0.0159 (P=0.906) 0.0379 (P=0.914)
Glucose -0.159 (P=0.159) 0.16 (P=0.138) 0.0218 (P=0.846) -0.0629 (P=0.159)
HbA1c -0.0241 (P=0.834) 0.197 (P=0.0711) 0.156 (P=0.17) 0.0294 (P=0.834)
Insulin 0.0455 (P=0.694) 0.223 (P=0.0417) 0.0382 (P=0.738) 0.00655 (P=0.694)
Total Cholesterol -0.092 (P=0.429) -0.292 (P=0.00771) -0.0434 (P=0.708) -0.176 (P=0.429)
High-density lipoprotein -0.151 (P=0.19) -0.438 (P=3.51e-05) -0.0721 (P=0.531) 0.02 (P=0.19)
Low-density lipoprotein -0.0402 (P=0.729) -0.196 (P=0.0764) -0.0109 (P=0.924) -0.122 (P=0.729)
Triglyceride -0.0495 (P=0.669) 0.156 (P=0.158) 0.0508 (P=0.658) -0.00888 (P=0.669)
Free fatty acids 0.148 (P=0.212) -0.00665 (P=0.953) -0.171 (P=0.141) -0.0646 (P=0.212)
C-reactive protein 0.423 (P=0.000129) 0.103 (P=0.356) -0.103 (P=0.369) 0.00779 (P=0.000129)
Alanine transaminase -0.00155 (P=0.989) 0.238 (P=0.0295) 0.0288 (P=0.801) -0.167 (P=0.989)
Aspartate transaminase 0.301 (P=0.00695) 0.195 (P=0.0758) -0.0204 (P=0.858) -0.0675 (P=0.00695)
Kleiner score steatose 0.312 (P=0.0043) 0.202 (P=0.0556) 0.0614 (P=0.579) -0.0479 (P=0.0043)
Fibrose 0.129 (P=0.253) 0.159 (P=0.138) 0.113 (P=0.311) 0.13 (P=0.253)
Lobular infl ammation 0.134 (P=0.247) 0.123 (P=0.261) 0.277 (P=0.0136) -0.0473 (P=0.247)
Large lipogranulomas 0.242 (P=0.0296) -0.00406 (P=0.97) 0.17 (P=0.124) 0.0815 (P=0.0296)
Portal infl ammation 0.0461 (P=0.681) -0.0329 (P=0.758) 0.157 (P=0.154) -0.0657 (P=0.681)
Ballooning 0.164 (P=0.143) 0.125 (P=0.243) 0.186 (P=0.0928) 0.0147 (P=0.143)
Glycogenated nuclei -0.0698 (P=0.541) 0.0536 (P=0.622) 0.023 (P=0.838) -0.144 (P=0.541)
NAS score 0.154 (P=0.197) 0.162 (P=0.154) 0.0855 (P=0.472) -0.0134 (P=0.197)
Supplemental Table 4. Correlation of MYD88 expression in four different tissues with features 
of the metabolic syndrome in subjects with NAFLD.









Supplemental Figure 1. HFC-fed Myd88-/- mice are not protected from the development of 
insulin resistance. Insulin levels following a 9-hr fast in plasma (A). Homeostasis model of 
assessment-insulin resistance (HOMA-IR) was assessed as a surrogate marker of insulin 
resistance (B). Blood glucose levels during an oral glucose tolerance test (OGTT) (C). Area 
under the curve (AUC) was calculated for the glucose tolerance test (D). Blood glucose levels 
during an insulin tolerance test (ITT) following a 6-h fast (E). AUC for the insulin tolerance test 
(F) was calculated. Data are expressed as mean ± SEM, n = 6 per group. (□) = WT mice, (■) 
= Myd88-/- mice. * P < 0.05 versus WT mice (Mann-Whitney U Test); ** P < 0.05 versus chow 





















Supplemental Figure 2. Transplantation 
efficacy. To confirm transplantation efficacy, 
whole blood was collected from the 
transplanted animals at the end of the study 
and genomic DNA was isolated to perform 
a PCR to genotype the WT and Myd88 
knockout allele. WT and global Myd88-/- DNA 
serve as a positive control (A).
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Background Macrophages have been implicated in obesity-related pathologies 
through their role in inflammation. Colony stimulating factor (Csf1) mediates 
macrophage development and function, thereby playing a key role in inflammation. 
Mice haploinsufficient for Csf1 (Csf1op/+) are protected against atherosclerosis, 
suggesting that macrophages may contribute to the pathogenesis of obesity-related 
disorders via Csf1 regulation.
Methods To assess the role of Csf1 in fatty liver disease and insulin resistance, we 
studied Csf1+/+ and Csf1op/+ mice fed a chow or high-fat cholesterol (HFC) diet. 
Results Although body weight did not differ between genotypes, Csf1op/+ mice 
showed a reduced lean body mass and an increased fat mass compared to controls. 
In line with a lower lean body mass, indirect calorimetric analysis revealed a lower 
metabolic rate in Csf1op/+ mice compared to Csf1+/+ mice. Hepatic, adipose tissue 
and systemic inflammation were reduced in Csf1op/+ compared to Csf1+/+ mice. 
Hepatic cell fractionations indicated that the Kupffer cells are responsible for the 
differences in liver inflammation. Csf1 haploinsufficiency also resulted in increased 
fasting-induced hepatic lipid accumulation. Whereas no differences were found in 
de novo lipogenesis, VLDL-TG synthesis and secretion were markedly reduced in 
Csf1op/+ mice, which might explain the increased hepatic steatosis. Despite reduced 
inflammation, whole-body glucose tolerance and fasting insulin levels did not differ 
between the genotypes.
Conclusion As haploinsufficiency of Csf1 affects macrophage function, our results 
demonstrate that Csf1 does not impact the development of insulin resistance. 
However, it does protect against the development of hepatic steatosis, suggesting 
an unexpected beneficial role for Csf1 in hepatic lipid metabolism. Treatment of 
inflammatory or autoimmune diseases with CSF-blockade or neutralization agents 
may thus give rise to adverse side-effects in the liver.




Obesity and its associated comorbidities are among the most challenging conditions 
in the 21st century, imposing a major burden on human health worldwide (1,2). 
Studies in the past two decades have left little doubt about the critical involvement 
of infl ammatory pathways in the mechanisms underlying insulin resistance and type 
2 diabetes (T2D) (3,4).
Macrophages, in addition to their established role in innate immunity, are regarded 
as key players in metabolic homeostasis and in the pathogenesis of diet-induced 
obesity and insulin resistance (5). Indeed, the production of pro-infl ammatory 
cytokines secreted by activated macrophages has been linked to the induction of 
insulin resistance in adipose tissue. Moreover, infl ammatory cytokines are thought to 
promote hepatic steatosis and facilitate foam cell and plaque formation in the vessel 
wall (6). The production of pro-infl ammatory cytokines secreted by the resident 
macrophages in the liver (Kupffer cells) is also linked to disruption of hepatic insulin 
signaling (7,8). Nonetheless, their role in obesity-related pathologies and the etiology 
of insulin resistance is still a matter of debate (9).
One essential regulator of macrophage homeostasis in vivo is macrophage colony-
stimulating factor, or Csf1 (10). Csf1 is a macrophage growth factor, stimulating the 
survival, proliferation and differentiation of mononuclear phagocytes, in addition to 
the spreading and motility of macrophages (11). Csf1 not only regulates macrophage 
survival and proliferation, but also macrophage activation (12). Csf1 has been shown 
to play an important role in chronic diseases and infl ammatory disease states (11-
13), providing therapeutic potential for neutralization or blockade of Csf1 in joint 
pathology, atherosclerosis, and cancer metastasis (13). Csf1 is expressed in liver 
(14-16), and adipocytes (17), and was shown to actively promote adipose tissue 
hyperplasia in rabbits and humans (17). Although, it has frequently been suggested 
that Csf1 contributes to the pathogenesis of obesity-related disorders, including 
insulin resistance and T2D (11,12,17), it has never been experimentally studied in 
mice. We decided to investigate the role of Csf1 in the development of liver steatosis 
and the susceptibility to obesity-induced insulin resistance. For this we used 
heterozygous mice defi cient for CSF-1 (Csf1op/+) that have plasma levels of CSF-1 of 
~65% of those in control mice (Csf1+/+) (18). In contrast to homozygous (Csf1op/op, op/
op) mice, the defi cient mice do not exhibit growth or skeletal defects, nor do they lack 
teeth, so it is possible to perform dietary intervention and obesity studies (19,20).
We demonstrated that haploinsuffi ciency of Csf1 is associated with reduced hepatic, 
adipose tissue and systemic infl ammation in mice. However, Csf1op/+ mice showed 
enhanced hepatic steatosis following an overnight fast, and have increased adiposity 
associated with the normal development of diet-induced insulin resistance. Our data 
therefore point towards a benefi cial role of Csf1 in the control of lipid metabolism in 
the liver, but it does not affect the development of systemic insulin resistance in mice.
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Research Design and Methods
Mice. All procedures were approved by the University of Groningen Ethics Committee 
for Animal Experiments, which adheres to the principles and guidelines established 
by the European Convention for the Protection of Laboratory Animals. Experiments 
were carried out on male Csf1+/+ and Csf1op/+ mice (supplied by Jackson Laboratory, 
Bar Harbor, ME, USA), back-crossed to C57BL/6J mice for 10 generations.
Mice were individually housed in a temperature-controlled room under a 12 h 
light-dark cycle, with free access to water and a standard chow diet (6.2% (w/w) 
fat and 0% (w/w) cholesterol; RMH-B, Hope Farms, Woerden, the Netherlands). 
At the age of 8-10 weeks, their diet was either maintained or switched to a high-fat 
cholesterol diet (HFC; 21% milk butter and 0.2% cholesterol; Scientific Animal Food 
and Engineering, Villemoisson-sur-Orge, France). They were kept on these diets for 
10 weeks.
Fractionation of liver cells. Liver cells of chow-fed Csf1op/op and Csf1op/+ mice were 
fractionated into hepatocytes and Kupffer cells as previously described (21). Briefly, 
mouse livers were digested by collagenase perfusion (Sigma-Aldrich Chemie BV, 
Zwijndrecht, the Netherlands) followed by 3-layer discontinuous density gradient 
centrifugation with 8.2% and 14.5% Nycodenz (Bio-Connect BV, Huissen, the 
Netherlands) to obtain both cell fractions. To check whether the fractionation resulted 
in clean hepatocyte and Kupffer cell fractions, Apoa1 was used as a marker for 
hepatocytes and Cd68 for Kupffer cells.
Liver lipids. Total liver lipids were extracted from the liver according to Bligh and 
Dyer’s method (22). Hepatic total cholesterol (TC) and triglycerides (TG) were 
quantified using commercially available kits (TC: cholesterol CHOD-PAP, Roche, the 
Netherlands; TG Hitachi, Roche, the Netherlands).
In vivo VLDL-TG production. Mice were injected intraperitoneally with Poloxamer 
407 (1g/kg body weight; BASF, Ludwigshaven, Germany) as a 50 mg/mL solution 
in saline as previously described (23). Blood samples were drawn by retro-orbital 
bleeding into heparinized tubes at 0, 30, 60, 120, and 240 min after injection. 
Immediately after the final blood draw, animals were sacrificed by cardiac puncture 
under isoflurane anesthesia. Plasma TG levels and TG production rates were 
determined as previously described (23). Nascent VLDL (d < 1.006) was isolated 
from the final plasma sample of each animal using a Optima TM LX tabletop 
ultracentrifuge (Beckman Instruments Inc., Palo Alto, CA, USA) at 108,000 rpm for 
150 minutes.
Determining de novo lipogenesis and chain elongation in vivo. A 2% sodium 
[1-13C]-acetate (99 atom %, Isotec/Sigma-Aldrich, Chemie BV, Zwijndrecht, the 
Netherlands) solution was given to the mice in their drinking water for 3 consecutive 
days. Analysis was performed according to Oosterveer et al (24).
Mitochondrial respiration. Mitochondrial respiration was measured in liver 
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mitochondria freshly isolated from chow-fed Csf1+/+ and Csf1op/+ mice using a 
2-chamber Oxygraph (Oroboros Instruments, Innsbruck, Austria). Malate, glutamate 
and pyruvate were used as substrates. State 3 respiration was measured by addition 
of adenosine diphosphate (ADP) to the mitochondria in suspension, and oligomycin 
was used to block adenosine triphosphate (ATP) synthase activity to refl ect 
respiration not coupled to ATP synthesis (state 4o). The maximal oxygen uptake 
rate (state uncoupled) was obtained by titration of the chemical uncoupler. Oxygen 
concentrations were recorded, and the fi rst derivative of the oxygen tension changes 
in time was displayed as oxygen fl ux. Respiratory control rates were calculated as the 
ratio between state 3 and state 4 in order to determine the coupling of mitochondrial 
respiration.
Statistical analysis. Data are expressed as mean ± SEM. Comparisons between 
groups were performed using unpaired Student’s two-tailed t tests. The level of 
signifi cance was set at P < 0.05.
Chapter 4
72
Figure  1.  Csf1 haploinsufficiency leads to fasting-induced hepatic steatosis. Plasma 
triglycerides (A), cholesterol (B) and hepatic triglyceride (C) levels were determined 
biochemically in chow- and high-fat cholesterol (HFC)-fed Csf1+/+ and Csf1op/+ mice. 
Representative pictures of hematoxylin & eosin (H&E) and Oil red O (ORO) stained liver 
sections taken from chow- and HFC-fed Csf1+/+ and Csf1op/+ mice (D). Hepatic triglyceride 
content in the fed state in chow-fed Csf1+/+ and Csf1op/+ mice (E). (□) = Csf1+/+ mice and (■) = 
Csf1op/+ mice. Data are expressed as mean ± SEM, n = 6 per group. * P < 0.05 versus Csf1+/+ 
mice (Mann-Whitney U Test).
Csf1+/+ Chow Csf1op/+ Chow Csf1+/+ HFC Csf1op/+ HFC 







Csf1 haploinsufficiency leads to fasting-induced hepatic steatosis.
As macrophages are key players in metabolic homeostasis (6), we first investigated 
the effects of Csf1 haploinsufficiency on plasma and liver lipid metabolism in both 
Csf1+/+ and Csf1op/+ mice fed a chow and a high-fat diet supplemented with 0.2% 
cholesterol (HFC) for 10 weeks. Plasma triglyceride (TG; Fig. 1A) and cholesterol 
(Fig. 1B) levels were lower in chow-fed Csf1op/+ mice than Csf1+/+ mice. However, 
this was not observed when Csf1op/+ mice were fed a HFC diet (Fig. 1A, 1B). In 
addition, we saw no difference in plasma free fatty acids (Supplemental Fig. 1A) and 
hepatic cholesterol levels (Supplemental Fig. 1B) between Csf1+/+ and Csf1op/+ mice 
fed either diet. However, hepatic triglyceride content was significantly increased in 
fasted chow- and HFC-fed Csf1op/+ mice compared to Csf1+/+ controls (Fig. 1C). This 
was confirmed by histological analysis of hematoxylin and eosin (H&E) and Oil red O 
(ORO) stainings in the livers of these mice, and highlights a predominant periportal 
steatosis in liver sections of Csf1op/+ mice fed a HFC diet (Fig. 1D). Of note, this 
2-fold increase in hepatic TG accumulation seen under fasting conditions was not 
observed in the fed state (Fig. 1E), suggesting an exaggerated fasting response in 
Csf1op/+ mice.
Downregulation of inflammatory mediators in the livers of Csf1op/+ mice.
As Kupffer cells facilitate the metabolic adaptations of hepatocytes during increased 
caloric intake (25) and co-culture studies have suggested a role for Kupffer cell-derived 
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factors in the maintenance of hepatic lipid homeostasis (26,27), we next investigated 
whether haploinsuffi ciency of Csf1 affects the level of hepatic infl ammation in Csf1op/+ 
mice. Hepatic infl ammation was reduced in Csf1op/+ mice as shown by reduced mRNA 
levels of Cd68, Mcp1 and Cd11b on both chow and HFC diet compared to Csf1+/+ 
mice (Fig. 2A). Similarly, the mRNA expression of the cytokines Tnfα, Il-1β and Il-6 
was lower in Csf1op/+ mice (Fig. 2B). To assess the contribution of Kupffer cells in our 
experimental model, we isolated the hepatocyte and Kupffer cell populations from 
the livers of chow-fed Csf1+/+ and Csf1op/+ mice. The expression of Csf1, Cd68, Tnfα, 
Il-6 and the M2 markers Fizz1 and Ym1 (Fig. 2D) were signifi cantly reduced in the 
Kupffer cell fraction of Csf1op/+ mice compared to Csf1+/+ mice. As the expression 
of these genes was not changed in the hepatocyte fraction (Fig. 2C), this suggests 
that Kupffer cells are the main drivers of the infl ammatory tone in the liver. We next 
determined Cd68 levels in stained liver sections to investigate whether reduced 
hepatic infl ammation was due to decreased activation of macrophages in Csf1op/+ 
mice. However, there was no difference in the number of activated macrophages in 
the liver, as determined by Cd68 staining (Fig. 2D, 2E). Therefore, our data suggest 
that fasting-induced hepatic steatosis is associated with reduced Kupffer cell-driven 
infl ammation in Csf1op/+ mice.
Fasting triggers β-oxidation in Csf1op/+ mice.
As effi cient hepatic fatty acid oxidation is obligatory to the metabolic response to 
fasting (28), we next examined whether fatty acid oxidation was affected in Csf1op/+ 
mice fed a chow diet. As a fi rst indication as to whether fatty acid oxidation is 
affected, we investigated the levels of β-hydroxybutyrate in the plasma of chow-
fed Csf1+/+ and Csf1op/+ mice. β-hydroxybutyrate levels were increased in fasted 
Csf1op/+ mice compared to Csf1+/+ mice (Fig. 3A). To assess mitochondrial function, 
mitochondria were isolated from fasted chow-fed Csf1+/+ and Csf1op/+ mice and 
subjected to respiratory measurements using an Oroboros Oxygraph. When malate 
was used as a substrate, absolute state 3 was elevated in the mitochondria from 
Csf1op/+ mice, whereas no differences were observed in state 4o respiration (Fig. 
3B). Furthermore, the respiratory control ratio (RCR), representing the degree of 
uncoupling or effi ciency of electron transport chain activity, was increased in Csf1op/+-
derived liver mitochondria compared to Csf1+/+ controls (Fig. 3C), indicating that liver 
mitochondria of Csf1op/+ mice use their oxygen more effi ciently than Csf1+/+ mice. 
This suggests that β-oxidation is, in fact, enhanced in livers of Csf1op/+ mice, which is 
likely a secondary effect to enhanced lipid storage in these mice.
Reduced VLDL-TG synthesis contributes to hepatic steatosis in Csf1op/+ mice.
To further trace the underlying mechanisms for the fasting-induced hepatic steatosis 
in Csf1op/+ mice, we examined the processes of very-low density lipoprotein (VLDL)-
TG secretion and de novo lipogenesis (DNL) in Csf1+/+ and Csf1op/+ mice fed a chow 
diet. To assess whether hepatic lipid secretion is changed in Csf1op/+ mice, we fi rst 
determined VLDL-TG production rates. Plasma TG levels were reduced in Csf1op/+ 
mice following an intraperitoneal injection with Poloxamer-407 (Fig. 4A). Consistent 
with this, hepatic VLDL-TG production was reduced in Csf1op/+ mice compared 
to Csf1+/+ mice (Fig. 4B). In addition, plasma VLDL composition was altered and 
contained a lower amount of TG in Csf1op/+ mice compared to plasma from Csf1+/+ 
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Figure 2. Downregulation of inflammatory mediators in livers of Csf1op/+ mice. Real-
time polymerase chain reaction (RT-PCR) analysis was performed to measure hepatic 
mRNA expression levels of colony stimulating factor (Csf-1), inflammatory genes cluster 
of differentiation 68 (Cd68), monocyte chemoattractant protein 1 (Mcp1), integrin, alpha M 
(Cd11b) (A), and cytokines tumor necrosis factor α (Tnfα), interleukin-1β (Il-1β) and Il-6 (B) 
in chow- and high-fat cholesterol (HFC)-fed Csf1+/+ and Csf1op/+ mice; (□) = Csf1+/+ mice on 
chow diet, (■) = Csf1op/+ mice on chow diet, (■) = Csf1+/+ mice on HFC diet and (■) = Csf1op/+ 
mice on HFC diet. Liver cells were fractionated into hepatocytes and Kupffer cells by 3-layer 
discontinuous density gradient centrifugation and mRNA expression of Csf-1, Cd68, Tnfα, 
Il-6, Fizz1 and Ym1 were determined in the hepatocyte (C) and Kupffer cell fraction (D) in 
chow-fed Csf1+/+ and Csf1op/+ mice. Representative pictures of immunohistochemical staining 
of Cd68 on liver sections (E) and quantification of Cd68 staining (F) in chow- and HFC-fed 
Csf1+/+ and Csf1op/+ mice. (□) = Csf1+/+ mice and (■) = Csf1op/+ mice. Data are expressed as 
mean ± SEM, n = 6 per group. The mRNA expression levels are normalized for Cyclophillin 
A (Ppia). Expression is shown as fold change compared to Csf1+/+ levels on chow diet. * P 
< 0.05 versus Csf1+/+ mice (Mann-Whitney U Test); ** P < 0.05 versus chow diet (two-way 
ANOVA test).
mice (Fig. 4C). As increased synthesis of fatty acids via the de novo lipogenesis 
pathway may also result in hepatic lipid accumulation, we next assessed the fractional 
C16:0 and C18 synthesis in liver homogenates from these mice following an oral 
load of [1-13C]-acetate. Mass isotopomer distribution analysis (MIDA) showed that 
fractional C16:0 (palmitate), C18:0 (stearate) and C18:1 (oleate) (Fig. 4D) syntheses 
were no different in Csf1op/+ mice than Csf1+/+ mice. Taken together, these results 
indicate that the increased hepatic lipid accumulation is mainly due to reduced 
VLDL-TG secretion in the Csf1op/+ mice.
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Figure 3. Fasting triggers β-oxidation in Csf1op/+ mice. Plasma β-hydroxybutyrate levels were 
determined as an overall measure of β–oxidation in chow-fed Csf1+/+ and Csf1op/+ mice (A). 
Respiratory analysis of liver-derived mitochondria of chow-fed Csf1+/+ and Csf1op/+ mice were 
measured by an Oxygraph. State 3 and 4o respiration levels (B) and respiratory control ratio 
(RCR) (C) were measured using malate as substrate. (□) = Csf1+/+ mice and (■) = Csf1op/+ 
mice. Data are expressed as mean ± SEM, n = 6 per group * P < 0.05 versus Csf1+/+ mice 
(Mann-Whitney U Test).
Figure 4. Reduced VLDL-TG synthesis contributes to hepatic steatosis in Csf1op/+ mice. An 
intraperitoneal injection with Poloxamer 407 was performed to measure the in vivo very-low 
density lipoprotein-triglyceride (VLDL-TG) production. Plasma VLDL triglyceride levels (A) 
and VLDL-TG production rates (B) were determined in chow-fed Csf1+/+ and Csf1op/+ mice; 
(□) = Csf1+/+ mice and (■) = Csf1op/+ mice. The composition of VLDL (C) was determined in 
chow-fed Csf1+/+ and Csf1op/+ mice; (□) = triglycerides (TG), (■) = phospholipids (PL) and 
(■) = cholesterol (TC). Fractional synthesis of C16:0 (palmitate), C18:0 (stearate) and C18:1 
(oleate) as a measurement of de novo lipogenesis were measured by giving [1-13C]-acetate in 
drinking water of chow-fed Csf1op/+ and Csf1op/+ mice (D). (□) = Csf1+/+ mice and (■) = Csf1op/+ 
mice. Data are expressed as mean ± SEM, n = 6 per group. * P < 0.05 versus Csf1+/+ mice 
(Mann-Whitney U Test).





Figure 5. Csf1op/+ mice are not protected from diet-induced obesity. Body weight of Csf1+/+ 
and Csf1op/+ mice fed a standard chow or high-fat cholesterol (HFC) diet and dual energy 
x-ray absorptiometry (DEXA) scan analysis was performed to assess lean mass and fat mass 
(A); (□) = Csf1+/+ mice on chow diet, (■) = Csf1op/+ mice on chow diet, (■) = Csf1+/+ mice on 
HFC diet and (■) = Csf1op/+ mice on HFC diet. Representative pictures of the adipose tissue 
sections (B) and adipocyte counts (C); (□) = Csf1+/+ mice and (■) = Csf1op/+ mice. Real time-
polymerase chain reaction (RT-PCR) analysis was performed to measure mRNA expression 
levels of inflammatory genes in the adipose tissue including colony stimulating factor (Csf-1), 
monocyte chemoattractant protein 1 (Mcp1), integrin, alpha M (Cd11b) and tumor necrosis 
factor α (Tnfα) (D); (□) = Csf1+/+ mice on chow diet, (■) = Csf1op/+ mice on chow diet, (■) = 
Csf1+/+ mice on HFC diet and (■) = Csf1op/+ mice on HFC diet. Data are expressed as mean 
± SEM, n = 6 per group. * P < 0.05 versus Csf1+/+ mice (Mann-Whitney U Test); ** P < 0.05 
versus chow diet (two-way ANOVA test).
Csf1op/+ mice are not protected from diet-induced obesity. 
As obesity is associated with macrophage accumulation in adipose tissue (29) and 
adipocyte Csf1 is a mediator of adipose tissue growth (17), we next assessed the 
diet-induced weight gain in Csf1+/+ and Csf1op/+ mice. Although body weight did not 
differ between the mice on chow or HFC diet, Dual-Energy X-ray Absorptiometry 
(DEXA) scan analyses demonstrated a reduced lean body mass and much increased 
fat mass (Fig. 5A) in Csf1op/+ mice compared to Csf1+/+ mice on both diets. Despite 
an increased adiposity in Csf1op/+ mice, the weight gain was similar in both mice 
following HFC feeding (data not shown). This confirmed that Csf1op/+ mice are not 
protected from diet-induced weight gain. A trend for increased adipocyte count was 
observed in Csf1op/+ mice fed a chow diet; however, adipocyte counts did not differ 
between the genotypes on a HFC diet (Fig. 5B, C). Next, we determined expression 
of genes governing macrophage function and cytokine production in the adipose 
tissue of Csf1+/+ and Csf1op/+ mice. Adipose tissue inflammation was decreased 
in HFC-fed Csf1op/+ mice as shown by reduced mRNA expression levels of Mcp1, 
Cd11b and Tnfα compared to Csf1+/+ mice (Fig. 5D).
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Figure 6. Csf1op/+ mice have a lower metabolic rate and reduced heat production. Indirect 
calorimetric cage analysis was performed to measure VO2 consumption (A), VCO2 production 
(B), heat production (C), food intake (D), total activity (E) in chow- and high-fat cholesterol 
(HFC)-fed Csf1+/+ and Csf1op/+ mice, and respiratory exchange ratio (RER) in Csf1+/+ and 
Csf1op/+ mice on a HFC diet (F). (□) = Csf1+/+ mice and (■) = Csf1op/+ mice. Data are expressed 
as mean ± SEM, n = 6 per group. * P < 0.05 versus Csf1+/+ mice (unpaired Student’s two-






Csf1op/+ mice have a lower metabolic rate and reduced heat production.
To determine whether this altered body composition is associated with an aberrant 
metabolic rate, mice were analyzed using indirect calorimetry. Consistent with 
a lower lean body mass, oxygen consumption (VO2; Fig. 6A) and carbon dioxide 
production (VCO2; Fig. 6B) were greatly reduced in Csf1
op/+ mice compared to 
Csf1+/+ mice. In addition, heat production (Fig. 6C) was decreased in Csf1op/+ mice 
compared to Csf1+/+ mice, whereas food intake (Fig. 6D) and activity (Fig. 6E) did 
not differ between the two genotypes on either diet. No differences in substrate use 
were found in Csf1op/+ mice when fed a chow diet (Supplemental Fig. 2A). However, 
the respiratory exchange ratio (RER) was markedly reduced in the dark phase 
following HFC feeding in Csf1op/+ mice (Fig. 6F), indicating that these mice oxidized 
more fatty acids than Csf1+/+ mice during this active period. Since Csf1op/+ mice have 
reduced lean body mass, we corrected VO2 consumption, VCO2 production, and 
heat production for lean mass. After this correction, there was no difference in VO2 
consumption (Supplemental Fig. 3A), VCO2 production (Supplemental Fig. 3B), 
or heat production (Supplemental Fig. 3C). Taken together, our data indicate that 
Csf1op/+ mice have a lower metabolic rate and reduced heat production than Csf1+/+ 
mice, which corresponds to the reduced lean body mass observed in these mice.
Csf-1 haploinsuffi cient mice are not protected from developing insulin 
resistance.
Work in the last few decades has shown that infl ammatory pathways are involved in 
the mechanisms underlying the development of insulin resistance and type 2 diabetes 
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Fig. 7. Csf1 haploinsufficient mice are not protected from developing insulin resistance. 
Plasma cytokine levels in Csf1+/+ and Csf1op/+ mice on a high-fat cholesterol (HFC) diet (A, B). 
Glucose tolerance test (C) was performed in Csf1+/+ and Csf1op/+ mice on chow or HFC diet 
following a 9-h fast. Plasma glucose (D) and insulin (E) were measured in Csf1+/+ and Csf1op/+ 
mice after an overnight fast. Homeostasis model of assessment-insulin resistance (HOMA-IR) 
as a surrogate marker of insulin resistance (F). (□) = Csf1+/+ mice and (■) = Csf1op/+ mice. Data 
are expressed as mean ± SEM, n = 6 per group. * P < 0.05 versus Csf1+/+ mice (Mann-Whitney 






(3,4). As Csf1op/+ mice exhibit lower levels of inflammation in the liver (Fig 1A, 1B) 
and adipose tissue (Fig. 5D), as well as a marked reduction in many inflammatory 
mediators in the circulation, including TNFα, IL1α, MIP1α, MIP1β and MCP1 (Fig. 
7A, 7B), we hypothesized that Csf1op/+ mice are protected from the development of 
insulin resistance. To this end, Csf1+/+ and Csf1op/+ mice were subjected to an oral 
glucose tolerance test following 10 weeks of chow and HFC feeding. Despite the 
lower inflammatory tone in Csf1op/+ mice, whole-body glucose tolerance (Fig. 7C) and 
fasted insulin levels (Fig. 7E) were no different between the genotypes. However, 
fasted glucose levels were lower in HFC-fed Csf1op/+ mice than controls (Fig. 7D), 
and may reflect the slight increase in plasma insulin levels seen in these mice (p = 
0.52). Indeed, the calculated homeostasis model of assessment-insulin resistance 
(HOMA-IR) index, a marker of insulin resistance, revealed no differences between 
Csf1+/+ and Csf1op/+ mice on either diet (Fig. 7F). This confirms that Csf1op/+ mice are 
not protected against the development of insulin resistance.




As macrophages have been implicated in the development of metabolic disease, 
we aimed to gain more insight into the role of macrophages in these pathologies by 
studying the role of Csf1, a macrophage growth factor, in the development of hepatic 
steatosis and insulin resistance. Using mice heterozygous for a Csf1 null allele, we 
demonstrated that Csf1 is important for the metabolic control of lipid metabolism in 
the liver. However, it does not offer protection against the development of insulin 
resistance in these mice.
Csf1 is an essential regulator of macrophage survival, proliferation and activation 
(11,12) and it has frequently been hypothesized but never experimentally addressed 
that macrophages via Csf1 regulation may contribute to the pathogenesis of obesity-
related disorders. We show that Csf1 haploinsuffi ciency contributes to reduced 
hepatic, adipose tissue and systemic infl ammation (Fig. 2A, 2B, 5D, 7A, 7B). This 
is in line with previous studies highlighting a therapeutic benefi t for depletion of 
CSFs, including Csf1, in many infl ammatory and/or autoimmune conditions in animal 
models (13). Our data also show that Csf1 haploinsuffi ciency results in reduced liver 
infl ammation driven by Kupffer cells (Fig. 2D), thus allowing us to investigate the 
role of Csf1 in the development of hepatic steatosis. Here, we show that reduced 
hepatic infl ammation in Csf1op/+ mice is associated with increased hepatic triglyceride 
accumulation (Fig. 1). Of note, increased hepatic lipid accumulation in these mice 
was only apparent after an overnight fast and not in the fed state. As fasting increases 
hepatic TG accumulation in rodents (30), our data show that Csf1 haploinsuffi ciency 
contributes to increased fasting-induced hepatic steatosis. Our results, therefore, 
suggest that Csf1-induced macrophages are important for protection against the 
development of hepatic steatosis and unravel an unexpected, benefi cial role of Csf1 
in hepatic lipid homeostasis.
To better defi ne the mechanisms that might underlie the increased fasting-induced 
steatosis in livers of Csf1op/+ mice, we assessed the processes of de novo lipogenesis, 
VLDL-TG secretion, and β-oxidation in mice fed a chow diet and fasted overnight. 
We saw no difference in de novo lipogenesis between Csf1+/+ and Csf1op/+ mice (Fig. 
4D). However, hepatic VLDL-TG synthesis and secretion (Fig. 4A, 4B) was markedly 
reduced in Csf1op/+ mice. Since the hepatic steatosis was observed in the periportal 
region (Fig. 1D), and VLDL-TG synthesis has been shown to occur in periportal 
hepatocytes (31), a decline in the process of VLDL-TG synthesis and secretion 
(Fig. 4A, 4B), might explain the increase in fasting-induced steatosis observed in 
these mice. In line with the increased hepatic fatty acid oxidation in the metabolic 
response to fasting (28), we also show that mitochondrial β-oxidation is enhanced in 
Csf1op/+ mice compared to Csf1+/+ mice (Fig. 3A-C). However, it does not explain the 
hepatic steatosis observed in these mice. We therefore speculate that the increase 
in mitochondrial β-oxidation is likely a consequence of increased hepatic steatosis 
rather than a cause. 
Macrophages play and important role in innate immunity and infl ammation and 
are associated with the development of obesity-induced insulin resistance (5), our 
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observation that Csf1 haploinsufficiency increases fasting-induced hepatic steatosis 
may seem counterintuitive. However, it has been demonstrated that alternatively 
activated Kupffer cells protect hepatocytes from the development of inflammation 
and the subsequent steatosis associated with high-fat diet-induced obesity (27,32). In 
line with this, myeloid-specific deletion of peroxisome proliferator activator receptor δ 
(Pparδ), which impairs alternative activation of Kupffer cells, contributes to increased 
lipid accumulation in the liver (26,27). In addition, co-culture of Kupffer cells and 
hepatocytes with lipopolysaccharides (LPS) to induce M1 polarization results in 
increased hepatocyte triglyceride accumulation (33). Furthermore, systemic loss of 
Il-10, a cytokine that drives macrophages to the M2 phenotype, results in hepatic 
triglyceride accumulation associated with obesity (32,34). In addition, it has recently 
been shown that fasting induces a response in liver that is associated with an 
increased number of Mac-2 positive crown-like structures, and involves an increase 
in M2-type macrophages (35). Since, Csf1-induced macrophages are associated 
with alternatively activated M2 properties (36), it is likely that the increased fasting-
induced steatosis we observed may reflect the reduced ability of Csf1 to control 
metabolic pathways during fasting. Nevertheless, as Csf1 haploinsufficiency resulted 
in an overall reduction of M1 (pro-inflammatory) and M2 (ant-inflammatory) markers 
in the liver, we cannot confirm that a shift in M1/M2 balance is responsible for the 
observed aberrant lipid metabolism in Csf1op/+ mice. Nor do our studies delineate 
which Kupffer cell-derived factors are important for this effect in the liver. However, 
previous data from co-culture studies with Kupffer cells and hepatocytes have shown 
that factors derived from Kupffer cells work in a trans-acting manner to maintain 
hepatic lipid homeostasis (33). In addition, Csf1-induced Kupffer cells play a key role 
in liver regeneration as a source of Il-6 in the liver after partial hepatectomy (37), this 
provides further support of an important role for Csf1 in the metabolic control of lipid 
homeostasis in the liver.
As macrophage activation in the liver and adipose tissue is linked to the development 
of obesity-induced insulin resistance, we also assessed the role of Csf1 in the 
development of insulin resistance (5). Although, Csf1 haploinsufficiency did not affect 
the level of obesity or diet-induced weight gain, DEXA scan analysis showed that 
adiposity was markedly increased in Csf1op/+ mice, both on chow and when following 
a HFC diet for 10 weeks (Fig. 5A). Of note, Csf1 is upregulated in adipose tissue 
from humans gaining weight with overfeeding and has been shown to contribute to 
adipose tissue deposition in humans (17). This is in contrast to our finding that Csf1 
haploinsufficiency triggers fat mass accumulation in the adipose tissue compartment. 
Although we cannot explain this discrepancy, another study also showed no effect of 
haploinsufficiency of Csf1 on diet-induced obesity in mice (20). In this study lean and 
fat mass were not assessed, nor its effect on the pathogenesis of obesity-associated 
diseases, like insulin resistance or NAFLD (20). Despite a marked increase in fat 
mass and a major reduction in systemic, adipose tissue and hepatic inflammation 
in Csf1op/+ mice, insulin resistance developed similarly over time in both WT and 
Csf1op/+ mice (Fig. 7C-F). Therefore, our results do not support a role for Csf1 in the 
pathology of insulin resistance in mice.
In summary, we have shown that Csf1 haploinsufficiency leads to reduced 
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Kupffer cell-driven infl ammation and increased fasting-induced hepatic steatosis, 
although it does not appear to protect from the development of insulin resistance. 
Our results therefore suggest that Csf1-induced macrophages are important 
for protection against the development of hepatic steatosis, but do not affect the 
etiology of insulin resistance. We have shown that Csf1 has a benefi cial role in lipid 
metabolism, suggesting that caution should be exercised with using CSF-blockade 
or neutralization agents in the treatment of infl ammatory diseases, since they may 
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Oral Glucose Tolerance Test. Chow- and HFC-fed Csf1+/+ and Csf1op/+ mice were 
fasted overnight for 9 h and a glucose bolus (2g/kg body weight) was given by oral 
gavage. Glucose levels were detected in blood collected from the tail tip prior to 
and at 15, 30, 60, 90 and 120 minutes after the gavage using an OneTouch Ultra 
glucometer (Lifescan Benelux, Beerse, Belgium).
Metabolic analysis in vivo. Mice were placed individually in indirect calorimetric 
cages (LabMaster TSE systems, Bad Homburg, Germany). Following an initial 24-h 
acclimatization period, mice were monitored every 13 min for 24 h for 3 consecutive 
days.
Analysis of plasma parameters. Plasma β-hydroxybutyrate levels were 
determined using a commercially available kit (Diasys Diagnostic Systems GmbH, 
Holzheim, Germany). Insulin was determined in plasma from overnight fasted mice 
using an enzyme-linked immunosorbent assay kit (Insulin (mouse) Ultrasensitive 
EIA, Alpco Diagnostics, Salem, NH, USA). Free fatty acids (FFA), triglycerides 
(TG), total cholesterol (TC), alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) were determined by commercially available kits, according 
to the manufacturer’s instructions (FFA: NEFA-HR, Wako Chemicals GmbH, Neuss, 
Germany; TG: Hitachi, Roche, the Netherlands; TC: cholesterol CHOD-PAP, Roche, 
the Netherlands; ALT and AST: Spinreact, Santa Coloma, Spain).
Tissue Preparation and Histology. Mice were euthanized and the livers were 
excised. Frozen-cut liver sections (5 μm) were fixated in liquid nitrogen and stained 
with Cd68 antibody (Abcam, Cambridge, UK) to reveal activated macrophages. 
Photographs were taken with a LEICA camera mounted on a LEICA DM3000 
microscope.
Real-Time Quantitative RT-PCR. Total RNA was isolated from the liver with QIAzol 
Lysis reagent (QIAGEN, Venlo, the Netherlands) according to the manufacturer’s 
instructions and homogenised. Total RNA (1 μg) from each individual mouse was 
converted into cDNA with Quantitect Reverse Transcription kit (QIAGEN, Venlo, 
the Netherlands) according to the manufacturer’s instructions. Quantification of 
gene expression was done by quantitative PCR on a Taqman (7900HT, Applied 
Biosystems, Warrington, UK) with SDS software (Applied Biosystems) by using 
SYBR Green Master Mix (Bio-Rad Laboratories B.V., Veenendaal, the Netherlands). 
The results were normalized to Cyclophillin A (Ppia) mRNA levels. The primers which 
are used are listed in Supplemental Table 1.
VLDL composition. VLDL-TG and cholesterol contents were determined as 
described (23). Phospholipid content was determined using a commercial kit (Diasys 
Diagnostic Systems GmbH, Holzheim, Germany).
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Supplemental Figure 1. No differences in plasma FFA and hepatic cholesterol levels between 
Csf1+/+ and Csf1op/+ mice. Plasma free fatty acids (A) and hepatic cholesterol (B) levels were 
determined biochemically in chow- and high-fat cholesterol (HFC)-fed Csf1+/+ and Csf1op/+ 
mice. (□) = Csf1+/+ mice and (■) = Csf1op/+ mice. Data are expressed as mean ± SEM, n = 6 
per group. * P < 0.05 versus Csf1+/+ mice (Mann-Whitney U Test). 
Supplemental  Figure  2. No differences in 
RER between chow-fed Csf1+/+ and Csf1op/+ 
mice. Indirect calorimetric cage analysis was 
performed to measure respiratory exchange 
ratio (RER) in chow-fed Csf1+/+ and Csf1op/+ 
mice (A). (□) = Csf1+/+ mice and (■) = Csf1op/+ 
mice. Data are expressed as mean ± SEM, n 
= 6 per group. * P < 0.05 versus Csf1+/+ mice 
(Mann-Whitney U Test). 
A B 
A 
Supplemental Table 1.  Primer sequences used for RT-PCR.
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Supplemental Figure 3. No difference in metabolic rate between Csf1+/+ and Csf1op/+ mice 
after correction for lean mass. Indirect calorimetric cage analysis was performed to measure 
VO2 consumption (A), VCO2 production (B), heat production (C), and food intake (D) after 
correction for lean mass in chow- and high-fat cholesterol (HFC)-fed Csf1+/+ and Csf1op/+ mice. 
(□) = Csf1+/+ mice and (■) = Csf1op/+ mice. Data are expressed as mean ± SEM, n = 6 per 
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Background Ceramide and derived glycosphingolipids have been implicated in the 
pathogenesis of obesity-induced insulin resistance. Pharmacological lowering of 
glycosphingolipid metabolism by the iminosugar AMP-DNM has shown promising 
results in improving glucose homeostasis and correcting hepatic steatosis in mice. 
However, AMP-DNM is associated with enhanced fat oxidation and a simultaneous 
reduction in food intake, which in theory could explain the lipid-lowering effects of 
AMP-DNM. As this has never been experimentally addressed, this study aims to 
unravel on the short-term effects of AMP-DNM on lipid metabolism and food intake 
in ad libitum- and pair-fed mice.
Methods We used C57BL/6J mice fed a methionine and choline-deficient (MCD) diet 
to induce hepatic steatosis. Mice were ad libitum-fed for 4 days with chow, MCD and 
MCD diet supplemented with 100 mg/kg/day AMP-DNM and subjected to metabolic 
cage analysis. In addition, to investigate the effect of AMP-DNM treatment on fat 
oxidation in the absence of differences in food intake, MCD-fed mice were pair-fed 
with AMP-DNM treated MCD-fed mice. Energy metabolism in vivo was assessed by 
indirect calorimetry, and by immunoblot analysis of AMPK and ACC and RT-PCR. 
Biochemical parameters in plasma and liver were measured.
Results AMP-DNM treatment inhibits glucosylceramide synthase, reduces food 
intake, increases whole-body fatty acid oxidation and diminishes hepatic lipid 
accumulation in ad libitum-MCD-fed mice. Moreover, using a pair-fed feeding 
strategy, we confirm that AMP-DNM promotes whole-body and hepatic fat oxidation 
in MCD-fed mice, which is not related to the appetite suppressor effect of AMP-DNM 
on fat oxidation.
Conclusion These data show that AMP-DNM has a direct effect on whole-body 
and hepatic fat oxidation unrelated to AMP-DNM’s inhibitory effect on food intake, 
supporting the reported value of AMP-DNM as a therapeutic target for obesity-
associated metabolic disease.




Despite an increased understanding of the importance of a healthy lifestyle, obesity 
and its related disorders, such as insulin resistance, non-alcoholic fatty liver disease 
(NAFLD) and type 2 diabetes (T2D) continue to rise (1). As current preventative 
and pharmacological therapeutic approaches have had limited success so far, it is 
evident that new strategies for treating these diseases are urgently needed.
Ceramides and its glycosphingolipid metabolites have been implicated in the 
pathogenesis of obesity-induced insulin resistance (2,3). Consistent with this, 
pharmacological lowering of glycosphingolipid metabolism by the iminosugar N-(5’-
adamantane-1’-yl-methoxy)-pentyl-1-deoxynojirimycin (AMP-DNM) signifi cantly 
improves glucose homeostasis and insulin signaling in rodent models of insulin 
resistance and T2D (4–6). In addition, AMP-DNM has been shown to restore 
hepatic insulin sensitivity and reverse hepatic steatosis as well as improve adipocyte 
function, and attenuate metabolic infl ammation in both adipose tissue and liver 
in different mouse models (5–8). Although, these data suggest that AMP-DNM 
may hold great promise as novel therapeutic target in metabolic disease, it has 
been suggested that some of the metabolic effects of AMP-DNM are not directly 
related to glucosylceramide (GlcCer) synthase inhibition (8,9). Indeed, lowering of 
glycosphingolipids by genetic knockdown of GlcCer synthase in hepatocytes does 
not reduce liver triglycerides in mice exposed to a high-fat diet (9). In addition, AMP-
DNM treatment has been demonstrated to lower lipid accumulation by promoting 
fat oxidation in the liver (7), thus providing an alternative mechanism for the lipid-
lowering effect of AMP-DNM treatment on lipid homeostasis in the liver.
AMP-DNM treatment is also associated with reduced food intake and signifi cant 
weight loss in mice (7,8,10). This suggests that AMP-DNM, in addition to GlcCer 
synthase inhibition, may also acts like a calorie restriction mimetic. Indeed, calorie 
restriction has been demonstrated to enhance fat oxidation, improve hepatic 
and systemic insulin sensitivity, and decrease the incidence of diabetes and 
atherosclerosis (11–13). Of note, AMP-DNM therapy leads to responses that overlap 
with these effects of calorie restriction mentioned above (4–8,14). Therefore, it is 
likely that AMP-DNM may mediate part of its effects on lipid metabolism through 
fasting-induced stimulation of fat oxidation initiated by suppression of appetite.
To unravel the short-term effects of AMP-DNM treatment on lipid metabolism and 
to identify if AMP-DNM may act like a calorie restriction mimetic, we made use of 
a methionine and choline-defi cient (MCD) diet previously shown to induce hepatic 
steatosis in C57BL/6J mice (15). Our study shows that inhibition of GlcCer synthase 
in MCD-fed mice results in reduced food intake, increased whole-body fat oxidation 
and protection against hepatic steatosis. Using a pair-fed feeding strategy, we also 
confi rm that AMP-DNM treatment promotes whole-body fat oxidation, and that 
this is unrelated to the appetite suppressor effect of AMP-DNM on fat oxidation. 
Collectively, our data suggest that the iminosugar AMP-DNM directly targets whole-
body fat oxidation in mice, supporting the benefi cial use of AMP-DNM as therapeutic 




Mice. All procedures were performed with approval of the University of Groningen 
Ethics Committee for Animal Experiments, which adheres to the principles and 
guidelines established by the European Convention for the Protection of Laboratory 
Animals. Experiments were carried out on male C57Bl/6J mice (Charles River, JAX 
laboratories, France), individually housed in a temperature-controlled room under 
a 12 h light-dark cycle with ad libitum access to water and food, unless stated 
otherwise. Animals were fed a chow diet (RMH-B; Hope Farms, Woerden, NL) or 
a methionine-choline deficient diet (MCD; ICN Biomedicals, Illkirch Cedex, France) 
supplemented with or without 100 mg AMP-DNM/kg body weight per day for 4 days. 
A run-in period of 2 days with chow+AMP-DNM was used to let the mice adjust to 
the compound.
In the pair-fed feeding study, the animals were fed the same amount of MCD diet 
as consumed by the AMP-DNM-treated MCD-fed animals. This was divided into two 
meals and given at 8:00 AM and 6:00 PM to avoid long durations of fasting.
Iminosugar. AMP-DNM was synthesized as described previously (16).
Metabolic analysis in vivo. Mice were placed individually in indirect calorimetric 
cages (LabMaster TSE systems, Bad Homburg, Germany). Following an initial 24-h 
acclimatization period, mice were monitored every 13 min for 24 h for 3 consecutive 
days. The respiratory exchange ratio (RER = VCO2/VO2) was used to estimate the 
percent contribution of fat and carbohydrates to whole-body energy metabolism in 
mice in vivo.
Fat oxidation rates were calculated by the equation 1,695 * (VO2) – 1,701 * (VCO2) 
according to Perronnet and Massicote (17).
Analysis of plasma parameters. Free fatty acids (FFA), triglycerides (TG), and 
total cholesterol (TC) were determined by commercially available kits, according to 
the manufacturer’s instructions (FFA: NEFA-HR, Wako Chemicals GmbH, Neuss, 
Germany; TG: Hitachi, Roche, Woerden, the Netherlands; TC: cholesterol CHOD-
PAP, Roche, Woerden, the Netherlands).
Liver lipids. Total liver lipids were extracted from the liver according to Bligh and Dyer 
(18). Hepatic free and total cholesterol (respectively FC and TC) and triglycerides 
(TG) were quantified using commercially available kits (FC: DiaSys Diagnostic 
Systems GmbH, Holzheim, Germany; Cholesterol CHOD-PAP, Roche, Woerden, 
the Netherlands and Triglycerides Hitachi, Roche, Woerden, the Netherlands), 
respectively. Ceramide and glucosylceramide (GlcCer) were determined in plasma 
and liver samples after lipid extraction according to Folch (19) by high-performance 
liquid chromatography analysis of orthophtaldehyde-conjugated lipids as described 
(4).
Real-Time Quantitative RT-PCR. Total RNA was isolated from the liver with 
QIAzol reagent (QIAGEN, Venlo, the Netherlands) according to the manufacturer’s 
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instructions. Total RNA (1 μg) from each individual mouse was converted into cDNA 
with Quantitect Reverse Transcription kit (QIAGEN, Venlo, the Netherlands) according 
to manufacturer’s instructions. Real time PCR (RT-PCR) was performed using a 
7900HT system (Applied Biosystems, Warrington, UK) by using Power SYBR Green 
Master Mix (Biorad, Veenendaal, the Netherlands). For each gene, a standard curve 
was generated with a serial dilution of a liver cDNA pool. Values were corrected using 
the housekeeping gene Cyclophillin A (Ppia). Primer sequences of Pdk4: forward 
TTGACTCCCACATTGGTTGA and reverse TCATGTGCACAAACTCAGAGC.
Immunoblot analysis. Livers were rapidly removed and frozen with liquid nitrogen. 
Powdered tissue was lysed by homogenization in buffer (150 mM NaCL, 50 mM Tris-
HCl (pH 7.5), 5 mM EDTA, 30 mM pyrophosphate, 50 mM NaF supplemented with 
protease (Complete, Roche Molecular Biochemicals, Almere, the Netherlands) and 
phosphatase inhibitor cocktails (Sigma, Zwijndrecht, the Netherlands), 1% Triton 
X-100 and 100 mM PMSF). Equal amounts of protein were separated by SDS-
PAGE and transferred to nitrocellulose (Bio-Rad, Veenendaal, the Netherlands). 
Antibodies against phospho and total AMP kinase (AMPK), phospho and total acetyl 
CoA carboxylase (ACC) and tubulin were purchased from Cell Signaling (Leiden, 
the Netherlands). The immune-complex was visualized using the molecular imager 
ChemiDoc xrs+ system (Bio-Rad, Veenendaal, the Netherlands). The densitometric 
analysis of bands was done with Image Lab software (Bio-Rad, Veenendaal, the 
Netherlands).
Statistical analysis. Data are expressed as means ± SEM. Data were statistically 
analyzed by performing a non-parametric Mann-Whitney test using GraphPad Prism 
to compare experimental groups (version 5.00 for Windows, GraphPad Software, 
San Diego, CA, USA). The level of signifi cance was set at P<0.05.
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Figure 1. AMP-DNM protects against hepatic steatosis in MCD-fed mice. C57BL/6J mice 
were ad libitum fed a chow, MCD or MCD diet supplemented with 100 mg/kg/day AMP-
DNM for 4 days. Hepatic triglyceride content (A) was determined. Plasma concentrations of 
triglycerides (B) and cholesterol (C) were quantified biochemically. Plasma ceramide (D) and 
glucosylceramide (Glccer) (E) were assessed. Data are expressed as means ± SEM, n = 12-
14 mice in each group. * P<0.05 versus chow diet; # versus MCD diet.
Results
AMP-DNM protects against hepatic steatosis in MCD-fed mice.
To investigate the short-term effects of AMP-DNM on lipid metabolism in the liver, 
C57BL/6J mice were fed ad libitum with chow, MCD or MCD diet supplemented with 
AMP-DNM (100 mg/kg body weight/day) for 4 days. As expected, hepatic steatosis 
was observed in MCD-fed mice when compared to chow-fed mice, and this was 
prevented by AMP-DNM treatment in MCD-fed mice (Fig. 1A). In addition, plasma 
triglycerides (Fig. 1B) and cholesterol levels (Fig. 1C) were significantly reduced 
in MCD-fed mice compared to chow-fed mice. AMP-DNM therapy resulted in a 
further decrease in plasma triglycerides (Fig. 1B) and cholesterol (Fig. 1C) levels 
compared to MCD-fed control mice. No differences were observed in plasma free 
fatty acids (FFA; Fig. S1A), hepatic free (Fig. S1B) and total cholesterol levels (Fig. 
S1C) between the groups. Moreover, no differences were observed in plasma 
ceramide (Fig. 1D) and glucosylceramide (Fig. 1E) levels between chow- and MCD-
fed mice. In line with AMP-DNM treatment in Ldlr-/- and APOE*3 Leiden mice on a 
high cholesterol diet (8,14), plasma ceramide (Fig. 1D) and glucosylceramide (Fig. 
1E) levels were significantly reduced in AMP-DNM treated MCD-fed mice compared 
to MCD-fed control mice. Hepatic ceramide levels were not changed between the 
groups (Table 1) and liver glucosylceramide levels were not different between chow- 
and MCD-fed mice and between AMP-DNM treated MCD- and MCD-fed mice (Table 
1). Taken together these data indicate that AMP-DNM treatment reduces plasma 
lipids and improves hepatic steatosis in ad libitum-MCD-fed mice.




GlcCer (nmol/g liver) 29.3 ± 2.5 48.1 ± 6.8 79.7 ± 11.2*
Ceramide (nmol/g liver) 306.6 ± 5.5 315.0 ± 13.8 336.3 ± 14.2
Table 1. Liver glycosphingolipid levels in ad libitum-fed mice.
Liver glucosylceramide (GlcCer) and ceramide levels in ad libitum-fed C57BL/6J mice with a 
chow diet, MCD diet or MCD diet supplemented with 100 mg/kg/day of AMP-DNM for 4 days. 
AMP-DNM reduces food intake and enhances whole-body fat oxidation in 
MCD-fed mice.
We next determined the effect of AMP-DNM on food intake and body weight in 
ad libitum-fed mice. Caloric intake was not different between chow- and MCD-fed 
mice, however, was signifi cantly decreased in AMP-DNM treated MCD-fed mice 
compared to MCD-fed mice (Fig. 2A). Body weight was signifi cantly lower in MCD-
fed mice compared to chow-fed mice (Fig. 2B); however, AMP-DNM treated MCD-
fed mice did not lose more weight than MCD-fed control mice (Fig. 2B). Next, we 
used indirect calorimetry to assess the effect of AMP-DNM treatment on whole 
body energy metabolism in these mice. No differences in VO2 consumption (Fig. 
2C), VCO2 production (Fig. 2C), heat production (Fig. 2D), activity (Fig. 2E), and 
respiratory exchange ratio (RER; Fig. 2F) were observed between chow- and MCD-
fed mice. Although, AMP-DNM treatment did not alter VO2 consumption in MCD-
fed mice, VCO2 production was signifi cantly reduced in AMP-DNM treated MCD-
fed mice compared to MCD-fed controls (Fig. 2C). This was not accompanied by 
a signifi cant reduction in heat production in (Fig. 2D), however, activity levels (Fig. 
2E) were markedly lower throughout the dark, active phase in AMP-DNM treated 
MCD-fed mice compared to MCD-fed mice. In addition, exposure to AMP-DNM led 
to consistent lower RER values throughout the entire dark phase in MCD-fed mice 
(Fig. 2F, p=0.004), indicating a relative shift in substrate use from carbohydrate to 
fat oxidation in AMP-DNM treated MCD-fed mice. Indeed, calculation of the fat and 
carbohydrate oxidation rates in these mice (7) confi rmed an increased contribution 
of fat oxidation to total fuel oxidation in AMP-DNM treated MCD-fed mice compared 
to MCD-fed control mice (Fig. 2G).
AMP-DNM has a direct effect on fat oxidation unrelated to food intake.
To investigate whether the effect of AMP-DNM treatment on fat oxidation in MCD-fed 
mice is a result of reduced food intake, MCD-fed mice were pair-fed with AMP-DNM 
treated MCD-fed mice. For this, MCD-fed mice were calorie restricted to a level 
of 55% of their normal food intake. As expected from pair-fed feeding, food intake 
(Fig. 3A) was not different between MCD- and AMP-DNM treated MCD-fed mice. 
In addition, body weight did not differ between both groups (Fig. 3B). Consistent 
with the observed effects of AMP-DNM treatment in ad libitum-fed mice (Fig. 2), 
VO2 consumption (Fig. 3C) was unaltered between both groups of mice, and VCO2 
production (Fig. 3D) was signifi cantly reduced in the light phase in AMP-DNM treated 
MCD-fed mice compared to MCD-fed controls. Moreover, heat production and activity 
levels were not different between pair-fed mice (data not shown). Of note, calorie 
restriction in MCD-fed mice resulted in a signifi cant drop in RER levels (Fig. 3E) in 
the dark phase to ~0.73, indicative of a fasting-induced increase in fat oxidation. This 
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Figure 2. AMP-DNM reduces food intake and enhances whole-body fat oxidation in MCD-
fed mice. Food intake (A) and body weight (B) were measured. Indirect calorimetry was 
performed to measure VO2 consumption or VCO2 production (C), heat production (D), total 
activity (E), respiratory exchange ratio (RER) (F) and fuel oxidation (G) in C57BL/6J mice fed 
ad libitum with chow, MCD or MCD diet supplemented with 100 mg/kg/day AMP-DNM for 4 
days. Data are expressed as means ± SEM, n = 5 mice in each group. * P<0.05 versus chow 
diet; # P<0.05 versus MCD diet.
was not observed in AMP-DNM treated MCD-fed mice as AMP-DNM treated MCD-
fed mice maintained an RER of ~0.86-0.9 throughout the entire day (Fig. 3E). This 
may indicate that AMP-DNM treated mice are not energy-compromised, suggesting 
that AMP-DNM might exert a direct effect on fat oxidation unrelated to food intake.
AMP-DNM leads to increased hepatic steatosis in pair-fed mice.
We next investigated the effect of AMP-DNM treatment on lipid metabolism in 
pair-fed mice. Plasma free fatty acids (FFA) were increased in AMP-DNM treated 
MCD-fed mice compared to MCD-fed control mice (Fig. 4A). Whereas AMP-DNM 
treated MCD-fed mice showed a reduction in plasma cholesterol levels compared 
to MCD-fed mice (Fig. 4B), plasma triglyceride levels were not different between the 
groups (Fig. 4C). However, hepatic fat accumulation was elevated in the AMP-DNM 
treated MCD-fed mice compared to MCD-fed mice (Fig. 4D). In addition, plasma 
ceramide levels were not changed between MCD- and AMP-DNM treated MCD-
fed mice (Fig. 4E). As expected, plasma glucosylceramide levels were reduced in 
AMP-DNM treated MCD-fed mice compared to MCD control mice (Fig. 4F), whereas 
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Figure 3. AMP-DNM has a direct effect on whole-body fat oxidation which is unrelated to food 
intake. C57BL/6J mice were pair-fed with MCD with and without supplemented AMP-DNM 
to the diet. Food intake (A) and body weight were measured (B). Indirect calorimetry was 
performed to measure VO2 consumption (C) VCO2 production (D), and respiratory exchange 
ratio (RER) (E). Data are expressed as means ± SEM, n = 4-5 mice in each group. * P<0.05 
versus MCD diet. 
MCD MCD+AMP-DNM
GlcCer (nmol/g liver) 50.7 ± 3.2 58.3 ± 15.5
Ceramide (nmol/g liver) 212.2 ± 9.5 258.5 ± 14.8
Table 2. Liver glycosphingolipid levels in pair-fed mice.
Liver glucosylceramide (GlcCer) and ceramide levels in pair-fed mice with MCD or MCD diet 
supplemented with 100 mg/kg/day of AMP-DNM for 4 days. 
liver ceramide and glucosylceramide levels were not altered between both groups 
of mice (Table 2).
AMP-DNM treatment directly targets hepatic fat oxidation in pair-fed mice.
To further investigate the effect of AMP-DNM treatment on hepatic fat oxidation 
in pair-fed mice, we examined gene expression of pyruvate dehydrogenase 
kinase isozyme 4 (Pdk4) in livers of MCD- and AMP-DNM treated MCD-fed mice. 








Figure 4. AMP-DNM leads to increased hepatic steatosis in pair-fed mice. C57BL/6J mice 
were pair-fed with MCD with and without supplemented AMP-DNM to the diet for 4 days. 
Plasma concentrations of free fatty acids (FFA) (A), cholesterol (B), and triglycerides (C) 
were quantified biochemically. Triglyceride content in the liver (D) was determined. Plasma 
ceramide (E) and glucosylceramide (GlcCer) (F) concentrations were measured. Data are 
expressed as means ± SEM, n = 4-5 mice in each group. * P<0.05 versus MCD diet.
mice compared to MCD-fed mice (Fig 5A). In addition, plasma β-hydroxybutyrate 
levels were significantly increased in AMP-DNM treated MCD-fed mice compared 
to MCD-fed mice, indicating that hepatic fat oxidation is enhanced in AMP-DNM 
treated MCD-fed mice. Moreover, AMP-DNM-treated MCD-fed mice have increased 
β-hydroxybutyrate levels compared to MCD-fed mice (Fig. 5B). Next we examined 
the energy-sensing kinase, AMP-activated protein kinase (AMPK), which is a crucial 
cellular nutrient and energy sensor, and regulates glucose and lipid metabolism (20). 
No differences in the phosphorylation status of AMPK (Fig. 5C) and total AMPK 
levels (Fig. 5D) between ad libitum-fed and MCD-restricted mice were observed. 
However, the phosphorylation status of AMPK was significantly increased in AMP-
DNM treated MCD-fed mice compared to both pair- and ad libitum-fed control mice 
(Fig. 5C). In addition, AMP-DNM treatment resulted in a significant reduction in total 
AMPK levels (Fig. 5D). Next we assessed the phosphorylation status of acetyl CoA 
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Figure 5. AMP-DNM treatment directly targets hepatic fat oxidation in pair-fed mice. C57BL/6J 
mice were pair-fed with MCD with and without supplemented AMP-DNM to the diet for 4 days. 
Gene expression in whole liver homogenate of pyruvate dehydrogenase kinase, isoenzyme 
4 (Pdk4) (A) was determined by RT-PCR and expressed as fold induction versus MCD 
diet. Plasma β-hydroxybutyrate levels were measured as a marker for beta-oxidation (B). 
Phosphorylation status of AMPK at threonine 172 (C) and ACC at serine 79 (E) were detected 
using immunoblot analysis with phospho-specifi c antibodies. Immunoblots were quantifi ed by 
densitometry and normalized against total protein levels of AMPK (D) and ACC (C). Data are 
expressed as means ± SEM, n = 4-5 mice in each group. * P<0.05 versus MCD diet. 
acid entry into the mitochondria and ultimately β-oxidation. AMP-DNM did not alter 
the phosphorylation status of ACC in livers of MCD-fed mice (Fig. 5E). However, we 
observed a signifi cant drop in both phospho and total levels of both ACC isoforms 
following AMP-DNM treatment in MCD-fed mice (Fig. 5E; pACC, MCD 1.02 ± 0.07 vs 
MCD+AMP-DNM 0.58 ± 0.05, p<0.01; ACC, MCD 1.13 ± 0.08 vs MCD+AMP-DNM 
0.57 ± 0.06, p<0.01). This may suggest that AMP-DNM directly affects the processes 
of fat acid oxidation and synthesis in livers of MCD-fed mice, independent from the 
observed appetite suppressor effect of AMP-DNM.



















In this study, we aimed to gain more insight into the short-term effects of AMP-
DNM on lipid metabolism. We wanted to identify if AMP-DNM mediates part of its 
lipid-lowering effects through acting as a caloric restriction mimetic. Using a MCD 
diet to induce hepatic steatosis in ad libitum-fed mice, we demonstrated that short-
term AMP-DNM treatment results in reduced food intake, increased whole-body 
fat oxidation and protection against the development of hepatic steatosis. Using a 
pair-fed feeding strategy, we confirmed that AMP-DNM directly induces whole-body 
and hepatic fat oxidation, which is not related to the appetite suppressor effect of 
AMP-DNM on fat oxidation. Therefore, our data suggest that the iminosugar AMP-
DNM might directly stimulate whole-body and hepatic fat oxidation, supporting the 
beneficial role of AMP-DNM as a therapeutic target in metabolic disease.
In line with previous reports in ad libitum-fed mice (5,7,8), we show that 
glucosylceramide synthase inhibition by the iminosugar AMP-DNM results in a 
reduction of hepatic steatosis in MCD-fed mice (Fig. 1A). In addition, we have also 
shown that AMP-DNM treatment of MCD-fed mice results in a 45% reduction of food 
intake (Fig. 2A) and this is accompanied by a significant increase in whole-body fat 
oxidation (Fig. 2F, 2G) compared to untreated MCD-fed mice. As similar observations 
of AMP-DNM on food intake and fat oxidation have been observed previously (7,8) 
and caloric restriction is known to induce fat oxidation (21,22), our results in ad 
libitum-MCD-fed mice suggest that this increase in whole-body fat oxidation might 
be a result of the severe reduction in food intake in AMP-DNM treated MCD-fed 
mice. However, using a pair-fed feeding strategy, we demonstrate that AMP-DNM 
treatment directly promotes whole-body fat oxidation, as reflected by an RER that 
is distinct from the normal response to starvation (Fig. 3E). Indeed, the calorie 
restriction-induced effect on fat oxidation was significantly more dramatic in pair-fed 
MCD-fed mice compared to AMP-DNM-treated mice (Fig. 3E), suggesting that AMP-
DNM-treated mice are not energy compromised in comparison to the MCD-pair-fed 
mice. This indicates that the enhanced fat oxidation observed in ad libitum-fed mice 
is independent of the appetite suppressing effect of AMP-DNM.
In addition to the stimulation of whole body fat oxidation, AMP-DNM treatment 
increased hepatic fat oxidation, which was associated with enhanced mRNA 
expression of Pdk4 (Fig. 5A) and increased production of ketone bodies in 
the circulation (ketogenesis) (Fig. 5B). In addition, we observed an increased 
phosporylation of pAMPK/AMPK (Fig. 5C) associated with a significant reduction 
in protein expression of both ACC isoforms (Fig. 5E) following AMP-DNM treatment 
in MCD-fed mice compared to both ad libitum- and MCD-pair-fed mice. Given their 
regulatory roles in both lipogenesis (ACC1), β-oxidation and ketogenesis (ACC2) 
(23,24), and the reported continuous fat oxidation in Acc2-/- mice (25), this may 
further provide evidence for a direct role AMP-DNM in the stimulation of fat oxidation 
in the liver. However, enhanced fat oxidation following AMP-DNM treatment in MCD-
fed mice was associated with increased hepatic steatosis compared to pair-fed 
controls (Fig. 4D). This is in contrast to the lipid-lowering effect of AMP-DNM on 
hepatic steatosis in ad libitum-fed mice, both in our study as reported by many others 
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(5,7,8,10). Although we can’t explain this controversial fi nding, it may be suggested 
that during starvation dietary fatty acids are immediately oxidized and thus not 
preferentially stored in the liver as triglycerides. Since, we show a starvation effect 
on fat oxidation in MCD-pair-fed but not in AMP-DNM treated mice, this may thus 
explain why hepatic steatosis is in fact increased in AMP-DNM-treated MCD-fed 
mice compared to MCD-pair-fed mice.
Although our data indicates that the effect of AMP-DNM on fat oxidation and food 
intake are seemingly unrelated, they could still be intertwined and thus it remains to 
be clarifi ed how AMP-DNM integrates these effects on food intake and fat oxidation. 
Although it is not known of AMP-DNM is able to cross the blood brain barrier, AMP-
DNM has previously been shown to stimulate the production of plasma peptide YY 
(PYY), a satiety-regulating hormone released from the L cells in the intestine in 
response to food intake (7). PYY has been demonstrated to reduce appetite and slow 
gastric emptying, most likely due to stimulation of the Y2 receptor in the hypothalamus 
(26,27), the central regulator of food intake (28). Furthermore, it has been shown to 
increase fat oxidation following acute and chronic PPY administration in C57BL/6 
mice (29), suggesting that PYY may modulate the integration between food intake 
and fat oxidation in ad libitum-fed mice. However, as the effect of AMP-DNM on 
food intake in our study is secondary to the alteration in substrate metabolism, and 
since there is unambiguous evidence to support a role for the liver in the control 
of food intake (30,31), we propose an alternative explanation involving an hepatic 
site of action for the observed effects of AMP-DNM on fat oxidation and food intake 
in AMP-DNM treated mice. The liver is an important metabolic sensor involved in 
the relay of humoral and neural signals via the brain stem to the hypothalamus 
(32). It has been postulated that hepatic fat oxidation could modulate vagal afferent 
activity and thus food intake by alterations in the hepatic membrane potential that 
cause a reduction in afferent spike frequency resulting in transmission of a satiety 
signal to the brain (30,31). In addition, hepatic fat oxidation may control food intake 
by producing ketones like 3-hydroxybutyrate that are used as fuels by peripheral 
nerve fi bers (33). Given that AMP-DNM stimulates hepatic fat oxidation and plasma 
ketones are elevated in our study, it is therefore plausible that AMP-DNM may 
indeed mediate the control of food intake by directly enhancing hepatic fatty acid 
oxidation and ketogenesis. However, further studies should be directed to support 
this hypothesis.
Based on the reduction in food intake in AMP-DNM treated mice, it might be 
suggested that AMP-DNM could be used as anti-obesity therapeutic. Although, 
AMP-DNM treatment did not result in a further decrease in body weight compared to 
both MCD-fed (Fig. 2B) and pair-fed mice (Fig. 3B), it might be that 4 days of AMP-
DNM treatment is too short to lead to a reduction in body weight. Indeed, prolonged 
treatment with AMP-DNM did result in reduced body weight (gain) (7,8), suggesting 
that AMP-DNM may hold therapeutic value as an anti-obesity agent.
In summary, our study demonstrates that AMP-DNM inhibits GlcCer synthase, 
reduces food intake, increases whole-body fat oxidation and protects against the 
development of hepatic steatosis in MCD-fed mice. Moreover, in the paired feeding 
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study, we confirm that AMP-DNM enhances whole-body fat oxidation and this is 
unrelated to the appetite suppressor effect of AMP-DNM on fat oxidation. Therefore 
this study suggests that AMP-DNM directly targets whole-body and hepatic fat 
oxidation in MCD-fed mice, supporting a beneficial role of AMP-DNM as a therapeutic 
strategy for obesity-associated metabolic disease.
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Figure S1. Effect of 4 days of AMP-DNM treatment on plasma and liver lipids. C57BL/6J mice 
were fed ad libitum a chow, MCD or MCD diet supplemented with 100 mg/kg/day AMP-DNM 
for 4 days. Plasma concentrations of free fatty acids (FFA) (A) and liver free cholesterol (B) 
and total cholesterol (C) content were measured biochemically. Data are expressed as means 
± SEM, n = 12-14 mice in each group. *P < 0.05 versus chow diet. 
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It is generally assumed that inflammation plays a crucial role in the etiology of obesity-
induced insulin resistance and type 2 diabetes (T2D). Inflammation in obesity is 
largely driven by tissue macrophages, and particularly the activated macrophages in 
metabolic tissues like adipose tissue and liver are believed to cause insulin resistance. 
Although, most studies have focussed on the role of adipose tissue macrophages, 
the liver has the largest population of macrophages, which includes the resident 
macrophages of the liver also known as Kupffer cells. In my thesis, we aimed to 
establish the role of Kupffer cells on the development of insulin resistance. Insulin 
resistance is the most important therapeutic target for the metabolic syndrome and 
therefore insulin resistance is the focus of this discussion. Of note, some of our 
hypotheses seemed to conflict with the current ideas about the role of inflammation 
as a cause for the development of insulin resistance. These findings indicate that 
our current view is still in its infancy, limiting the use of inflammation as a preventive 
and therapeutic target. Below I will review the role of hepatic inflammation in the 
development of insulin resistance and discuss the caveats in obesity-induced insulin 
resistance.
1. Current state of the art
1.1. Mechanism of insulin resistance
Obesity is the most common cause of insulin resistance in humans. Therefore, obesity-
induced insulin resistance is one of the dominant factors underlying both metabolic 
syndrome and the rising frequency of T2D. It is clear that T2D is a heterogeneous 
disease, making the etiology of insulin resistance complex (1). Chronic, low-grade 
tissue inflammation is a well-known cause of obesity-induced insulin resistance (2,3). 
In humans, obesity is associated with increased levels of inflammatory cytokines, 
including tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6) (4) and 
increased levels of C-reactive protein (CRP) (5). Two transcription factor signaling 
pathways have been linked to the pro-inflammatory effects of obesity and insulin 
resistance: the nuclear factor-κB (NF-κB) pathway, which is activated by inhibitor 
of NF-κB (IκB) kinase β (IKKβ), and the c-Jun NH2-terminal kinase (JNK) pathway. 
Obesity and high-fat diets activate IKKβ/NF-κB and JNK pathways in different cell 
types including adipocytes, hepatocytes and macrophages (6). These pathways 
are activated by pro-inflammatory stimuli including cytokines such as TNFα and 
interleukin-1 (IL-1) and toll-like receptors (TLRs). Moreover, intracellular stressors 
like reactive oxygen species (ROS), endoplasmic reticulum (ER) stress, ceramides 
and various protein kinase C (PKC) isoforms have also been shown to activate 
JNK and NF-κB (7-10). Phosphorylation of insulin receptor substrate (IRS) 1 and/
or 2 at serine sites by either JNK or IKKβ potently inhibits insulin action (Fig. 1; 
reviewed in (11,12)). Pharmacological or genetic inhibition of IKKβ/NF-κB and JNK 
signaling have been found to protect experimental animals and humans from diet-
induced insulin resistance (13,14). In addition, heterozygous IKKβ+/- mice fed a high-
fat diet or crossed with obese ob/ob mice, are protected against the development 
of insulin resistance (15). Moreover, genetic deletion of JNK-1 in mice results in 




























Figure 1. Cellular mechanisms for activating infl ammatory signaling. The IKKβ/NF-κB and 
JNK pathways ahave been linked to the pro-infl ammatory effects of obesity and insulin 
resistance. These pathways are activated by cytokines, TLRs or intracellular stressors, 
including ceramides, ROS, ER stress and PKCs. IKKβ and JNK activation leads to serine 
phosphorylation of IRS-1 and IRS-2, and consequently inhibits insulin signaling.
demonstrating the importance of JNK signaling in obesity-induced infl ammation and 
insulin resistance.
1.2. Infl ammation and insulin resistance in adipose tissue and liver
Adipose tissue is an important initiator of the infl ammatory response to obesity. The 
discovery of adipose tissue being infi ltrated with increasing numbers of macrophages 
in obese mice and humans has led to a major mechanistic breakthrough into the 
understanding of how obesity and infl ammation are connected (17,18). As part 
of the chronic infl ammatory process, activation of adipose tissue macrophages 
(ATMs) results in the secretion of chemokines, which attract pro-infl ammatory 
macrophages into the adipose tissue where they form crown-like structures (19). 
These tissue macrophages then release pro-infl ammatory cytokines that further 
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activate the inflammatory pathway in neighbouring adipocytes, thereby exacerbating 
inflammation and insulin resistance (reviewed in (20)).
In addition to inflammation and insulin resistance within the adipose tissue, the same 
process can occur in the liver. Hepatocyte-driven inflammation has been demonstrated 
to play a role in the etiology of insulin resistance. Expression of constitutively-
active IKKβ in the liver resulted in hepatic and systemic insulin resistance (21). 
Moreover, mice lacking IKKβ in the hepatocytes retain insulin responsiveness in 
the liver in response to high-fat feeding, obesity or aging, but these mice develop 
insulin resistance in skeletal muscle and adipose tissue (22). Moreover, secretion 
of pro-inflammatory cytokines by the Kupffer cells, the resident macrophages of the 
liver, are linked to disruption of hepatic insulin signaling (23). Consistent with this, 
enhanced expression of inflammatory genes in the liver following high-fat feeding is 
associated with reduced insulin sensitivity in mice (21,24). These studies suggest 
that insulin resistance is causally related to hepatic inflammation (21-23).
Although activation of pro-inflammatory pathways in insulin target tissues (adipose 
tissue, liver and muscle) is strongly associated with the development of systemic 
insulin resistance, recent reports, including this thesis, have raised doubt on the 
causality of this association. Hence, the general role of inflammation as inducer 
of insulin resistance may be questioned and it has become of significant interest 
to precisely understand the link between inflammation and insulin resistance. Only 
then, it will be possible to design the much-needed novel therapies to combat T2D.
2. The controversial role of hepatic inflammation and insulin 
resistance
2.1. Discrepancies in the models used to study the role of inflammation in 
the pathogenesis of insulin resistance
In this thesis, we have demonstrated using 3 different mouse models that hepatic 
inflammation does not necessarily cause insulin resistance. We have assessed 
the role of inflammation in the development of insulin resistance by making use of 
a high-fat cholesterol (HFC) diet, which is known to induce hepatic inflammation 
already after 7 days of treatment (25). First, we have established that short-term 
HFC feeding results in pronounced Kupffer cell-driven hepatic inflammation in low-
density lipoprotein receptor knockout (Ldlr-/-) mice (Chapter 2). However, we did not 
observe any signs of systemic or hepatic insulin resistance in these mice during the 
onset of obesity. In addition, sustained hepatic inflammation induced by 15 weeks 
of HFC feeding did not aggravate the development of hepatic or systemic insulin 
resistance in Ldlr-/- mice compared to mice fed the high-fat control diet without 
excess cholesterol (HFnC) and a regular high-fat (HF)-diabetogenic diet. As we do 
not find a correlation between the level of hepatic inflammation, insulin resistance 
and/or obesity, our data, suggest that HFC-induced hepatic inflammation does not 
contribute to insulin resistance in Ldlr-/- mice (Chapter 2). Second, global deletion 




adaptor for most TLRs and IL-1 receptor family members, results in reduced hepatic 
infl ammation but does not lead to protection from obesity-induced insulin resistance 
(Chapter 3). In fact, insulin resistance was even exacerbated in high-fat fed 
Myd88-/- mice, while body weight or adiposity remained unaffected (26,27). Third, 
colony stimulating factor 1 insuffi cient (Csf1op/+) mice show lower infl ammatory levels 
in the liver, adipose tissue and plasma, but still develop systemic insulin resistance 
(Chapter 4).
In support of this, more studies have shown a disconnection between insulin 
resistance and hepatic infl ammation (28-30). In contrast, hepatic insulin resistance 
is not necessarily associated with the presence of infl ammation in the liver as mice 
overexpressing diacylglycerol O-acyltransferase 2 (DGAT2) in the liver displayed 
hepatic insulin resistance in the absence of liver infl ammation on a chow diet (30). 
Kupffer cell depletion, by clodronate encapsulated liposomes, has shown to reduce 
hepatic infl ammation, but these mice still develop insulin resistance (29).
Different experimental approaches (genetically engineered mouse models, Kupffer 
cell depletion, and dietary intervention studies) may be an explanation for the 
discrepancies about the role of infl ammation in the development of insulin resistance. 
Hepatic infl ammation could be studied by 2 different approaches, including 
hepatocyte- or Kupffer cell-driven hepatic infl ammation. However, the question now 
rises whether hepatocyte-driven infl ammation is functionally different from Kupffer 
cell-driven infl ammation and whether or not there is a distinctive role in their control 
of insulin resistance. A caveat of our experiments could be that the reduced hepatic 
infl ammation is solely due to decreased expression of infl ammatory genes in the 
Kupffer cells and not due to hepatocytes. This would explain why insulin signaling 
remains unaffected (Chapter 4). Nevertheless, the overall infl ammatory tone in 
the liver is high, and does not affect insulin signalling. Hence, it should be clear 
that infl ammation in the adipose tissue, rather than liver is likely to be the dominant 
mechanism in insulin resistance. In Ldlr-/- (Chapter 2) and Myd88-/- (Chapter 3) mice 
we did not assess the role of adipose tissue infl ammation in the development of 
insulin resistance. Therefore these studies cannot answer the question whether total 
adiposity may be the driving force behind the development of insulin resistance in our 
model. However, Csf1 insuffi cient mice have reduced adipose tissue infl ammation 
but still develop insulin resistance. So the adipose tissue cannot explain the 
development of insulin resistance in Csf1op/+ mice (Chapter 4).
In contrast to global Myd88 defi ciency, deletion of Myd88 from the hematopoietic 
compartment results in the protection from infl ammation-induced insulin resistance 
(Chapter 3). In our global Myd88-/- mouse we cannot rule out the role of other cell 
types including the hepatocytes in the development of infl ammation-induced insulin 
resistance. However, in our hematopoietic defi cient Myd88 model Myd88 is depleted 
in all bone-marrow derived cells, including the Kupffer cells (Chapter 3). Therefore 
these suggest that Kupffer cell-mediated hepatic infl ammation is indeed involved in 
the development of insulin resistance. In addition, mice with brain-specifi c deletion 
of Myd88 are protected from hypothalamic infl ammation as well as peripheral insulin 
resistance induced by either palmitate or a HF diet (31).
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A better understanding why the above mentioned models do not exhibit (hepatic) 
inflammation-induced insulin resistance is of significant interest, as these mechanisms 
of insulin resistance.
2.2. The controversial role of TNFα in inflammation-induced insulin 
resistance
As described above, TNFα, derived from the expanding adipose tissue, is one of the 
cytokines that has been linked to the development of obesity and insulin resistance 
(32). However, several studies question a role for this cytokine and its signaling 
pathway in the development of insulin resistance (33-36). Ob/ob mice that lack TNFα 
or its receptors (p55 or p75) show a partial protection against the development of 
insulin resistance (34). Remarkably, using the same mice, Schreyer et al. showed 
that mice lacking the TNF receptors, p55 and p75, demonstrated an exacerbation 
of insulin resistance (37). In addition, insulin sensitivity in ob/ob mice that only lack 
the p75 TNFR2 is not affected (38). Other studies also do not support a role for the 
TNFR in the development of insulin resistance in mice (35). In contrast, it has been 
suggested that deletion of the TNFR1 exacerbates insulin resistance (33). Moreover, 
in a gain of function mutant mice expressing the nonsheddable TNFR1 (p55delta 
ns mice), resulting in chronic low-grade inflammation, we have shown that hepatic 
inflammation is not associated with insulin resistance (28). Subsequently, these mice 
were fed a chow diet for one year and were not prone to develop insulin resistance, 
nor did 12 weeks of HF feeding at the age of one year accelerate the onset of insulin 
resistance in these mice (28). Although it has been demonstrated that the pro-
inflammatory cytokine TNFα was able to induce insulin resistance in rodents (32), 
neutralizing antibodies against TNFα do not significantly improve insulin sensitivity 
in obese type 2 diabetic patients (39). In contrast to what has been suggested by 
others (40,41), circulating concentrations of TNFα are not increased in patients with 
insulin resistance (42,43). Thus, while initial studies described a causal link between 
TNF receptor signaling and insulin resistance, recent data cannot confirm this, and 
also patient data using TNFR receptor blockers to improve insulin signaling are not 
encouraging.
A possible explanation for the lack of in vivo efficacy of TNFα treatment in patients with 
insulin resistance could be the large difference between circulating and tissue levels 
of TNFα. TNFα exerts its effects in a paracrine fashion. Given that interstitial adipose 
tissue levels are 1-2 orders of magnitude higher than circulating TNFα concentrations 
(44), the possibility arises that that TNFα blocking agents may neutralize the TNFα 
levels in the circulation only. This leaves the TNFα concentrations in the adipose 
tissue virtually unaffected. As a result, the effects of TNFα to cause decreased 
insulin sensitivity are not inhibited because of insufficient penetration into the tissues 
(45). Nevertheless, treatment of rheumatoid arthritis patients with TNFα inhibitors 
improved insulin resistance and led to a decreased rate of progression to T2D (46).




of insulin resistance. Previous reports have revealed that lipopolysaccharide (LPS) 
levels are increased following a high-fat diet and induce hepatic steatosis and insulin 
resistance in obese mice (47). Moreover, treatment with antibiotics resulted in a 
reduction of LPS levels and improved the steatosis and insulin resistance in obese 
mice (48). In addition, administration of TNFα induces acute hepatitis (49); however, 
it does not mimic the chronic low-grade infl ammation associated with obesity. Mice 
expressing non-sheddable TNFR1 have hepatic infl ammatory gene expression level 
of approximately 10- to 100-fold lower than mice receiving a single injection with 
TNFα (28). Both LPS and TNFα induce an acute infl ammatory response, while in 
our studies we have a more physiologically relevant situation of chronic low-grade 
hepatic infl ammation. Therefore the level of infl ammation is of signifi cant importance 
in the development of insulin resistance.
2.3. The controversial role of IKKε in obesity-induced insulin resistance
In addition to the involvement of the classical IκB kinases, IKKα and IKKβ, IKKε has 
been suggested as novel player in the etiology of obesity-related insulin resistance 
(50). Interestingly, studies addressing a role of IKKε in obesity and insulin resistance 
have also shown confl icting results. In a study by Chiang et al., IKKε-/- mice appear to 
be protected from diet-induced weight gain, adipose tissue infl ammation and whole-
body insulin resistance (50). However, Scheja et al., did not confi rm this fi nding. 
Indeed, insulin resistance developed to a similar extent in IKKε-/- and WT mice 
following 19 weeks of HF diet feeding (51). Moreover, body weight, fasting glucose 
and insulin levels, and homeostasis model of assessment-insulin resistance (HOMA-
IR) did not differ between WT and IKKε-/- mice (51). In addition, infl ammatory levels 
in the adipose tissue, liver, and the circulation were not decreased in IKKε-/- mice 
(51). A possible explanation that could underlie this discrepancy between the two 
studies could be variations in the degree of diet-induced obesity observed between 
both studies. For instance, insulin sensitivity was only maintained in IKKε-/- mice 
protected against HF-induced weight-gain (50), whereas IKKε-/- mice that gained 
weight following HF feeding also developed insulin resistance (51). This could be 
due to the higher fat content of the diet (59 cal% (50) versus 45 cal% (51)) or the 
earlier onset of the dietary regimen (6 weeks of age (50) vs 14-18 weeks (51)).
Despite these controversies, amlexanox, a high-affi nity inhibitor of IKKε used in the 
clinic to treat asthma, allergic rhinitis and aphthous ulcers, has recently been tested 
as a potential treatment option for obesity and related disorders in mice (52). Daily 
administration of amlexanox revealed that HFD-induced weight gain was prevented 
in mouse models of obesity. Moreover, amlexanox improved insulin sensitivity, 
attenuated hepatic steatosis and reduced adipose tissue infl ammation. In addition, 
amlexanox promoted energy expenditure in adipose tissue through increased 
thermogenesis (52). Amlexanox may thus be an interesting candidate for clinical 
evaluation in the treatment of obesity and related disorders.
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3. Balance between inflammatory mediators for metabolic 
control
Despite the ambiguities discussed above, macrophages are important players in the 
development of insulin resistance. Some of the ambiguities may be due to the fact 
that not all studies have thoroughly investigated the macrophage subtypes that may 
be more relevant for their role in diseases than measuring their cytokine production. 
Macrophages show heterogeneity in their function, as local environmental factors 
shape their properties and activation state (53,54). Macrophage are able to produce 
cytokines and their activation has been roughly defined across 2 separate polarization 
states, M1 and M2 (53,54). M1 or “classically activated” macrophages are induced 
by pro-inflammatory mediators such as LPS and IFN-γ. M1 macrophages have 
enhanced production of the pro-inflammatory cytokines TNFα and IL-6. In vitro, M2 or 
“alternatively activated” macrophages are generated by stimulation of macrophages 
with IL-4 and/or IL-13 (55). M2 macrophages have low pro-inflammatory cytokine 
expression and instead these macrophages produce high levels of anti-inflammatory 
cytokines like IL-10. In the normal situation there is a balance between M1 and 
M2 macrophages, and between pro- and anti-inflammatory cytokines. The balance 
between M1 and M2 macrophage populations within visceral adipose tissue appears 
to be crucially involved in the development of obesity-associated insulin resistance 
(56). It has been demonstrated that adipose tissue macrophages (ATMs) in lean mice 
are polarized towards the alternatively activated M2 state, whereas ATMs in obese 
mice have a classically activated M1 profile (57). Not only in the adipose tissue, but 
also the macrophages in the liver, the Kupffer cells, have these M1 or M2 properties 
(55,58). Moreover, previous reports have suggested that alternatively activated 
M2 macrophages protect hepatocytes from the development of inflammation and 
steatosis associated with high-fat diet-induced obesity (29,59). CSF-1-induced 
macrophages are known to be associated with alternatively activated M2 properties 
(60). We have shown that Csf1 insufficiency resulted in reduced Kupffer cell-mediated 
hepatic inflammation and fasting-induced hepatic steatosis. This increased liver 
accumulation is likely due to a decrease in very-low density lipoprotein- triglyceride 
(VLDL-TG) synthesis and not to differences in de novo lipogenesis or β-oxidation 
(Chapter 4). In line with this, genetic ablation of Pparδ impairs alternative activation 
of Kupffer cells, leading to the development of hepatic steatosis (59,61). Moreover, 
co-culture of Kupffer cells with LPS to induce M1 polarization results in increased 
hepatic triglyceride accumulation (62). In addition, Kupffer cell depletion studies show 
that Kupffer cells are important in liver lipid metabolism and triglyceride accumulation 
(29,62-64). Moreover, deletion of IL-10 results in hepatic triglyceride accumulation 
associated with obesity (29,65). Altogether these data demonstrate that Kupffer cells 
play an important role in the development of hepatic steatosis. In addition, it has 
been suggested that a shift in the resident macrophage polarization is sufficient to 
induce metabolic dysregulation (61). Together these results indicate a crucial role for 
alternatively activated Kupffer cells in control of metabolic homeostasis (Chapter 4). 
Hence, a proper balance between pro- and anti-inflammatory mediators is necessary 




4. Novel targets to restore insulin sensitivity
Since many studies showed that infl ammation plays a crucial role in the etiology of 
obesity-induced insulin resistance, anti-infl ammatory drugs would be a likely choice 
in restoring insulin sensitivity. However, the use of experimental anti-infl ammatory 
therapies has not been overly successful. In rodents, TNFα blocking agents have 
been shown to improve insulin sensitivity and lower blood glucose levels, but have 
been either ineffective or modestly effi cacious in humans (66,67). Moreover, Il-1β 
inhibitors have also been used in the treatment of T2D, again with only moderate 
success (68,69). Until a specifi c anti-infl ammatory agent shows effi cacy in humans, 
the role of infl ammation in causing insulin resistance in obese and T2D subjects 
remains incompletely established (45). Discussion of anti-infl ammatory therapy 
raises the fundamental question of whether we should inhibit infl ammation in the fi rst 
place. Infl ammation is a host response to danger, usually in the form of a pathogen or 
injury, which is necessary for wound repair and survival. Removing this infl ammatory 
signal could make the system vulnerable to continuing damage and subsequent 
exposures (2).
Given that obesity is the most common cause of insulin resistance in man and the 
obesity epidemic underlies the increasing prevalence of T2D, it is obvious that the 
most effective form of therapy would be to prevent or treat the underlying obesity 
(45). In this thesis we have shown that Ldlr-/- (Chapter 2), Myd88-/- (Chapter 3) 
and Csf1op/+ (Chapter 4) mice all become obese and develop insulin resistance. 
Body weight reduction leads to a loss of adipose tissue as well as liver triglycerides, 
which further leads to improvements in peripheral and hepatic insulin sensitivity, and 
prevention of hepatic injury (70,71). In addition to lifestyle changes, current therapies 
utilize bariatric surgery for morbidly obese patients to treat insulin resistance 
(70,71). The results of gastric bypass surgeries is rapid improvements in insulin 
resistance and decreased hyperglycemia in T2D patients well in advance of the 
onset of signifi cant weight reduction (45). A possible explanation might be that the 
gut microbiota is altered in these patients. Of note, gut microbiota are altered in 
mice with a Roux-en-Y gastric bypass (RYGB) that resemble many of the metabolic 
outcomes in humans. Moreover, these changes were independent of weight change 
or caloric restriction. In addition, transfer of gut mirobiota from RYGB-treated mice 
to non-operated, germ-free mice resulted in weight loss and decreased fat mass. 
These data provide evidence that changes in the gut microbiota contribute to reduced 
weight gain and adiposity after gastric bypass surgery (72). Unfortunately, we did 
not assess the role of gut microbiota in our models. Therefore we cannot exclude if 
gut microbiota plays an important role in our models. However, it has already been 
suggested that the intestinal microbiota is associated with obesity in both mice and 
humans and plays a role in the development of NAFLD (73). Therefore, therapeutic 
purposes to modify the gastrointestinal microbiota would be very important in 
treating metabolic disease. Gnobiotic (germ-free) mice are resistant to HFD-induced 
obesity (74) and colonization of gnobiotic mice with conventional mouse microbiota 
increases adipose tissue mass (75). In addition, increased levels of circulating 
bacteria or bacterial products, including LPS, have been associated with insulin 
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resistance (76). It is known that antibiotics, which modify the intestinal flora, have 
an effect on metabolism. Indeed, animals that receive antibiotics gain more weight 
than animals without antibiotic treatment (77). In line with this, early exposure to 
oral antibiotics in infants was associated with overweight in later childhood (78,79). 
It remains to be established how well these processes or mechanisms observed in 
mice can be extrapolated to humans. Despite marked differences between mice and 
humans, some promising clinical investigative studies have emerged. For example, 
the blood levels of bacterial DNA are elevated in pre-diabetic patients and can be 
predictive of diabetes development in subsequent years, raising the possibility that 
blood bacterial DNA may be a biomarker for disease progression (80). Furthermore, 
a recent clinical trial revealed that even though body weight was unaffected, insulin 
sensitivity was improved in obese individuals receiving fecal transplants from lean 
subjects (81).
In Chapter 5 we have shown that the iminosugar N-(5’-adamantane-1’-yl-methoxy)-
pentyl-1-deoxynojirimycin (AMP-DNM) acts as a caloric restriction mimetic in the 
presence of glucosylceramide synthase inhibition. Glucosylceramide (GlcCer) 
synthase inhibitors, like AMP-DNM, have been shown to have great promise as novel 
therapeutics in metabolic disease, including T2D, insulin resistance, NAFLD, non-
alcoholic steatohepatitis (NASH) and atherosclerosis (82-86). We and others have 
shown that AMP-DNM reduced food intake (85,87,88). Caloric restriction (CR) is 
known to increase longevity in diverse species (89,90), including mice and humans. 
In experimental models, CR decreases circulating levels of cholesterol, triglyceride, 
and glucose, increased insulin sensitivity in the liver and peripheral tissue and 
decreases the incidence of diabetes and atherosclerosis (91,92). AMP-DNM exhibits 
many effects that are also observed following caloric restriction, making AMP-DNM 
a potential target in treating NASH and insulin resistance. However, additional 
research is needed to investigate if AMP-DNM could be used as a therapeutic target 
in the development of insulin resistance.
5. Shortcomings and new approaches to study the role 
inflammation in the development of insulin resistance
All of the mechanistic research that describes the role of inflammation in the 
development of insulin resistance is performed in high-fat diet-fed C57BL/6 mice. In 
response to a high-fat diet or aging, C57BL/6 mice become obese, hyperinsulinemic 
and severely insulin resistant, whereas 129S6 mice do not develop hyperinsulinemia 
and insulin resistance (93,94). All diet-induced obesity models develop both 
obesity and inflammation, making it difficult to dissect the role of either obesity or 
inflammation in the development of insulin resistance. Moreover, it is also hard to 
assess inter-organ effects in obesity-induced insulin resistance because in diet-
induced obesity models the high-fat diet affects all organs at the same time. It has 
been demonstrated that diabetes-prone C57BL/6 and diabetes-resistant 129S6 mice 
at 6 weeks of age already show pre-existing differences in the inflammatory milieu in 
metabolic active tissues before differences in metabolic parameters can be detected. 




background as a risk factor to metabolic disease (95). These observations clearly 
impact the choice of models and dietary strategy for metabolic studies, as high-fat 
diets rapidly induce obesity in mice. Future studies may include the use of a systems 
biology approach in investigating the role of infl ammation-induced insulin resistance. 
For this, different and/or more time points should be considered. The novelty of this 
systems biology approach is that by comparing young animals using a sensitive 
computational approach, the focus is on factors that can potentially predispose from 
disease in a prospective manner and avoid fi ndings that are mainly secondary to 
obesity or metabolic differences. With this approach, differences between C57BL/6 
and 129S6 mice in multiple organs were examined, allowing them to conclude that 
infl ammation in the adipose tissue, and to a lesser extent in liver, is associated with 
the predisposition to insulin resistance. Moreover, gene network enrichment analysis 
was able to identify gene sets involved in signal transduction, protein secretion 
pathways, and glucose metabolism which were differentially expressed between the 
mouse strains in adipose tissue at 6 week of age (95). It is known that many of 
these pathways can interact with infl ammatory pathways, and this crosstalk could 
represent an entry point to the manifestation of metabolic diseases.
Concluding remarks
Although, it has been suggested that there is synergy between obesity and 
infl ammation in the development of insulin resistance, we have shown in this thesis 
that hepatic infl ammation is not under all circumstances causally linked to the 
pathogenesis of insulin resistance. Our data clearly show that the current knowledge 
about the role of infl ammation in the development of insulin resistance is far from 
understood. This might also explain why anti-infl ammation therapy has, so far, failed 
to translate into meaningful therapeutic advances. In addition, we have also shown 
that cross-talk between Kupffer cells and hepatocytes is important for protecting 
hepatocytes from the development of hepatic steatosis These data suggest that a 
fi ne balance of infl ammatory mediators is necessary for the optimal metabolic control 
in the liver.
In order to further unravel the role of (hepatic) infl ammation in the development of 
insulin resistance we could benefi t from the use of alternative approaches, including 
a systems biology approach with more or different time points. In addition, research 
needs to be performed in studying the role of crosstalk between different organs, but 
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Over the last decade obesity rates have reached pandemic proportions worldwide 
and as a result obesity has developed into a global health issue. In parallel with 
the obesity epidemic, obesity-related disorders, including the metabolic syndrome 
are rising. In Chapter 1, the metabolic syndrome was introduced as a cluster of 
metabolic disorders, largely driven by obesity, and characterized by dyslipidemia, 
insulin resistance, and non-alcoholic fatty liver disease (NAFLD). NAFLD is 
considered as the hepatic manifestation of the metabolic syndrome and refers to a 
spectrum of liver disorders, including hepatic steatosis, non-alcoholic steatohepatitis 
(NASH), advanced fibrosis, cirrhosis and ultimately liver cancer/failure. NASH is an 
advanced stage of NAFLD, involving both hepatic lipid accumulation (steatosis) and 
inflammation. The liver is comprised of different cells types, including hepatocytes, 
Kupffer cells, endothelial cells, stellate cells and immune cells. Kupffer cells are the 
resident macrophages in the liver and they play an important role in the etiology of 
NAFLD and NASH. Moreover, considerable evidence points towards a crucial role 
for low-grade inflammation as a causal factor in obesity-induced insulin resistance 
and type 2 diabetes (T2D). In the present thesis, we used 3 different mouse models, 
to study the role of inflammation in the etiology of NAFLD and insulin resistance, i.e., 
Ldlr-/- mice, Myd88-/- mice, and Csf1op/+ mice.
Since the significance of hepatic inflammation in driving the pathogenesis of insulin 
resistance is unclear, we aimed to unravel the role of Kupffer cell-driven hepatic 
inflammation in the pathogenesis of insulin resistance (Chapter 2). To this end, we 
used mice deficient for the low-density lipoprotein receptor (Ldlr-/-) and fed these 
mice a high-fat cholesterol (HFC) diet to induce hepatic inflammation. We made 
use of short-term and long-term dietary feeding interventions to study the effect of 
hepatic inflammation in the absence and presence of obesity. Although we show that 
short-term HFC feeding leads to hepatic inflammation, systemic or hepatic insulin 
resistance was not introduced in lean Ldlr-/- mice fed this diet. In addition, long-term 
high-fat diet feeding resulted in obese Ldlr-/- mice with insulin resistance; however, 
this was not exacerbated by cholesterol-induced hepatic inflammation. Hence, 
our data dissociate hepatic inflammation from insulin resistance and suggest that 
hepatic inflammation is a consequence rather than a cause of metabolic dysfunction 
in obesity. Our data therefore provide evidence to question a direct role of Kupffer 
cell-driven hepatic inflammation in the development of insulin resistance in mice.
The signaling pathways of toll-like receptor (TLR) and interleukin-1 (IL-1) drive 
nuclear factor-κB (NF-κB)-mediated transcription of inflammatory genes and have 
been shown to contribute to the development of NASH and insulin resistance. Since 
TLR and IL-1 signaling activate NF-κB via myeloid differentiation primary response 
gene 88 (Myd88), we hypothesized that Myd88 might also play an important role in 
the development of NAFLD and insulin resistance (Chapter 3). In mice, we found 
that Myd88 deficiency resulted in decreased hepatic inflammatory levels and reduced 
hepatic steatosis. However, these mice were not protected from the development of 
systemic insulin resistance. To further investigate the role of leukocyte Myd88 in 
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NASH, we made use of the Ldlr-/- mouse model, a validated model to study NASH. 
For this purpose, we transplanted Ldlr-/- mice with bone marrow from WT or 
Myd88-/- mice and fed these mice a HFC diet. Myd88-/- transplanted mice showed 
reduced hepatic infl ammation and hepatic steatosis. Of note, these mice were 
protected from HFC-induced insulin resistance. Next, we evaluated if hepatic MYD88 
expression could play a role in the disease progression in humans. In morbidly obese 
patients with different stages of NAFLD, we found a correlation between MYD88 
expression in the liver and the levels of C-reactive protein (CRP), ASAT and Kleiner 
score for steatosis. These data validate our fi ndings in mice that Myd88 plays an 
important role in the development of NAFLD.
Macrophages are regarded as key players in metabolic homeostasis and in the 
pathogenesis of diet-induced obesity and insulin resistance. One essential regulator 
of macrophage homeostasis in vivo is macrophage colony-stimulating factor, 
or Csf1. Although, Csf1 has been suggested to contribute to the pathogenesis 
of obesity-related disorders, including insulin resistance and T2D, this has never 
been experimentally addressed. In Chapter 4, we investigated the role of Csf-1 in 
the development of fatty liver disease and insulin resistance. Our data show that 
Csf1op/+ mice exhibit fasting-induced hepatic triglyceride accumulation, which might 
be explained by a reduction in VLDL-TG secretion. Moreover, indirect calorimetric 
analysis revealed a lower metabolic rate in Csf1op/+ mice, which was in line with a 
decrease in lean body mass in these mice. In addition, Csf1 insuffi ciency resulted in 
reduced Kupffer cell-driven hepatic infl ammation. Despite reduced infl ammation in 
the liver, adipose tissue and the circulation, Csf1op/+ mice are not protected against 
the development of insulin resistance. These data suggest that Csf1-induced Kupffer 
cells are important for protection against the development of hepatic steatosis, but 
do not affect the etiology of insulin resistance.
Ceramide and its glycosphingolipid metabolites have been implicated in the 
pathogenesis of obesity-induced insulin resistance. N-(5’-adamantane-1’-yl-
methoxy)-pentyl-1-deoxynojirimycin (AMP-DNM), an inhibitor of the enzyme 
glucosylceramide synthase catalyzing glycosphingolipid biosynthesis, has been 
shown to improve glucose homeostasis and insulin signaling. In Chapter 5, we aimed 
to unravel the short-term effects of AMP-DNM treatment on lipid metabolism and to 
identify if AMP-DNM may act like a calorie restriction mimetic. To this end, we made 
use of a methionine and choline-defi cient (MCD) diet to induce hepatic steatosis in 
C57BL/6J mice. Our data show that AMP-DNM treatment results in reduced food 
intake, increased whole-body fat oxidation and protection against hepatic steatosis 
in MCD-fed mice. In the paired feeding study, we have demonstrated that AMP-
DNM treatment directly promotes whole-body fat oxidation, which is unrelated to 
the appetite suppressor effect of AMP-DNM on fat oxidation. These data suggest 
that the iminosugar AMP-DNM directly targets whole-body fat oxidation in mice, 
supporting the benefi cial use of AMP-DNM as therapeutic strategy to alleviate 
obesity-associated metabolic disease.
The fi nal chapter (Chapter 6) discusses the major fi ndings of this thesis, places 




implications of the results.
In conclusion, the studies described in this thesis show that in the models used 
hepatic inflammation is not necessarily causally linked to the development of insulin 
resistance. Our data clearly suggest that the current knowledge about the role of 
inflammation in the development of insulin resistance is far from understood. This 
might also explain why anti-inflammation therapy has, so far, failed to translate into 
meaningful therapeutic advances. In addition, we have also shown that cross-talk 
between Kupffer cells and hepatocytes is important for protecting hepatocytes from 
the development of hepatic steatosis. These data suggest that a fine balance of 
inflammatory mediators is necessary for the optimal metabolic control of the liver.
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Samenvatting
In de laatste decennia is overgewicht een pandemie geworden en heeft het zich 
ontwikkeld tot een wereldwijd gezondheidsprobleem. Parallel met deze epidemie 
heeft er een stijging plaatsgevonden van overgewicht gerelateerde aandoeningen, 
zoals het metabool syndroom. In hoofdstuk 1 wordt het metabool syndroom 
geïntroduceerd als een groep van metabole aandoeningen, grotendeels gedreven 
door overgewicht, en gekarakteriseerd door een verandering in het lipidenprofi el 
(dyslipidemie), insuline resistentie en niet-alcoholische leververvetting (NAFLD). 
NAFLD wordt beschouwd als de lever manifestatie van het metabool syndroom en 
beschrijft een breed spectrum van lever aandoeningen, zoals vetophoping in de 
lever (lever steatose), leverontsteking (NASH), fi brose, cirrose en uiteindelijk lever 
kanker en/of leverfalen. NASH is een vergevorderd stadium van NAFLD waarbij 
zowel lever steatose als ontsteking betrokken zijn. De lever bestaat uit verschillende 
typen cellen, namelijk hepatocyten, Kupffer cellen, endotheel cellen, stellaat cellen 
en immuun cellen. Kupffer cellen zijn de macrofagen van de lever en zij spelen een 
belangrijke rol bij het ontstaan van NAFLD en NASH. Veel bewijsmateriaal wijst 
nu op een cruciale rol voor ontstekingen als oorzaak in overgewicht geïnduceerde 
insuline resistentie en type 2 diabetes (T2D).
In dit proefschrift hebben we drie verschillende muismodellen gebruikt om de rol van 
ontstekingen bij de ontwikkeling van NAFLD en insuline resistentie te bestuderen: 
de Ldlr-/- muis, de Myd88-/- muis en de Csf1op/+ muis.
Aangezien het belang van ontstekingen in de lever in de pathogenese van insuline 
resistentie onduidelijk is, hebben we gekeken naar de rol van de Kupffer cel 
gedreven lever ontstekingen bij het ontstaan van insuline resistentie (hoofdstuk 2). 
Hiervoor hebben we Ldlr-/- muizen gebruikt die we een hoog-vet cholesterol (HFC) 
dieet hebben gegeven om lever ontsteking te induceren. We hebben een korte 
(2 wk) en lange termijn (15 wk) hoog-vet dieet (verschillend in vet en cholesterol 
gehalte) gegeven om het effect van lever ontstekingen in aan- en afwezigheid van 
overgewicht te bestuderen. Hoewel we laten zien dat korte termijn HFC voeding 
leidt tot lever ontsteking, ontwikkelden de slanke Ldlr-/- muizen op dit dieet geen 
systemische of lever insuline resistentie. Bovendien, leidde lange termijn hoog-vet 
dieet tot het ontstaan van insuline resistentie in dikke Ldlr-/- muizen, echter, dit was 
niet verergerd door cholesterol geïnduceerde lever ontsteking. Vandaar dat onze 
resultaten geen verband laten zien tussen lever ontsteking en insuline resistentie 
en het suggereert dat lever ontsteking eerder een gevolg dan een oorzaak zijn van 
metabole dysfunctie bij overgewicht. Onze gegevens leveren bewijs om een directe 
rol van lever ontsteking in het ontstaan van insuline resistentie in muizen in twijfel 
te trekken.
De signalerings routes van toll-like receptor (TLR) en interleukine-1 (IL-1) 
leiden tot activatie van nuclear factor-κB (NF-κB) gemedieerde transcriptie van 
ontstekingsgenen en deze routes dragen bij aan de ontwikkeling van NASH en 
insuline resistentie. Aangezien TLR en IL-1 signalering beide NF-κB activeren via 




ook Myd88 een belangrijke rol speelt bij de ontwikkeling van NAFLD en insuline 
resistentie (hoofdstuk 3). In muizen hebben we gevonden dat Myd88 deficiëntie 
leidt tot een verlaging van lever ontsteking en een vermindering van lever vervetting. 
Echter, deze muizen zijn niet beschermd tegen de ontwikkeling van systemische 
insuline resistentie. Om verder de rol van leukocyt Myd88 in NASH te onderzoeken, 
hebben we het Ldlr-/- muismodel gebruikt omdat het een gevalideerd model is om 
NASH te bestuderen. Hiervoor hebben we Ldlr-/- muizen getransplanteerd met 
beenmerg cellen van wildtype (WT) of Myd88-/- muizen en hebben deze muizen 
een HFC dieet gevoerd. Myd88-/- getransplanteerde muizen laten een verlaging 
zien van zowel lever ontsteking als lever vervetting. Bovendien zijn deze muizen 
beschermd tegen HFC geïnduceerde insuline resistentie. Vervolgens hebben we 
bekeken of MYD88 expressie in de lever een rol speelt in de ziekte vooruitgang in 
mensen. In morbide obese patiënten met verschillende stadia van NAFLD hebben 
we een correlatie gevonden tussen MYD88 expressie in de lever en de niveaus 
van C-reactive protein (CRP, een acuut fase eiwit en een marker voor systemische 
ontsteking), ASAT (marker voor lever schade) en Kleiner score voor steatose (mate 
van lever steatose). Deze gegevens valideren onze bevindingen in muizen dat 
Myd88 een belangrijke rol speelt in de ontwikkeling van NAFLD.
Macrofagen worden gezien als belangrijke spelers in metabole homeostase en in 
de pathogenese van dieet geïnduceerd overgewicht en insuline resistentie. Eén van 
de belangrijke regelaars van macrofaag homeostase in vivo is macrophage colony-
stimulating factor, ook wel Csf1 genoemd. Hoewel er wordt gesuggereerd dat Csf1 
bijdraagt aan de pathogenese van overgewicht gerelateerde aandoeningen, zoals 
insuline resistentie en T2D, is dit nooit experimenteel onderzocht. In hoofdstuk 
4 hebben we de rol van Csf1 bestudeerd in de ontwikkeling van vette lever 
ziekte en insuline resistentie. Onze resultaten laten zien dat Csf1op/+ muizen een 
vasten geïnduceerde lever triglyceride opstapeling hebben die mogelijk verklaard 
kan worden door een verlaagde VLDL-TG secretie. Bovendien laat indirecte 
caloriemetrische analyse zien dat Csf1op/+ muizen een lagere stofwisseling hebben 
en dit is in overeenstemming met een lagere vetvrije massa (spiermassa). Daarnaast 
leidt Csf1 insufficiëntie tot een verlaging van Kupffer cel gedreven ontsteking in de 
lever. Ondanks verminderde ontsteking in de lever, het vet weefsel en de circulatie 
zijn Csf1op/+ muizen niet beschermd tegen de ontwikkeling van insuline resistentie. 
Deze resultaten suggereren dat Csf1 geïnduceerde Kupffer cellen een belangrijke 
rol spelen bij de bescherming tegen de ontwikkeling van lever vervetting, maar Csf1 
heeft geen invloed op het ontstaan van insuline resistentie.
Ceramide en de bijbehorende glycosphingolipide metabolieten zijn betrokken 
bij de pathogenese van overgewicht geïnduceerde insuline resistentie. Het 
iminosuiker N-(5’-adamantane-1’-yl-methoxy)-pentyl-1-deoxynojirimycin (AMP-
DNM), een remmer van het enzym glucosylceramide synthase die de biosynthese 
van glycosphingolipides katalyseert, laat zien dat het de glucose homeostase 
en insuline signalering verbeterd. In hoofdstuk 5 hebben we ons gericht op het 
ontrafelen van de korte termijn effecten van AMP-DNM op de vetstofwisseling 
en om te identificeren of AMP-DNM als een eetlust remmer kan fungeren. Hierbij 
hebben we gebruik gemaakt van een methionine en choline-deficiënt (MCD) dieet 
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om lever steatose te induceren in C57BL/6J muizen. Onze resultaten laten zien dat 
behandeling met AMP-DNM resulteert in verminderde voedselinname, verhoogde 
vetverbranding op lichaamsniveau en bescherming tegen lever steatose in MCD 
gevoede muizen. Door middel van het verlagen van de voedselinname van de MCD 
controle muizen hebben we vervolgens aangetoond dat behandeling met AMP-DNM 
direct leidt tot een bevordering van ververbranding op lichaamsniveau en dit is niet 
gerelateerd aan de eetlust onderdrukking van AMP-DNM op de vetverbranding. 
Deze resultaten suggereren dat het iminosuiker AMP-DNM rechtstreeks een effect 
heeft op vetverbranding op lichaamsniveau in muizen en dat ondersteunt het 
gebruik van AMP-DNM als een mogelijke therapeutische strategie om overgewicht 
geassocieerde metabole ziekten te verlichten.
Het laatste hoofdstuk (hoofdstuk 6) bespreekt de belangrijkste bevindingen van 
dit proefschrift, plaatst ze in de context van het onderzoeksveld en richt zich op de 
klinische toepassingen van de resultaten.
In het kort, de in dit proefschrift beschreven studies tonen aan dat in de gebruikte 
modellen lever ontsteking niet per se causaal gekoppeld zijn aan de ontwikkeling 
van insuline resistentie. Onze resultaten suggereren dat de huidige kennis met 
betrekking tot de rol van ontsteking in de ontwikkeling van insuline resistentie verre 
van begrepen is. Dit zou ook verklaren waarom anti-ontstekingstherapieën tot nu 
toe niet hebben geleid tot betekenisvolle therapeutische vooruitgang. Verder hebben 
we aangetoond dat cross-talk tussen Kupffer cellen en hepatocyten belangrijk is 
voor de bescherming van hepatocyten bij de ontwikkeling van lever steatose. Deze 
resultaten suggereren dat een juiste balans van ontstekingsmediatoren belangrijk is 





Eindelijk is het zover, mijn proefschrift is af!! De afgelopen 6 jaar heb ik met veel plezier 
gewerkt op de afdeling Moleculaire Genetica. Tevens heb ik veel geleerd en al met al heeft dit 
geleidt tot de totstandkoming van dit proefschrift. En daarvoor wil ik iedereen bedanken die 
mij hierbij geholpen heeft.
Allereerst wil ik beginnen met het bedanken van mijn promotor Marten Hofker. Beste Marten, 
bedankt dat jij het in mij zag om mij als AIO in jouw groep op te nemen, terwijl Folkert zich 
afvroeg of ik er wel al klaar voor was om AIO te worden. Bedankt voor je opbeurende woorden 
en suggesties als het even tegen zat. We hebben niet veel manuscripten samen geschreven, 
maar dat hebben we op het laatste moment nog een klein beetje ingehaald met het Myd88 
manuscript. Daarnaast moet ik mijn copromoter Debby Koonen bedanken. Debby, ik ben 
ontzettend blij geweest dat jij ons lab kwam versterken in 2009. In het begin liep het allemaal 
wat stroef tussen ons, maar naderhand was ik zeer blij dat jij erbij kwam met je goede 
ideeën en inzichten. Ik heb een hoop van je geleerd met name over het schrijven van de 
verschillende manuscripten en daar ben ik je erg dankbaar voor. En we hebben samen een 
drietal mooie manuscripten afgeleverd!! Tegen de tijd dat je dit leest, ben je aardig op weg in 
je zwangerschap en kun je bijna met zwangerschapsverlof. Succes met de laatste loodjes en 
veel plezier samen met Tim en je “5de” maar dan ‘echte’ kleine baby.
Daarnaast wil ik de leden van de leescommissie: Prof. Bert Groen, Prof. Patrick Rensen en 
Prof. Robert Porte, bedanken dat ze de moeite en de tijd hebben genomen om mijn proefschrift 
positief te beoordelen, ondanks dat de hoofdstukken niet gepubliceerd waren.
Bart en Kuif, allebei erg bedankt voor jullie kritische kijk op de lopende experimenten en de 
manuscripten. Bart, we hebben altijd leuke discussies gehad over voetbal en met name wie 
er kampioen zou worden in dat jaar. Gelukkig heb ik de afgelopen 3 jaar kunnen zeggen dat 
AJAX kampioen is geworden!! En hebben we daarom leuke en lekkere AJAX tompoucen 
kunnen eten! Beste Pascal, we hebben maar een aantal experimenten samen gedaan, maar 
bedankt voor je hulp met de hepatocyten en Kupffer cel isolaties en de Oroboros proeven. En 
bedankt voor je input op de manuscripten. Veel succes met je nieuwe baan!!
Marcel en Marcela, we zijn samen begonnen en jullie zijn inmiddels klaar en ik mag als laatste 
van ons de rij sluiten met het verdedigen van mijn proefschrift. Allebei bedankt voor de leuke 
kaas fondue avonden en het bespreken van onze dagelijkse beslommeringen.
Marijke, je was mijn steun en toeverlaat in moeilijke tijden, ik kon altijd bij je terecht voor zowel 
wetenschappelijke als persoonlijke zaken. Daarom ben ik ook erg blij dat jij mijn paranimf wilt 
zijn. Ik was blij dat jij er bij was toen ik gebeten werd door een muis en ik vervolgens naar de 
Eerste Hulp moest. We hebben er in ieder geval achteraf om kunnen lachen. Maar ook wil ik 
je bedanken voor de dagen dat er muizen gecanuleerd en geclampd moest worden. Helaas 
is het experiment niet gegaan zoals wij hoopten en hebben we 5 dagen voor niets zo vroeg 
aanwezig moeten zijn op het CDL.
Niels en Henk, bedankt dat jullie altijd klaar stonden om mij te helpen met de muizen 
experimenten. Van een beenmerg transplantatie tot een ip injectie, niets was jullie te gek!! 
Helemaal nadat ik geen injecties meer mocht geven aan de muizen. Niels, jij nog in het 
bijzonder bedankt voor de altijd leuke en gezellige treinritjes waarin we het altijd over van 
alles konden hebben. Daarnaast was alles natuurlijk niet mogelijk zonder de andere analisten 
Daphne, Nicolette, Bastiaan en Elinda. Elinda om maar met jou te beginnen. Bedankt dat 
jij mij in het begin alle technieken hebt willen leren en willen helpen met het uitvoeren van 
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het lab werk. Nicolette, bedankt voor je kritische blik op de uitgevoerde experimenten en 
de interpretatie ervan. Daphne, bedankt dat je mijn “reserve” paranimf wilde zijn en mij hebt 
geholpen met de voorbereidingen van de “grote” dag. Beste Bastiaan, bedankt dat je mij hebt 
willen hebben met de Bodipy experimenten, die we helaas niet hebben kunnen gebruiken in 
ons Csf1 manuscript. Maar ook bedankt voor je hulp met de layout van het proefschrift. Veel 
succes met je nieuwe baan als research assistent in Soupthampton!
Dear PhD students Nanda and Fareeba, I would like to thank you for all your help with the last 
experiments you had to perform for me while I was not working anymore at the department. 
Hopefully, we will be rewarded with accepted manuscripts. Paulina, Alina, Tobias, Frederico, 
Laser and Jan-Willem thank you for the nice time on the lab. I wish you all the best and good 
luck fi nishing your PhD.
Ingrid van der Strate bedankt voor alles wat je hebt gedaan om veel administratief en 
organisatie werkzaamheden uit mijn handen te houden en dat ik voor van alles bij jou terecht 
kon. Ingrid Engelsman, we kennen elkaar nog niet zo lang, maar bedankt dat je toch een 
aantal zaken voor mijn promotie hebt willen uitzoeken/regelen.
Tevens wil het lab van kindergeneeskunde bedanken voor het helpen opzetten van alle 
experimenten tijdens mijn 1ste jaar als AIO. Folkert en Bert jullie hebben altijd goede 
suggesties gehad als we even vast zaten met een experiment, zoals het voorstel om nog 
een experiment doen met het stofje AMP-DNM voor ons MCD manuscript. Tevens wil ik Rick 
bedanken voor de canulaties voor het clampen. Echter hebben deze experimenten ons niet 
verder kunnen helpen in het Ldlr-/- model. Theo wil ik bedanken voor alle berekeningen die er 
zijn gedaan voor de verschillende experimenten. Albert, bedankt voor alle hulp met betrekking 
tot de experimenten met de Oroboros. Dirk-Jan bedankt voor je altijd goede suggesties en 
opmerkingen.
Verder wil ik graag alle mensen van het CDL bedanken voor het verzorgen van mijn vele 
individueel gehuisveste dieren in de afgelopen 5 jaar. Arjen, ik wil jou in het bijzonder bedanken 
voor de dagen dat we hepatocyten hebben geïsoleerd. Ik kon bij jou altijd even mijn verhaal 
kwijt en het was altijd gezellig.
Daarnaast wil ik graag de leden van de “IOP” groep bedanken: Gert-Jan van Ommen, Tonnie 
Rijkers, Cisca Wijmenga, Timon van Haeften, Yvonne van der Schouw, Charlotte Onland-
Moret, Clara Elbers, Florianne Bauer, Jana van Vliet-Ostaptchouk, Sander Rensen en Wim 
Buurman. Het was niet altijd even makkelijk om jullie studies in mensen te begrijpen, maar dat 
zal voor jullie net zo zijn geweest als ik het over de verschillende muis modellen had.
Ook wil ik natuurlijk mijn (schoon)familie bedanken, Frans en Geja, Jasper dank voor jullie 
vertrouwen in de goede afl oop. Bianca, mijn zusje, fi jn dat jij vandaag één van mijn paranimfen 
wilt zijn en er altijd maar in geloofd hebt dat ik het zou afronden. Ton, leuk om je in de familie 
te hebben en ervoor te zorgen dat mijn “kleine” zusje niet meer helemaal in haar eentje in 
Nijkerk woont. Pap en mam, jullie hebben altijd vertrouwen in mij gehouden, ook als het even 
tegen zat, dank jullie wel!!
En natuurlijk lieve Sander, bedankt voor alle ondersteuning die ik tijdens mijn gehele AIO 
periode van je heb gekregen. Ik weet dat het niet altijd makkelijk was voor ons allebei. Maar 
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